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 Pancreatic cancer resulted in nearly 42,000 deaths in 2016 making it the third 
leading cause of cancer-related death in the United States (1). The high mortality rate 
stems from that fact that treatment options are limited as less than 20% of patients are 
candidates for surgical tumor removal because pancreatic cancer is usually detected after 
it has metastasized to other organs.  Cancer metastasis is a multistep process where tumor 
cells migrate from a primary tumor into the vasculature, where the circulating tumor cell 
can then roll on and bind to the vascular epithelial wall before extravasating to a 
secondary location.  If this cascade is interrupted at any point, metastasis is abrogated. 
Therefore given its severity, understanding and treating pancreatic cancer metastasis is 
critically important in reducing the high mortality rate associated with the disease. 
In this dissertation, the metastatic cascade is first discussed in detail to outline the 
various areas where treatments can be implemented to disrupt the process and halt 
metastasis.  Next, the biophysics of selectin-mediated cell adhesion is addressed before 
exploring the relevant function of selectin ligands present on pancreatic cancer cells, 
mainly PODXL, MUC16 and CD44.  Finally giant obscurins, giant tumor suppressing 
proteins which play a role in cancer migration, and monobodies, an antibody alternative 
which can be engineered to treat metastatic cancer, are discussed (Chapter 1).  
Having established a background in several key players involved in pancreatic 
cancer metastasis we explore the critical parameters of selectin-mediated pancreatic 
tumor cell tethering and rolling.  First the equations and models vital to understanding 




spectroscopy, we characterized the binding interactions of MUC16 and PODXL to E- and 
L-selectin at the single-molecule level.  To further analyze the response of these 
molecular interactions under physiologically relevant regimes, we used a microfluidic 
assay in conjunction with a mathematical model to study the biophysics of selectin-ligand 
binding as a function of fluid shear stress.  We demonstrate that both MUC16 and 
PODXL-E-selectin-mediated interactions are mechanically stronger than like L-selectin 
interactions at the single-molecule level, and that these interactions display a higher 
binding frequency at all contact times.  Finally we determined that several key kinetic 
parameters regulate the average velocity of ligand-coated microspheres rolling on 
selectin-coated surfaces in shear flow (Chapter 3). 
We then sought to evaluate the critical parameters of the pancreatic tumor 
adhesion to hyaluronic acid (HA) mediated by rolling on E-selectin in physiologically 
relevant flow. We show that tumor cells rolling on E-selectin were significantly more 
likely to bind to HA than non-rolling cells at both low and high shear stresses. Further, 
the ligand-E-selectin interaction initiates adhesion to HA in a twofold manner, both 
physically slowing cells and allowing cells to orient close to the surface and increasing 
the on rate of adhesion.  Understanding the biophysics of selectin-ligand bonds and their 
responses to physiologically relevant shear stresses is vital for developing diagnostic 
assays and/or preventing the metastatic spread of tumor cells by interfering with selectin-
mediated adhesion (Chapter 4). 
We next looked to characterize the presence and absence of giant obscurins in 
pancreatic cells and assess their effect on cell migration and cytoskeletal dynamics. Here 




cancer cell lines, but are expressed at high levels in normal pancreatic tissue and non-
tumorigenic human pancreatic ductal epithelial cells (HPDE). Stable clones of HPDE 
cells lacking giant obscurins have decreased RhoA activity and increased PI3K/AKT 
activity which in turn leads to major cytoskeletal alterations including increased actin 
dynamics at cell-cell junctions, faster microtubule growth and decreased focal adhesion 
density.  Additionally, the loss of obscurin in HPDE cells leads to faster and more 
dynamic cell migration and treating these cells with a PI3K inhibitor decreases migration 
speeds in both confined and unconfined microchannels. This work is important because 
identifying biomarkers that increase cell migration and cytoskeletal dynamics such as 
giant obscurins is critically important to the prevention and treatment of pancreatic cancer 
metastasis (Chapter 5). 
Next we explore the binding mechanics of the monobody YS1, an antibody 
alternative derived from the fibronectin scaffold. Using alanine-scanning mutagenesis 
simulations, we identified two residues (R33 and E47) in the conserved monobody 
scaffold that are critical to the binding interaction between the monobody YS1 and its 
ligand, maltose-binding protein (MBP). Using steered molecular dynamics simulations 
we predicted that mutations to these residues in the YS1 scaffold would substantially 
destabilize the YS1-MBP interface and that the R33A mutation has a greater 
destabilization effect, weakening hydrogen binding between all scaffold residues and 
MBP and not just between R33 and MBP. We validated the simulation using two 
biophysical tools, single-molecule force spectroscopy and surface plasmon resonance. 




the monobody interactions with a target, providing guidance for the improved 
engineering of monobodies (Chapter 6). 
Finally we conclude by summarizing the results of this work and discussing future 
work including planned in vivo experiments, which will assess pancreatic cell 
tumorigenicity and metastasis in multiple mouse models (Chapter 7).  In summary, this 
dissertation reviews and utilizes current biophysical measurements to evaluate multiple 
pancreatic cancer cell biomarkers that affect various stages along the metastatic cascade 
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Despite the effort put into the research and treatment of cancer, it remains the 
second leading cause of death worldwide, behind heart disease.  In 2016, it was estimated 
that almost 1.7 million new cases of cancer will be reported and nearly 700,000 cancer 
related deaths will occur in the United States alone (1). Interestingly, the overall 
incidence of death from cancer has decreased from 2003-2013; however, this is likely 
attributed to decreases in the rates of specific cancers, rather than broad improvements in 
treatment.  Lung cancer and colorectal cancer deaths have decreased substantially since 
the 1990’s as smoking numbers declined and prevalence of colonoscopies increased (2, 
3).  Despite the falling rates of several cancers and the numerous treatments options, 
which are developed every year, the rates of certain cancers including pancreatic, liver, 
and uterine corpus cancers have continued to increase (1).   
While cancer death rates have decreased 21% since 1991, cancer deaths continue 
to rise for two of the most deadly forms of cancer: liver and pancreatic.  Specifically 
pancreatic cancer resulted in nearly 42,000 deaths in 2016 making it the third leading 
cause of cancer related death in the United States (1).  Pancreatic cancer incidences and 
death rates have increased 1.2% and .4% respectively since 2000 (1). Currently no 
reliable methods exist for the early detection of pancreatic cancer.  This coupled with the 
fact that the symptoms of pancreatic cancer usually go unnoticed until the disease has 
progressed has led to the poor prognosis usually associated with pancreatic cancer.  As a 
 2 
result the average 1-year and 5-year survival rates are only 29% and 7% respectively (4).   
This largely stems from that fact that treatment options are limited. In fact less than 20% 
of patients are candidates for surgical tumor removal because the cancer is usually 
detected after it has metastasized to other organs.  The average life expectancy after 
diagnosis with the metastatic disease is only 3-6 months (4).   Therefore, understanding 
and treating pancreatic cancer metastasis is critically important in reducing the high 
mortality rate associated with the disease. 
Cancer metastasis is a highly coordinated process by which tumor cells spread 
from a primary tumor to a secondary distal tissue, and metastasis is responsible for about 
90% of deaths from solid tumors (5). The metastatic cascade is a complex multistep 
process, in which cancer cells migrate from the primary tumor to the circulatory system 
where they extensively interact with the endothelial wall before eventually extravasating 
and colonizing a distal organ, forming a secondary tumor.  Throughout this process, cell 
migration and the protein-protein interactions mediated by adhesive proteins known as 
selectins are critically important. This work will focus on treating several steps of the 
metastatic cascade including pancreatic tumor cell rolling and attachment to ligands 
found on the vessel walls as well as the identification of a pancreatic tumor suppressor, 
which alters the mechanics of pancreatic cell migration. 
 
1.1 The metastatic cascade 
 
Although metastasis is the major cause of death from cancer, despite studying the 
process for over 200 years, cancer metastasis remains controversial (6).  In 1889 the 
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“seed and soil” model of cancer metastasis was suggested by Stephen Paget.  It suggests 
that cancer metastasis relies on both the cancer cell and the nature of the distal tissue 
environment much like “When a plant goes to seed, its seeds are carried in all directions, 
but they can only live and grow if they fall on congenial soil” (7).   This theory has been 
developed more recently as studies have shown that although tumor cells pass through 
the vasculature of many organs, metastatic tumor cells can only develop in favorable or 
congenial organs (8).  Currently this hypothesis is generally accepted although it has been 
expanded upon, where the “seed” refers to not only the metastatic cell but also a cancer 
stem cell or initiating cell and the “soil” refers to the stroma or organ microenvironment 
(9). 
Once a primary tumor has formed, it is the combination several factors including 
continued tumor proliferation, vascularization, accumulated genetic changes and the 
activation of intricate signaling pathways which can prompt cells to enter the metastatic 
cascade.  Throughout each step of the cascade, tumor cells must migrate, attach to, and 
navigate considerably different microenvironments including tissue at the primary and 
distal sites as well as blood vessel endothelium (6).  To successfully form a secondary 
tumor, cells acquire the necessary genetic modifications to allow for the navigation of 
each of these diverse and sequential steps, each of which can be rate limiting as a failure 
at any step would stop the metastatic process (10).   
 
1.1.1 Primary tumor formation  
Tumors result from the abnormal proliferation of cells, where normally healthy 
cells gradually become malignant through a progressive sequence of genetic mutations.  
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These genetic alterations select for cells with an increased propensity for survival, 
proliferation, and migration. The act of tumor initiation, progression and eventual 
metastasis is not fast. The growth rates of tumors are generally slow with doubling times 
on average of 160 days but varying from 44 days to over 1,800 days (11, 12).  As a result 
tumors growing to 1 cm, take an average of 12 years to form.   
Although metastasis can occur when the tumor is small most metastases are 
thought to occur when the tumor is large at the later stages of tumor development (10).  
However, all cells in a malignant tumor are not equally metastatic due to genetic 
alterations, which can activate the metastatic genetic program in these progenitor cells 
(13).  Metastatic clones result from divergent gene expression from the primary tumor, 
and as a result the tumor itself is a heterogeneous environment consisting of both 
metastatic and non-metastatic tumor cells (14, 15). 
 
1.1.2 Tumor vascularization 
Because of the extensive metabolic demand and growth of tumor cells, they 
require access to oxygen and nutrients. Therefore, vascularization of the tumor is 
necessary for tumors to exceed 1-2 mm in diameter (16). Cancer cell secretion of 
angiogenesis factors is a critical step in establishing the vascular system necessary for 
tumor survival (16).  Interestingly, many tumor types including pancreatic 




1.1.3 Mechanisms of cell invasion  
Following vascularized tumor formation the ability of cells to invade the 
surrounding tissue is critically important to initiating the metastatic process. Cancer cells 
can invade the surrounding stroma and adjacent tissue by migrating either as detached 
single cells or collectively as cell sheets or clusters (18).  In the tumor, neighboring cells 
are connected through cell-cell contacts, which are stabilized through the E-cadherin 
connections by adjacent cells.  Intracellularly, E-cadherin links adherence junctions to the 
actin cytoskeleton through interactions with b-catenin, a-catenin and p120 catenin (19). 
During the progression of cancer, genetic mutations affect cell plasticity and 
result in distinct phenotypical changes including the collective to amoeboid transition 
(CAT), the epithelial to mesenchymal transition (EMT), and the mesenchymal to 
amoeboid transition (MAT) (20, 21).  EMT is a primary indication of cancer progression 
to an aggressive form and is present in pancreatic cancer progression (22).  EMT is 
defined loss of epithelial characteristics and the gain of mesenchymal gene expression.  
Specifically, cells undergoing EMT develop the loss of E-cadherin, the subsequent 
disruption of adherence junctions, and increased production of mesenchymal markers 
such as vimentin and of N-cadherin. The switch from E- to N-cadherin enhances cell 
motility allowing cells to migrate away from the primary tumor in a mesenchymal 
fashion.  Additionally, the migration of cells away from a primary tumor requires the 
remodeling of the extracellular matrix (ECM).  Cells degrade the matrix to form 
migrational tracks through the excretion of matrix metalloproteinases, which are 
unregulated for nearly every type of cancer (23). 
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1.1.4 Circulating tumor cells 
Tumor cells, migrating away from the primary tumor, must navigate to and 
through the vascular endothelium in a process known as intravesation. This critical step is 
necessary to gain access to the circulatory system.  Once in the circulatory system, cancer 
cells are now referred to as circulating tumor cells (CTCs). Here they face a series of 
hydrodynamic forces, interactions with immune cells, and collisions with both blood cells 
the endothelial cells of the vessel wall (5).  Since only the CTCs that can overcome these 
pressures can seed tumors at a distal location, only a small fraction of CTCs survive and 
successfully generate metastasis.  In fact, using mouse tail-vein injections as a model, this 
number is estimated at only 0.01% (24).   
Once in the circulatory system, the path that a CTC travels is influenced by a 
number of parameters including the blood flow patterns, the size of the vessels and the 
interplay between disruptive shear forces and cell-cell adhesion, which leads to the arrest 
of cells in the blood vessels.  As cells circulate they experience shear stress, which results 
from the differing velocities of the fluid (blood) throughout the cross-section of the 
vessel.  In a cylindrical vessel, the blood velocity is the highest at the center and zero at 
the vessel walls. This change in fluid velocity leads to the shear force felt by CTCs, 
which is a force per unit area and commonly has units of Newtons per square meter 
(N/m2) or dynes per square centimeter (dyn/cm2).  The average shear stress levels vary 
between 1-4 dyn/cm2 in the venous system to 4-30 dyn/cm2 in arterial circulation (25). 
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1.1.5 Adhesion to the vessel wall and extravasation 
In order for a tumor cell to extravasate from the vasculature to a secondary 
location, the cell must first adhere to the vessel wall.  This process can occur through 
physical occlusion or through cell-cell adhesion.  Physical occlusion occurs if a cell 
enters a vessel that has a diameter less than the radius of the cell.  Since CTC diameters 
are generally larger than 10 um, occlusion occurs primarily in small blood vessels or in 
capillaries (5).  Adhesion occurs in larger blood vessels and is dependent on specific 
interactions between CTC ligands and receptors on the endothelial wall.  
Circulating tumor cells in the vasculature interact with selectins on the endothelial 
wall and it is these selectin-ligand interactions that mediate cell rolling and lead to firm 
adhesion.  The probability of cellular arrest in the vasculature relies on the frequency of 
contact between membrane bound ligands expressed by CTCs and receptors expressed on 
endothelial cells, as well as the time or extent of these interactions.  The interacting time 
(residence time) is dependent on the interplay between the adhesive forces of the 
receptor-ligand bonds formed between the endothelial wall and the CTC and the shear 
forces exerted on the CTC as it flows through the vasculature.  At higher shear stresses, 
cells are expected to increase their contact frequency with the endothelial wall but 
decrease their adhesion time as CTCs spend less time in contact with the vascular wall 
(5). 
Interestingly the probability of cellular arrest is expected to be highest at 
intermediate shear stress levels.  This is a direct function of the kinetic (koff and kon) and 
micromechanical properties (reactive compliance and tensile strength) of the single 
ligand-receptor bond, which will be expanded on in Chapter 2.  The strength of these 
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bonds and their ability to quickly form will dictate both the cell’s ability to bind to the 
endothelium at a designated shear stress and the type of binding interaction (i.e. cell 
tethering, transient rolling, stable rolling, firm adhesion).  Several key characteristics are 
required for the formation of ligand-receptor bonds necessary to mediate cell binding in 
shear flow. These bonds require a relatively fast on-rate (kon), which allows for bonds to 
form at short interaction times.  Next, they must have a high tensile strength to overcome 
hydrodynamic forces, which will disrupt bond formation and retention.  Finally ligand-
receptor bonds must have slow off-rates, (koff) which allow for a prolonged bond lifetime 
and ensure the formation of new bonds. 
Selectin-ligand bonds, which will be discussed in detail in Chapter 1.2 have high 
on-rates, high tensile strengths and fast off-rates and therefore can facilitate transient, 
faster rolling interactions and in some instances slower cell rolling.  Integrin-ligand and 
HA-ligand interactions have slower on-rates and low off-rates.   These interactions occur 
only after selectin-mediated rolling has occurred or at low shear stresses and result in 
stable or firm adhesion due to the low off-rate of these interactions. Following tumor 
cells arrest in the vasculature, cells will release soluble factors and then can extravasate 
or migrate from the vasculature to a secondary location.  
 
1.1.6 Formation of secondary tumor 
If the tumor cell has navigated this cascade and successfully migrated to a distal 
location, the secondary tumor can then grow if the microenvironment is suitable for 
growth.  However, because the new environment may be unsuitable for growth, tumors 
cells will often rest in a dormant state until they can adapt and grow (26).  Once the 
 9 
metastases begin growing the process starts again, with the requirement for tumor 
vascularization and the ability to form new metastases.  
If the metastatic cascade is disrupted at any point tumor cells cannot seed new 
tumors at a secondary location.  For instance, by disrupting a cancer cell’s ability to 
migrate, the cascade is broken at either the invasion/intravastation/extravasation step in 
the cascade, while blocking a cell’s ability to adhere to the vessel wall will again disrupt 
this process.  This work will herein focus on these two facets of the metastatic cascade, 
[1] exploring how pancreatic cancer cells bind and firmly adhere to the vascular 
endothelium in shear flow and [2] how tumor suppressors, which when lost from 
pancreatic epithelial cells increase cell migration and tumorigenicity. 
 
1.2 Biophysics of selectin-mediated adhesion 
 
Cell adhesion is vital to several biological processes ranging from inflammation 
to cancer metastasis.  As discussed in Chapter 1.1.5 cell adhesion as it pertains to 
metastasis relies on the formation of bonds primarily between tumor cell surface ligands 
and selectins or integrins expressed by endothelial cells.  E-, P-, and L-selectins are a 
family of three physically similar adhesion proteins.   At the animo end, all three selectins 
have a lectin domain with a similar sequence to c-type lectins, a calcium dependent 
animal.  This domain is followed by an epidermal growth factor like domain, a variable 
number of short consensus repeats, the transmembrane domain and finally the short 
carboxyl terminal tail (27).  While E-, P-, and L-selectins share a similar structure, the 
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binding kinetics and distribution differ considerably leading to their distinct roles in 
cancer metastasis.   
E-selectin (CD62E) is expressed on activated vascular endothelial cells.  It must 
be activated at the transcription level and protein levels peak after 4-6 hours once 
exposed to an inflammatory stimuli (27).  P-selectin (CD62P) is expressed on platelets 
and can also be induced on vascular endothelium through exposure to the cytokines 
interlukin-4 or oncostatin M (28).  L-selectin (CD62L) is constitutively expressed on the 
surface of leukocytes.   
At the lectin domain, selectins bind to glycosylated ligands in the presence of 
calcium. Binding occurs on a shallow region that overlaps a calcium coordination site 
opposite of the EGF domain (29).  While the lectin domains are conserved in all three 
selectins, the length of the repeated consensus sequence regions result in differing 
binding mechanics.  All three selectins recognize sialofucosylated oligosaccharides such 
as sialyl-Lewis x (sLex) and its isomer sialyl-Lewis a (sLea) which are the terminal 
components of glycoproteins and glycolipids expressed on interacting cells (30-33).     
Notably, sLex is absent from normal tissue in the pancreas (34, 35), but present in 
pancreatic ductal adenocarcinoma and high-grade pancreatic intraepithelial neoplasia 
lesions (34).  However, the binding affinity of selectins for monocovalent sLex/a is low, 
and therefore it is vital to distinguish between structures that only interact with selectins 
in vitro and the functional selectin ligands (36) that interact with selectins selectively and 
with high affinity in vivo and whose depletion suppresses selectin-dependent binding.  
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1.2.1 2D receptor-ligand kinetic – the micropipette assay 
Numerous techniques exist to study receptor-ligand binding mechanics. These 
techniques, like surface plasmon resonance rely on one protein (either the receptor or 
ligand) to be in solution.  This limits their measurement to 3D binding constants; 
however, the receptor-ligand binding relevant to cancer metastasis occurs in 2D, leading 
to differing binding mechanisms and kinetics (37).  Recently assays were developed to 
measure 2D binding mechanics in the absence and presence of shear flow.   
The micropipette aspiration technique uses a receptor coated red blood cell 
(RBC), which is brought into contact with a ligand coated bead or a polymorphonuclear 
leukocyte. The RBC and bead/leukocyte are stabilized via a micropipette and piezo-
displacement respectively (38). They are then brought in contact for prescribed periods of 
time and the micropipette is retracted at a set velocity. The rector-ligand interaction is 
monitored using video-microscopy and the rupture force is calculated by multiplying the 
stiffness of the RBC membrane with the extension of the RBC at the moment of bond 
rupture (38). This technique can be used to determine 2D dissociation constants as well 
as the 2D binding affinity per contact area (AcKao) (39). 
 
1.2.2 Single molecule force spectroscopy 
 In addition to the micropipette aspiration technique two ultrasensitive probes are 
used in force spectroscopy studies to measure binding interactions: BPF and MFP.  In 
BPF the force is measured by the displacement of a glass microsphere, which has been 
immobilized on a RBC.  In MFP the force is measure by the deflection of a cantilever.  
While both of these techniques measure forces in a physiologically relevant range from 5 
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pN to 1 nN (27) the remainder of this section will focus on MFP as it is directly relevant 
to the present work.  
 MFP utilized atomic force microscopy (AFM) where a flexible receptor-coated 
cantilever can deflect in response to forces generated when it is brought in contact with a 
ligand-coated surface.  The cantilever deflection is measured via a laser and can be 
transformed into forces by multiplying the deflection by the spring constant of the 
cantilever. MFP experiment can be preformed using a functionalized cantilever 
contacting a ligand coated glass substrate, a functionalized cantilever contacting a cell 
immobilized on a glass surface or a cantilever with an immobilized cell contacting a cell 
on a glass surface (40, 41).  Using intact cells has two benefits as it ensures that the 
membrane receptors and ligand are in their physiological orientation and that they are 
intact with the cytoskeleton.  However, with this method, cell deformability and 
interactions with non-specific targets can complicate the results.  Recently ligands 
supported in lipid bilayers (ligand-receptor system) have produced similar kinetic 
constants to the cell-receptor system (40, 42). 
 By plotting the distance traveled by cantilever against the force both the loading 
rate and rupture force of the receptor-ligand bond can be determined (41, 42).  
Furthermore, by plotting the natural log of the loading rate against the rupture force the 
Bell model kinetic parameters, unstressed dissociation constant (koff) and the reactive 
compliance of the bond (xβ) can be determined.  These parameters rely on the contact 
duration of the binding interaction and the retraction velocity of the cantilever (42).  
Details on this calculation are explored in Chapter 2.1.  Further, for these measurements 
to be accurate it is vital that only one bond form per retraction.  To ensure this receptor 
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and/or ligand densities are selected to allow for 10-35% bond formation.  In this binding 
range, greater that 80% on the interactions will involve a single bond based on Poisson 
statistics (27).  Other controls involve treating the sample with the calcium chelator 
EDTA or a functional anti-selectin antibody to abrogate binding and ensure the accuracy 
of the measurements.   
 
1.2.3 Slip bonds and catch bonds 
Numerous receptor-ligand pairs have been studied using either BPF or MFP.  
These binding interactions include integrin-VCAM-1, cadherin-cadherin, and ligand-E-
/L-/P-selectin binding.  The rupture of these bonds can exhibit two behaviors, which are 
identified as catch and slip bonds. Catch bond lifetimes increase with the application of 
an external force while the lifetime of a slip bond decreases with the application of an 
external force (43).  Catch bonds are often pictured as the common child’s toy, the finger 
trap, where pulling your fingers apart (applying force) decreases the chance that the trap 
will successfully be removed.  
The kinetic and micromechanical properties of selectin-meditated interactions 
were originally estimated by monitoring leukocyte interactions with selectins in shear 
flow however, this methodology could not exclude the formation of multiple bonds and 
relies on assumptions to determine the force applied to the bond (44). Utilizing BPF or 
MFP has been adopted to accurately measure the properties of the slip bond at the single 
molecule level.  Using single molecule force spectroscopy the rupture of E-, P- and L-
selectin to P-selectin glycoprotein-1 (PSGL-1), the primary selectin ligand presented on 
neutrophils was studied over a physiologically relevant level of loading rates (41, 45).     
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The PSGL-1-L-selectin bond was found to have a higher koff, a higher xβ and a 
lower tensile strength than either the PSGL-1 bond with E- or P-selectin, thus indicating a 
weaker bond strength (with E-/L-selectin) and explaining the faster rolling of neutrophils 
on L-selectin (41, 46).  The PSGL-1-E-selectin bond has a higher koff and lower xβ than 
the PSGL-1-P-selectin bond indicating that the E-selectin mediated interaction has a 
shorter bond lifetime in the absence of force, but increased resistance to rupture in 
presence of force which may decrease neutrophil rolling velocities on E-selectin in shear 
flow (27, 41).  It is worth noting that single molecule force spectroscopy typically yields 
lower koff and higher xβ when compared to flow chamber assays likely due to the 
increased ability to measure single bonds via BPF and MFP. 
Selectin-ligand binding can exhibit both slip and catch bond behavior.  To 
account for this behavior the two-pathway model was developed.  Here the selectin-
ligand bond is considered to be most stable under some nominal applied force.  
Consequently at low and high force regimes the bond is unstable and will rupture.  
Therefore the graph of bond lifetime plotted against rupture force increases with applied 
force in the catch regime and decreases with applied force in the slip regime.  The 
presence of catch bonds in selectin binding has been observed through both single 
molecule force spectroscopy and flow chamber assays (43).  In these experiments 
immobilized PSGL-1 was brought in contact with P-selectin at a constant force and the 
bond lifetimes were recorded.  As a result the biphasic pattern of bond lifetime versus 
rupture force was observed indicating the switch from catch to slip bond (47). The 
existence of catch/slips bonds is thought to regulate the binding of leukocytes in shear 
flow (48). 
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1.2.4 Adhesion mechanics in shear flow  
Increasing evidence suggests that receptor-ligand interactions mediate tumor cell 
arrest in microvasculature. While the single molecule kinetic and micromechanical 
properties of these binding events affect the binding characteristics of cells in the 
presence of flow, they are properties that are measured in the absence of an applied force 
and therefore it is important to explore these interactions in physiologically relevant 
conditions.  The flow chamber assay has such been utilized to recapitulate binding in the 
presence of hydrodynamic flow (31, 49).  
In this assay, a cell or ligand coated bead passes through the flow chamber and is 
thought to be in “free motion” when it is traveling at or near the hydrodynamic velocity 
of the fluid.  If the cell initiates bonds with the receptor coated surface its velocity is 
depressed and the formation of bonds will tether the cell to the surface.  If a cell 
continues to travel significantly slower than the hydrodynamic velocity it is said to be 
rolling on the surface, mediated through the repeated formation and dissociation of 
receptor-ligand bonds.  If a cell is stationary on the surface for several seconds to 
minutes, it is considered to be firmly adhered or arrested.   
The mechanics of cell rolling on selectins is a complex process that relies on 
many factors including the strength of receptor-ligand bonds, cell deformability, 
microvilli extension, and surface receptor and ligand densities.  However, this system can 
be simplified by a series of assumptions that will be detailed in Chapter 2.2.  From the 
flow chamber assay, the bond lifetime can be determined from the tethering time of the 
cell on the substrate at low receptor and ligand densities.  Dissociation kinetics can be 
calculated by plotting the bond lifetime against the fraction of bound cells at a given 
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shear stress.  In selectin-ligand binding the stressed dissociation rate (kr) was found to 
increase with increasing shear stresses. From this data unstressed dissociation constant 
and reactive compliance can be estimated. 
Receptor-ligand binding interactions in flow conditions are found to fall into four 
categories based on the values of the unstressed dissociation constant and reactive 
compliance.  As either the reactive compliance or unstressed dissociation constant of 
binding interactions decrease for specific binding pairs expressed on the cell surfaces, 
cell-cell interactions transition from displaying no adhesion, to transient adhesion, to 
rolling and eventually firm adhesion at a given shear stress (49).  This state diagram 
explains why selectin-mediated adhesion typically results in cell rolling, as the single 
bond kinetic properties are in the range necessary to facilitate this interaction. 
 However, as mentioned previously, these experiments are performed at low 
receptor densities to encourage the formation of single bonds.  While this increases the 
analytical power of these assays it is not physiologically relevant, because multiple bonds 
can form in shear flow.  Recently a comprehensive model has been developed that 
incorporates multiple bond formation into the calculation of 2D receptor-ligand kinetics 
in shear flow (50, 51).  This model will be discussed in greater detail in Chapter 2.2.   
 
1.2.5 Functional selectin ligands – PODXL, MUC16 and CD44 
It is vital to distinguish between structures that only interact with selectins in vitro 
and the functional selectin ligands that interact with selectins selectively and with high 
affinity in vivo and whose depletion suppresses selectin-mediated binding.  Our lab has 
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recently identified podocalyxin (PODXL), mucin 16 (MUC16) and CD44 as functional 
selectin ligands in pancreatic and colon carcinoma (42, 52, 53).   
PODXL is a transmembrane glycoprotein that belongs to the CD34 family of 
proteins.  It was originally found in the kidney where it is an integral component of 
glomerural podocytes (54).  It is a transmembrane protein with a molecular weight of 49 
kDa, however due to extensive O-linked glycosylation the observed molecular weight is 
approximately 140 kDa (55).  The PODXL molecule possesses a short cytoplasmic tail 
on the C-terminal, a single pass transmembrane domain, a short juxtamembrane stalk and 
cysteine-containing globular domain, and a longer extracellular mucin-like domain, 
which is heavily glycosylated.  
While PODXL is expressed in kidney cells, recently it has been found to be 
present in the developing embryo and highly expressed in some tumor types. Clinically, 
PODXL expression is associated with highly aggressive tumors and poor prognosis in 
several cancers (56) including invasive colorectal cancer (57); it has also been identified 
as  a diagnostic marker for pancreatic ductal adenocarcinomas originating in 
gastrointestinal and bile ducts (58).  Increased levels of PODXL in tumor cells have also 
been associated with increased invasion and migration (5) which is thought to result from 
the activation of RhoA though direct binding with erzin (59).  However, work in our lab 
has found this relationship to be more complicated in pancreatic cancer cells with 
endogenously express PODXL.  PODXL has also been identified as a major functional 
ligand of E-selectin that is expressed on pancreatic tumor cells (52, 53). 
MUC16, also known as cancer antigen 125 or CA-125 is a component of cells in 
the respiratory track and epithelia in the female reproductive track. Since MUC16 is a 
 18 
heavily glycosylated protein it acts as a hydrophilic protective barrier on the apical side 
of epithelial cells (60).  MUC16 has also been identified as tumor biomarker for certain 
types of cancer (61).   The MUC16 molecule has a cytoplasmic tail, a transmembrane 
region, extracellular SEA modules and a repeated amino acid sequence, which is high in 
serine, threonine, and proline.  The extracellular region is heavily O-glycosylated and 
therefore has an observed molecular weight between 3000-5000 kDa (62). 
MUC16 is a heavily glycosylated transmembrane protein, which is expressed in 
epithelial ovarian cancer (61, 63) and metastatic pancreatic cancer cells but not in normal 
pancreatic cells (53, 64).  MUC16 binds to mesothelin which may allow tumor cells to 
more easily bind to themselves, and thus increase tumor mass at metastatic sites, and can 
increase cell migration and invasion in pancreatic cancer (62, 65).  MUC16 expression 
strongly correlates with poor survival for both ovarian and pancreatic cancer (62, 66). 
Furthermore MUC16 binds to both E- and L-selectins in shear flow. While both MUC16 
and PODXL serve as functional E-/L-selectin ligands (52, 53), little is known about the 
mechanical properties of these interactions.   
CD44 is expressed on multiple human cell types, and is critical in several cellular 
functions including lymopcyte homing, inflammation and tumor metastasis. CD44 is the 
major cell ligand for hyaluronic acid (HA), fibrin(ogen) and P-selectin (67-69). It is a 
single pass transmembrane protein that undergoes alternate slicing of 20 exons to produce 
several different isoforms. Exons 1-5, 16-18 and 20 are spliced together to from the 
smallest isoform of CD44 known as CD44s (68).  Exons 6-15 can be alternately spliced 
together and inserted in the extracellular domain to form CD44 variant isoforms 
(CD44v).  As a result the unglycosylated form of CD44s has a molecular weight of 37 
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kDa while CD44v has a molecular weight ranging from 100-250 kDa (70).   CD44 has a 
short cytoplasmic tail on the C-terminal, a single pass transmembrane domain, a short 
stalk region, which the variants are inserted, and extracellular hyalauronan-binding 
domain, which can be glycosylated. 
While CD44 has been extensively studied it remains unclear where CD44 
enhances or limits cancer metastasis (71-73).  However, what is known is that CD44 is a 
functional P-selectin ligand and HA ligand (67-69).  HA is a major component of the 
extracellular matrix in most tissue, and is upregulated on the surface of endothelial cells 
activated with an inflammatory stimuli (74, 75). HA binding to CD44 has been indicated 
to increase cancer metastasis and invasion (76, 77) and the HA-CD44 bond has been 
found to enable the slow cell rolling and firm adhesion of cells (67, 78, 79).   
 
1.3 Giant obscurins and cancer 
  
 While it is clear that selectin ligands like PODXL and MUC16 are involved in 
pancreatic cancer metastasis, numerous other tumor suppressors and oncogenes play a 
pivotal role in cancer progression and metastasis.  Interestingly, an analysis of over 13 
thousand genes in breast and colorectal cancer found that out of 189 highly mutated 
genes only TP53 and OBSCN were commonly mutated in both tumor types (80). In a 
separate study involving pancreatic cancer, the oncogenes KRAS and TP53 were found 
to be commonly mutated as expected, however mutations in the OBSCN gene were also 
observed in pancreatic intraepithelial neoplasia and pancreatic ductal adenocarcinoma 
(81, 82). 
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Obscurins are giant cytoskeletal proteins with structural and regulatory roles. At 
first, obscurins were found to play a role in the structural organization and contractile 
activity of striated muscles (83). Obscurins are encoded by the OBSCN gene, which spans 
150 kb on chromosome 1q42 (84, 85).  The gene can undergo alternate splicing which 
results in at least 4 isoforms (84, 85).  Obscurin A is ~720 kDa and contains various 
signaling and adhesion domains, including repetitive immunoglobulin (Ig) and 
fibronectin-III (Fn-III) domains on the amino-terminus and IQ motif, src-homology 3 and 
Rho-guanine nucleotide exchange factor (Rho-GEF) and pleckstrin homology (PH) motif 
interspersed by nonmodular sequences on the carboxyl-terminus (86, 87).  Obscurin B, 
has a mass of ~870 kDa and contains two serine/threonine kinase domains in place of the 
nonmodular sequences (84, 85). Smaller isoforms, which contain the serine/threonine 
kinase domains may also be expressed independently (~55 kDa) or in tandem (~145 kDa) 
(88). 
Most of what is known about obscurins pertains to what is known about their 
function in skeletal and cardiac muscle.  However recently, studies have shown that 
obscurins are present in many cell types and affect several cellular functions.  Obscurin 
isoforms are present in breast, colon, and skin epithelial cells lines, primarily at the cell-
cell junctions, the golgi, the nucleus, and the plasma membrane (89).   Mutant forms of 
the obscurin protein were found in solid tumors, indicating that the loss of obscurin may 
play a role in cancer formation and progression (80, 90). 
Recent studies show that in normal breast epithelial cells, obscurins were highly 
expressed and distributed at cell-cell junctions, (89), however obscurins are markedly 
decreased in breast cancer cell lines and late stage breast cancer biopsies (89, 91).  
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Further, the depletion of giant obscurins from breast epithelial cells is correlated with 
increased apoptotic resistance (89), adherence junctions disruption leading to epithelial-
to-mesenchymal transition (EMT), increased tumorigenicity, microtentacle formation, 
and metastasis (91, 92).    
Interestingly because giant obscurins A and B contain several critical binding 
domains they were found to affect multiple cellular processes resulting in increased cell 
migration and tumor formation in vivo.   The PH domain of obscurin binds to the p85 
regulatory subunit of PI3K in breast epithelial cells leading to increased cell migration 
and EMT (93). Further, the loss of obscurin, and consequently the loss of the obscurin-
rhoGEF domain has been found to reduce levels of active RhoA in breast epithelial cell 
lines.  Decreases in RhoA activity can affect many cellular processes including cell 
migration, actin contractility and microtubule dynamics (94-96) as well as drive tumor 
cell migration and invasion (97). Further, because myosin II is a downstream effector of 
the RhoA/ROCK pathway and myosin II activity promotes tyrosine-phosphorylation of 
paxillin, alterations to RhoA activity can affect formation of focal adhesions (98, 99).   
While these studies have been explored in breast epithelial cell lines, the role of 
giant obscurins in pancreatic cancer has gone unexplored. While mutations in the OBSCN 
gene have been associated with pancreatic ductal adenocarcinoma (81, 82) little is known 
about how giant obscurins affect the growth and migration of pancreatic cells in ways 
that are relevant to the metastatic process. However, given that giant obscurin has 
numerous binding domains, the effect of obscurin depletion in other cancers, and its 
implications in pancreatic cancer we look to comprehensively evaluate the loss of 
obscurin from pancreatic cell lines in this work (Chapter 5).  
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1.4 Cancer metastasis treatments and hurtles 
 
As mentioned previously 90% of deaths related to cancer are from the resulting 
metastasis and not the primary tumor; however, little attention has been paid to 
developing antimetastasis drugs due to several significant hurtles.  Most chemotherapy 
treatments focus on primary tumors and currently only several antimetastatic drugs have 
been developed and licensed (100).  However most do not show clinically beneficial 
results and therefore any breakthrough in cancer metastasis treatment will lead to 
considerable improvements in therapy and patient outcome (101).   
 Currently there are two types of FDA licensed or internationally available types of 
drugs that have been developed to treat cancer metastasis (102-104).  They are anti-
vascular/anti-angiogenesis drugs and matrix metalloproteinase (MMP) inhibitors (103, 
104).  Unfortunately, due to minimal survival benefits for patients and indiscriminant 
molecular inhibitions that result in side effects, these drugs are not succeeding clinically 
(100).  As a result, these drugs, with the exception of some antibodies offer no 
therapeutic benefits.  As we established earlier the metastatic process is complicated and 
long, and targeting angiogenesis or MMPs (cell invasion) targets only a small portion of 
this process. Finding new targets and delivery methods are critically important to 
developing new drugs, which can decrease metastasis and increase patient survival in a 
clinical setting (101). 
One such potential target is sialic acid, which composes the binding interface 
between PODXL and MUC16 and the lectin domain of selectins.   Sialic acid plays a role 
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in the cell binding pertinent to cancer metastasis and can act as a potential target because 
metastatic cell lines express higher levels of sialyl glycoproteins and glycolipids (100).  
In fact, patient tumors with higher levels sialyl Lewis x or a antigens are linked with poor 
prognosis.  Other potential targets are cell-signal inhibitors, TGF-β inhibitors, cell 
adhesion molecules and cell motility inhibitors (105, 106).  While these targets and/or 
inhibitors have potential, they have not yet been licensed. 
 Both small molecules and antibodies are currently being developed to treat the 
various components of cancer metastasis.  Small molecule drugs can be designed to 
restore the function or expression of a metastasis suppressor protein.  Drugs affecting 
NM23, E-cadherin, TGF-β and NDRG1 are undergoing clinical trials (105).  Monoclonal 
antibodies are also an attractive option.  Antibodies can be targeted to the sialic acid 
antigen, to block the rolling and adhesion of cancer cells in circulation.  Furthermore 
antibodies binding to c-Met, TGF-β, MKK4 have already developed and are in preclinical 
trials.  Interestingly preclinical results have shown that antibodies against TGF-β have a 
weak effect on primary tumor growth but strongly suppress cancer metastasis (107).  In 
general if the target is considered specific, then antibodies are thought to be a very 




1.5 Monobodies an antibody alternative 
 
One possible alternative to antibodies are antibody mimetic scaffold proteins like 
monobodies. While monoclonal antibodies have typically been explored as therapeutic 
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biomolecules, they are large in size, require eukaryotic expression for production (108), 
and offer poor thermal stability (109). As a result of these downfalls, synthetically 
designed antibody mimetic proteins based on molecular scaffolds have recently gained 
popularity. While engineering these proteins a conserved protein scaffold acts as a base 
and combinatorial engineering techniques are utilized to select for high affinity binding, 
conformational stability or any relevant parameter (110, 111). As a result, engineered 
protein scaffolds have been used as both therapeutics (112) and diagnostics (113).   
One such antibody mimetic protein is the monobody which is derived from the 
tenth fibronectin III domain (FNfn10) scaffold (114, 115). Similar to the immunoglobulin 
complementarity determining region, this ~94 amino acid peptide contains a β-sheet 
backbone or scaffold and three commonly modified loop domains (114, 115). The three 
loops are diversified using phage or yeast display combinatorial libraries in order to 
produce proteins known as monobodies, with high binding affinities (116-118) and the 
capability to bind to numerous targets such as small ubiquitin-related modifiers (SUMO) 
(119), maltose-binding protein (MBP) (116, 117), and fyn kinase (120). Monobodies 
offer similar binding affinity to antibodies with several advantages including the absence 
of disulfide bonds, ease of production in bacterial systems (114, 121), and high thermal 
stability (122).  These are just some of the reasons why monobodies have become 
attractive alternatives to antibodies as therapeutic biomolecules. 
Recently, monobodies have been designed to act as potential cancer treatments.  
Monobody NS1 was engineered to bind to RAS proteins and inactivate the RAF dimer, 
which in turn was indicated to lead to changes in cell cycle progression (123).  
Additionally, monobodies have been designed to bind to the Src homology 2 domain at 
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the phosphotyosine-binding site effectively inhibiting Bcr-Abl kinase activity resulting in 
the cell death of chronic leukemia cell lines in vitro (124).  Because of their thermal 
stability and small size, monobodies have considerable potential as a cancer therapy.   
However, to this day monobodies have not been engineered as a treatment for 
cancer metastasis.  Therefore, a better understanding of monobody interactions with their 
ligands will allow for improved monobody design and hopefully the design of 
monobodies to target metastatic antigens such as PODXL and MUC16. Furthermore, 
with the growth of structural databases and increased computing speeds structure-based 
design of therapeutic molecules is becoming increasingly viable and important (125, 
126). With an increased interest in the development of scaffold based mimetic proteins, 
an understanding of monobody-ligand interaction will lead to the creation of better-











CALCULATIONS AND MODELS 
 
The following section will detail some of the calculations, models and assumptions used to 
complete this work, specifically the calculations and flow-based adhesion models utilized in 
Chapters 3 and 4. 
 
2.1 Bell model for determining single molecule force spectroscopy kinetic 
parameters 
 
The first expression on force dependence on bond lifetime was proposed by GI Bell 
is seminal 1978 paper (127).   
 
𝑘𝑟(𝑓) = 𝑘𝑟0exp (
𝑟𝐨𝑓
𝑘𝐵𝑇
)                                   Equation 2.1.1 
 
In this equation 𝑘𝑟(𝑓) is the reverse reaction rate or dissociation constant as a 
function of force.  𝑘𝑟0 is the dissociation constant in the absence of an applied force.   𝑓 is 
the applied force per bond.  𝑟𝐨 is a parameter that describes how strongly the reaction rate 
changes with force, having units of length. Finally 𝑘𝐵𝑇 is the Boltzmann constant times 
the absolute temperature (127, 128).  
When using the AFM to measure single bond unbinding the cantilever is retracted 
at a constant velocity and therefore ∆𝑥/∆𝑡 is constant.  Neglecting the deformability of 
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 where 𝑘𝑓 is the spring constant of 
the cantilever.  Because the mechanical loading is slow compared to thermal impulses the 
probability of bond rupture is represented by a first order kinetic process, with a 
dissociation rate that is time dependent (129). Therefore for a small time interval (t, t + 
dt) the probability of bond rupture is expressed by the following equation: 
 
𝑝(𝑡, 𝑓) = 𝑘𝑟(𝑓)exp �−∫ 𝑘𝑟(𝑓(𝑡′))𝑑
𝑡
0 𝑡
′�                   Equation 2.1.2 
 
 The first term is the probability of bond rupture for a short time interval (dt), 
while the second term represents the probability of the bond to survive until time t.  
When the time is such that the 𝑓 = 𝑓𝑐𝑟𝑖𝑡 , and the bond is about to rupture.  This 
corresponds to a peak in the probability distribution where 𝜕𝑝
𝜕𝑓
= 0.  If we assume a linear 





ln𝑘𝑟(𝑓)� 𝑓 = 𝑓𝑐𝑟𝑖𝑡                   Equation 2.1.3 
 
By substituting the Bell model (Equation 2.1.1) into the above equation and 








ln 𝑟𝑓                          Equation 2.1.4 
 
Therefore the relationship between the log of the loading rate and the rupture force is 









�                   Equation 2.1.5 
 
By plotting the natural log of the loading rate (𝑟𝑓) against the rupture force 𝑓𝑐𝑟𝑖𝑡 
the slope and y-intercept are as seen above.  Therefore the reactive compliance (𝑥𝛃) and 
unstressed dissociation constant (𝑘𝑜𝑓𝑓0 ) can easily be found. These parameters will be 










𝑖𝑛𝑡𝑒𝑟𝑐𝑒𝑝𝑡 𝑥𝛃                              Equation 2.1.6 
 
2.2 Flow based determination of bond number and AcMrMlKon – The multibond 
model 
 
To determine the 2D binding affinity (AcMrMlKon) and the number of bonds 
needed to facilitate cell or ligand coated microsphere binding we must first determine the 
dissociation constant in the presence of shear flow for a slip bond (𝑘𝑜𝑓𝑓).  The following 
equation is based on the bell model and is used to determine the 𝑘𝑜𝑓𝑓 in the presence of 
shear flow for a single bond interaction (50). 
 
𝑘𝑜𝑓𝑓 = 𝑘𝑜𝑓𝑓0 exp (
𝑥𝛃𝑓
𝑘𝐵𝑇
)                                  Equation 2.2.1 
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In the above equation, 𝑘𝑜𝑓𝑓0  is the dissociation constant in the absence of force as 
determined above, 𝑥𝛃 is the reactive compliance as determined above, f is the force on the 
cell, and 𝑘𝐵𝑇 is the Boltzmann constant times the absolute temperature.  However, cell 
binding/unbinding may be facilitated by additional bonds, especially in selectin-mediated 
binding and therefore the equation is modified to incorporate multiple bonds, which 
break either at once (Equation 2.2.2) or in a stepwise fashion (Equation 2.2.3). 
 
 𝑘𝑜𝑓𝑓,𝑛 = 𝑘𝑜𝑓𝑓0 exp (
𝑥𝛃𝑓
𝑛𝑘𝐵𝑇
)                                Equation 2.2.2 
 
The dissociation constant in the presence of force for multiple breaking bonds is 
(𝑘𝑜𝑓𝑓,𝑛) is the same as what we established in Equation 2.2.1 with the applied force on 
the cell divided by the number of bonds (n) that are formed.  In the second case, bonds 
break in a stepwise fashion such that the force is distributed amongst the remaining 
bonds.  The cell will dissociate from the surface when the last bond has broken.  
Therefore the bond lifetime is: 
 




𝑖=1                    Equation 2.2.3 
 

















                         Equation 2.2.4 
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Now that we have determined the dissociation constant in the presence of 
hydrodynamic force we can use these values in conjunction with an analytical model 
developed by Cheung and Konstantopoulos to determine the 2D kinetics of cell binding 
in shear flow (50). First the probability of the cell forming i-number bonds to a substrate 
mediated through a constant number of receptor and ligand bonds is determined.  The 
probability vector is: 
 
𝑃𝑜 ,  𝑃1,𝑃2,𝑃3, …  𝑃𝑖 … 𝑃𝐴𝑐𝑀𝑚𝑖𝑛 ,                               Equation 2.2.5 
 
Here 𝑀𝑚𝑖𝑛 is defined as the minimal site density of either receptor molecules (Mr) 
or ligand molecules (Ml) as this number will dictate the maximum number of bonds that 
can be formed between the cell and the substrate.  Pi is the probability of i-bonds forming 
with i ranging from 0 to 𝐴𝑐𝑀𝑚𝑖𝑛 with 𝐴𝑐 being the area of contact between the cell and 
substrate. Assuming a one-step kinetic system with a receptor (R) binding to its ligand 
(L) to form a bond (B) the interaction will take the form of the following equation. 
 




𝐵                                           Equation 2.2.6 
 
Here kon is the on-rate and is koff is the dissociation constant of the unstressed 
bond. The rate of change of the probability of bonds forming is governed by the 





= 𝑘𝑜𝑓𝑓𝑃𝑖+1(𝑖 + 1) − �
𝑘𝑜𝑛
𝐴𝑐
(𝐴𝑐𝑚𝑟 − 𝑖)(𝐴𝑐𝑚𝑙 − 𝑖) + 𝑖𝑘𝑜𝑓𝑓�𝑃𝑖        
                              + 𝑘𝑜𝑛
𝐴𝑐
{𝐴𝑐𝑚𝑟 − (𝑖 − 1)}{𝐴𝑐𝑚𝑙 − (𝑖 − 1)}𝑃𝑖−1              Equation 2.2.7 
 
This equation represents the change in the probability of forming i number bonds 
over some time t. Therefore, Pi is the probability of having i number bonds.  The first left 
hand term is the probability of (i+1) bonds losing a bonding in the span of time t.  The 
second term is the probability of i bonds losing or gaining a bond in time t while the third 
term is the probability of (i-1) gaining a bond in time t. If we assume the small number of 
bonds formed will have no affect on the available number of receptors and ligands 
available for binding we can make several simplifying assumptions.  In this regard, we 
can neglect the i and (i-1) in the terms (𝐴𝑐𝑚𝑟 − 𝑖) and (𝐴𝑐𝑚𝑟 − (𝑖 − 1)).  Solving for Pi, 






exp (−〈𝑖〉)                                Equation 2.2.8 
 






(1 − exp�−𝑘𝑜𝑓𝑓,𝑛𝑡�)                Equation 2.2.9 
 
Here, t is the contact time between the ligand and receptors.  For the experiments 
discussed in Chapters 3 and 4, this time can be approximated to be the time the cell or 
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microsphere spends as it passes over the ligand coated glass surface.  This approximation 
is valid given the height of the flow chamber ~22.5 microns, which allows flowing cells 
to easily contact the ligand-coated surface (50).  Given this we can define the contact 
time as x/Ud, or the length of each ligand coated patch divided by the hydrodynamic cell 
velocity. Therefore we can approximate the probability of cells binding (NB/NT) to the 






𝑖=𝑛 = 1 − ∑ 𝑃𝑖(𝑥)
𝑛−1
𝑖=0                  Equation 2.2.10 
 
By knowing the off-rate, which can be determined through single molecule for 
spectroscopy, the force on the cell which has been reported in literature for cells and 
microspheres (131) and the experimentally observed fraction of binding cells for each 
ligand patch length, the number of bonds needed to facilitate binding (i) and the 2D 
binding on rate (𝐴𝑐𝑚𝑟𝑚𝑙𝑘𝑜𝑛) can be calculated.   These parameters are calculated by 
minimizing the sum of the squares of the residual for (NB/NT) at each patch length and 
optimizing these two variables to accurately represent the experimental data. 
 
2.3 Shear stress calculation 
 
 Determining the shear stress at the binding interface is critically important to 
ensure that shear stresses are maintained in a range that is physiologically relevant.  To 
determine the wall shear stress several assumptions must be made and they are as 
follows:  The flow in the chamber is laminar. The system is at steady state and the density 
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and viscosity remain constant.  The flow is only in one dimension and the flowchamber 
width and length are much greater than the height.    
 The dimensions of the flow chamber are 2 cm × 500 µm × 20 µm or 2 cm × 1000 
µm × 22.5 µm (length × width × height) and therefore the Reynolds number of flow 
Re<<1.  Given that Re<2000, the flow can be considered laminar.  The system is 
operated with a syringe pump and no changes in cell velocity were noted as they passed 
through the field of view.  The buffer is largely composed of water, because water is a 
non-compressible Newtonian fluid we can assume it is at density and viscosity are 
constant.  Next measurements were recorded at the interior of the device where fluid flow 
is one-dimensional.  Finally both the chamber width and length are much greater than the 
chamber height.   
   Given that our assumptions are justified we can set up our system and solve for 
the shear stress of the binding interface.  To solve this classic transport problem, the 
boundary must be established.  The system can be approximated as parallel plate flow 
system, the fluid velocity is established in the x direction (𝑣𝑥 ), and the velocity the 
bottom wall (y=0) and the top wall (y=h) is equal to zero because of the no slip condition. 
Also we establish that the pressure at both the inlet and outlet are equal to 𝑃𝑜 and 𝑃𝐿.  We 




+ ∇ ∙ (𝑝𝑣) = 0                                    Equation 2.3.1 
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 Here, the velocity of the fluid is 𝑣 and the fluid density is 𝑝.  Expanding the 
equation and considering that the fluid is at steady state and incompressible (∂𝑝
∂t
= 0) and 








= 0                                            Equation 2.3.2 
 
Using the Naviar-Stokes equation we can then solve for the velocity and shear 
stress profiles.  Looking at the x component of flow the Naviar-Stokes equation takes the 
following form. 
 






















� − 𝑝𝑔𝑥  
                       Equation 2.3.3 
 
Here, 𝑔𝑥 is gravity in the x direction. If we acknowledge the assumption that flow 
is only in the x direction, the system is at steady state and apply the result found in 
Equation 2.3.2 then the left side of the equation reduces to zero and the right side reduces 
to the following: 
 





− 𝑝𝑔𝑥                               Equation 2.3.4  
 
Grouping terms and defining a new pressure term P* which incorporates the 
pressure and gravity terms yields the equation: 
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−𝑃∗ = 𝜇 𝜕
2𝑣𝑥
𝜕𝑦2
                                         Equation 2.3.5 
 
 Solving for 𝑣𝑥 and applying the boundary conditions that 𝑣𝑥 = 0 at 𝑥 = 0 and ℎ 





(ℎ𝑦 − 𝑦2)                                    Equation 2.3.6 
 
To cancel out the pressure term we solve for the volumetric flow rate by 
integrating the average velocity by the cross sectional area of the flow chamber.  This 




                                            Equation 2.3.7 
 
In the preceding equation Q is the volumetric flow rate, h is the height of the flow 
chamber and w is the width of the flow chamber.  We can then solve for the shear stress 
at the wall and substitute in Equation 2.3.7 in for P*.  This allows us to calculate shear 









                                        Equation 2.3.9 
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Therefore we can calculate the shear stress at the wall if either the flow rate is 



















DISTINCT KINETIC AND MECHANICAL 
PROPERTIES GOVERN MUCIN 16- AND 
PODOCALYXIN-MEDIATED TUMOR CELL 
ADHESION TO E- AND L-SELECTIN IN 
SHEAR FLOW  
 
Selectin-mediated tumor cell tethering to host cells, such as vascular endothelial 
cells, is a critical step in the process of cancer metastasis.  We recently identified 
sialofucosylated mucin16 (MUC16) and podocalyxin (PODXL) as the major functional 
E- and L-selectin ligands expressed on the surface of metastatic pancreatic cancer cells.  
While the biophysics of leukocyte binding to selectins has been well studied, little is 
known about the mechanics of selectin-mediated adhesion pertinent to cancer metastasis.  
We thus sought to evaluate the critical parameters of selectin-mediated pancreatic tumor 
cell tethering and rolling.  Using force spectroscopy, we characterized the binding 
interactions of MUC16 and PODXL to E- and L-selectin at the single-molecule level.  To 
further analyze the response of these molecular interactions under physiologically 
relevant regimes, we used a microfluidic assay in conjunction with a mathematical model 
to study the biophysics of selectin-ligand binding as a function of fluid shear stress.  We 
demonstrate that both MUC16 and PODXL-E-selectin-mediated interactions are 
mechanically stronger than like L-selectin interactions at the single-molecule level, and 
display a higher binding frequency at all contact times. The single-molecule kinetic and 
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micromechanical properties of selectin-ligand bonds, along with the number of receptor-
ligand bonds needed to initiate tethering, regulate the average velocity of ligand-coated 
microspheres rolling on selectin-coated surfaces in shear flow. Understanding the 
biophysics of selectin-ligand bonds and their responses to physiologically relevant shear 
stresses is vital for developing diagnostic assays and/or preventing the metastatic spread 




E- and L-selectins play a vital role in cell-cell interactions pertinent to cancer 
metastasis.  E-selectin (CD62E) is expressed on activated vascular endothelial cells and is 
thought to promote the tethering and rolling of malignant cells, acting as a critical step for 
their extravasation to the interstitial space and eventual seeding of new metastatic foci 
(31, 132, 133).  L-selectin (CD62L) is constitutively expressed on the surface of 
leukocytes, and promotes the recruitment of leukocytes to the metastasizing tumor 
microenvironment; deficiencies in L-selectin lessen metastatic spread in mice (36, 134).  
Although E- and L-selectins share a similar structure, their binding kinetics and 
distribution differ considerably leading to distinct roles in cancer metastasis.  At the lectin 
domain, selectins recognize sialofucosylated oligosaccharides such as sialyl-Lewis x 
(sLex) and its isomer sialyl-Lewis a (sLea) on interacting cells (30-33).  Notably, sLex is 
absent from normal pancreas tissue (34, 35), but its expression is observed in pancreatic 
ductal adenocarcinoma and high-grade pancreatic intraepithelial neoplasia lesions (34).  
Because the binding affinity of selectins for monocovalent sLex/a is low, it is vital to 
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distinguish between structures that only interact with selectins in vitro and the functional 
selectin ligands (36) that interact with selectins selectively and with high affinity in vivo 
and whose depletion suppresses selectin-dependent binding.  We recently identified 
sialofucosylated mucin 16 (MUC16) and podocalyxin (PODXL) as the major functional 
E- and L-selectin ligands expressed on the surface of metastatic pancreatic cancer cells 
(52, 53). 
PODXL is a transmembrane glycoprotein that belongs to the CD34 family of 
proteins.  Clinically, PODXL expression is associated with highly aggressive tumors and 
poor prognosis in several cancers (56) including invasive colorectal cancer (57); it has 
also been identified as  a diagnostic marker for pancreatic ductal adenocarcinomas 
originating in gastrointestinal and bile ducts (58).  MUC16 is a heavily glycosylated 
transmembrane protein, which is expressed in epithelial ovarian cancer (61, 63) and 
metastatic pancreatic cancer cells but not in normal pancreatic cells (53, 64).   Although 
both MUC16 and PODXL serve as functional E-/L-selectin ligands (52, 53), little is 
known about the mechanical properties of these interactions. 
To determine the mechanical properties of the PODXL/MUC16-E-/L-selectin 
interactions, we utilized single-molecule force spectroscopy and microfluidic adhesion 
assays coupled with a mathematical model. Using force spectroscopy, we determined the 
kinetic (𝑘𝑜𝑓𝑓° ) and micromechanical (𝑥𝛽 and tensile strength) properties of receptor-ligand 
interactions at the single-molecule level.  By combining these measurements with 
microfluidic adhesion assays and mathematical modeling, we determined that the 𝑘𝑜𝑓𝑓°  
and tensile strength of these selectin-ligand bonds, along with the number of bonds 
needed to mediate tethering, regulate the velocity of ligand-coated microspheres rolling 
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on selectin-coated surfaces in shear flow. This integrated approach contributes to the 
understanding of how two major pancreatic cancer surface glycoproteins bind to E-/L-
selectins in the presence of hydrodynamic shear, which can lead to the improved 
diagnosis and prevention the metastatic spread of pancreatic cells. 
 
3.2. Materials and Methods 
 
3.2.1 Reagents and monoclonal antibodies 
Anti-human PODXL monoclonal antibody (3D3) was from Santa Cruz 
Biotechnology (Santa Cruz, CA) while the anti-human MUC16 monoclonal antibody 
(M11) was from Dako (Carpinteria, CA). PEI was from Polysciences (Warrington, PA). 
DMPC was from Avanti Polar Lipids (Alabastar, AL). 
 
3.2.2 Cell culture, whole cell lysis and immunoprecipitation 
Human pancreatic adenocarcinoma SW1990 cells were obtained from the 
American Type Culture Collection (Manassas, VA).  SW1990-PODXL KD and 
SW1990-MUC16 KD cells were generated as previously described (52, 53).  All 
SW1990 cells were cultured in DMEM with 10% FBS with 700 µg/ml G418 and 0.5 
µg/ml puromycin added to the PODXL-KD and Mucin16-KD media, respectively (Life 
Technologies, Carlsbad, CA).  SW1990 whole-cell lysate was prepared through treatment 
with 2% Nonidet P-40 followed by centrifugation (52, 53).  PODXL and MUC16 were 
immunopurified using anti-PODXL mAb (3D3) or anti-MUC16 mAb (M11), 
respectively, using protein G agarose beads (Invitrogen) (135-138). 
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3.2.3 Lipid bilayer preparation 
To prepare the solutions used for the lipid bilayer, 8 mg of DMPC (1,2-
dimyristoyl-sn-glycero-3-phosphocholine) was added to 8 mL of lipid buffer B (Tris-
HCl, 50 mM NaCl, 1 mM CaCl2, 0.1% (w/v) Triton X-100) (40, 42, 67, 139).  130 μL of 
either MUC16 or PODXL (concentration 80 μg/ml) was added to 370 μl of the lipid 
solution and resulting solution was incubated at 37°C for 2h.  Following incubation, the 
solution was transferred to 10 kDa MWCO dialysis cassette and dialyzed against 1 L of 
lipid buffer A (20 mM Tris-HCl, 50 mM NaCl, 1 mM CaCl2).  Buffer A was changed 
three times every 12 h.  After 48 h the dialyzed solution was stored at 4°C under nitrogen.  
Glass slides were plasma cleaned for 5 min and then incubated with 100 ppm PEI in 0.5 
mM KNO3 for 20 min.  Following cleaning with DI water and air, slides were placed in a 
vacuum desiccator for at least 2 h before use.  4 μL protein-lipid solution was added to 
the slide for 2 h and the droplet was maintained using a moist towel.  Slides were washed 
3X using Hank’s Balanced Salt Solution (HBSS) before being submerged in HBSS for 
use in experiments.  In select experiments, 10 mM EDTA was added to the HBSS and 
slides were submerged in the EDTA/HBSS solution. 
 
3.2.4 Cantilever functionalization 
Molecular force probe cantilevers from Bruker nano (Camarillo, CA) were 
silanized with 2% (v/v) 3-amino-propyltriethoxysilane in acetone (67, 140).  Cantilevers 
were incubated for 1 h in 30 μg/ml anti-human IgG-Fc mAb (Abcam, Cambridge, MA) in 
D-PBS containing a 50-fold molar excess of the bis(sulfosuccinimidyl) croslinker (BS3; 
Peirce, Rockford, IL) before quenching with Tris buffer.  Cantilevers were then incubated 
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in either 10 μg/ml E-selectin Fc chimera or 10 μg/ml L-selectin Fc chimera (R&D 
systems, Minneapolis, MN) in D-PBS for 2 h at room temperature and blocked with 1% 
BSA in D-PBS to limit nonspecific interactions.  The concentrations of selectins were 
optimized to ensure for a low proportion of binding events in force spectroscopy 
experiments (~20 per 100 contacts).  
 
3.2.5 Single Molecule Force Spectroscopy and Data Acquisition 
Experiments were conducted using a MFP (Asylum Research, Santa Barbara, 
CA).  A triangular cantilever tip with spring constant of 10 pN/nm was calibrated using 
thermal noise amplitude.  The deflection was measured by laser reflection on a split 
photodetector.  The petri-dish containing the lipid bilayer or SW1990 cells was 
positioned directly under the cantilever and adjusted so that each approach generated a 
slight depression force (~5 nN) on the sample before reproach.  The dwell time was set to 
20 msec and the reproach velocity was varied from 5-25 μm/sec.  Rupture forces and 
loading rates were determined from force-distance traces using Igor Pro 4.09 software 
(Wavemetrics, Lake Oswego, OR).  For each receptor-ligand pair the successful rupture 
events were sorted based on the magnitude of the loading rate and ensemble-averaged 
every 50 rupture events.  For each set of binned data the average rupture force and 
loading rate was calculated and fit to the Bell model (67).  Using a least-squares fit to the 
linear region of a graph of rupture force against the logarithm of the loading rate the Bell 
model parameters including the unstressed of- rate 𝑘𝑜𝑓𝑓°  and the reactive compliance 𝑥𝛽 
were tabulated (67). 
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3.2.6 Western blot analysis 
Immunopurified MUC16 or PODXL were separated using a 3-8% Tris-acetate 
SDS-PAGE gel (Bio-Rad, Hercules, CA) under reducing conditions. Proteins were 
transferred to an Immuno-blot PVDF membrane and blocked for 30 min using 
StartingBlock blocking buffer (Thermo Scientific, Waltham, MA).  Membranes were 
stained with either anti-PODXL mAb (3D3) or anti-MUC16 mAb (M11) and rinsed with 
TBS/0.1% Tween 20, before being incubated with the appropriate horseradish peroxidase 
(HRP)-conjugated secondary antibody. SuperSignal West Pico chemiluminescent 
substrate (Life Technologies) was used to develop the immunoblots (52, 53). 
 
3.2.7 Preparation of MUC16 and PODXL coated microspheres 
10µm polystyrene microspheres (2.5x107 microspheres/ml; Polysciences, 
Warrington, PA, USA) were incubated for overnight at 4°C (constant rotation) with 
either PODXL or MUC16 immunopurified from SW1990 cell lysate, diluted to a 
predetermined concentration with binding buffer (0.2M carbonate/bicarbonate buffer 9.2 
pH) as described previously (135-138).  Protein coated microspheres were washed 2X 
with D-PBS and blocked with D-PBS/1% BSA for 60 min at room temperature. 
Microspheres were re-suspended to a concentration of 2x106 microspheres/ml in D-
PBS/0.1% BSA for use in flow-based assays.  MUC16 and PODXL expression on the 
surface of microspheres was determined by flow cytometry (Becton, Dickinson, Franklin 
Lakes, NJ) (135-138).   
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3.2.8 Quantification of MUC16 and PODXL site densities on microspheres and 
SW1990 cells 
The site densities of MUC16 and PODXL on microspheres and SW1990 cells 
were determined by quantitative flow cytometry using a primary anti-MUC16 or anti-
PODXL mAb along with an appropriate FITC-conjugated secondary antibody. 
Background levels were determined by incubating microspheres or cells with properly 
matched isotype controls (53). To correlate fluorescent intensity values with Molecules of 
Equivalent Soluble Fluorochrome (MESF) units, we used the Quantum FITC-5 MESF 
Kit (Bangs Laboratories, Fisher, IN) and established a calibration curve according to the 
manufacturer’s instructions. The MESF values of MUC16- or PODXL-bearing 
microspheres or cells were determined using calibration curve. Next, Simply Cellular 
anti-mouse IgG microspheres (Bangs Laboratories, Fisher, IN) with a known antibody 
binding capacity (ABC) were utilized to determine the fluorescence to protein (F/P) ratio 
of the antibody staining process. The F/P ratios for PODXL and MUC16 staining were 
2.4 and 1.7 FITC to IgG, respectively. The site densities of MUC16 and PODXL on the 
microsphere or cell surface were determined by multiplying the net MESF values (anti-
MUC16 or anti-PODXL mAb minus the matched isotype control) of MUC16 and 
PODXL by the inverse of their respective F/P ratios and dividing by the surface area. The 
surface area of microspheres (10 µm in diameter) is 314 μm2.  The surface area of 
SW1990 was estimated to be 1940 μm2 as determined by tracing suspended circular cells 
and using image J for analysis. Flow cytometry assays were performed using a BD 
FACSCalibur ,and data analysis was performed using BD CellQuest Pro software (BD 
Biosciences, San Jose, CA).   
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3.2.9 Selectin patterning via photoligography 
A pre-cleaned glass slide was spin coated with micropostit photoresist (S1805, 
Rohm and Haas, Philadelphia, PA) and exposed to UV through a patterned chrome mask 
using a previously developed method (51).  To render the patterned slide hydrophobic it 
was sonicated in 0.1% (v/v) octadecyltrichlorosilane (OTS) for 30 min.  The slide was 
then incubated in FITC-conjugated goat anti-human IgG Fc fragment specific antibody 
(Sigma, St. Louis, MO) before being immobilized with either recombinant E- or L-
selectin Fc chimera at concentrations of 5, 10 and 20 μg/ml. As the goat anti-human IgG 
Fc antibody recognizes and binds the Fc epitope of chimeric selectins, it was selected to 
ensure the correct orientation of the E-/L-selectin molecules (51, 140). The photoresist 
was removed using 5% photoresist remover (Rohm and Haas) in acetone before the slide 
was blocked in 1% BSA in D-PBS for at least 1h prior to the running of experiments.  
For rolling velocity experiments, the pre-cleaned glass slide was not patterned. 
3.2.10 Quantification of E- and L-selectin site densities 
E- and L-selectin site densities were determined using a modified Dissociation-
Enhanced Lanthanide Fluorescent Immunoassay (DELFIA) method (51). First, E- and L-
selectin were labeled with europium (Eu+3) using the DELFIA Eu-Labelling Kit 
(PerkinElmer, Waltham, MA) according to the manufacturer’s instructions. Labeled 
proteins were isolated using gel filtration chromatography through a column packed with 
Sephadex G50 (1x10 cm) packed on top of Sepharose 6B (1x9 cm) (both from Sigma). 
50 mM Tris-HCl (pH 7.8) supplemented with 0.9% sodium chloride and 0.05% sodium 
azide served as the elution buffer. 1 ml elution fractions were collected from the columns 
and assayed for protein content using the BCA assay (Thermo Fisher Scientific, 
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Rockford, IL) and Eu+3-chelate fluorescence (Figure 3.8). Fractions testing positive for 
both protein and Eu+3 were pooled and concentrated by centrifugal filtration through 
30,000 MWCO centrifugal filter units (EMD Millipore, Billerica, MA). Concentrated 
proteins were resuspended in DI water. The final protein concentration was measured 
using the BCA assay via NanoDrop (Thermo Fisher). 
Eu3+ conjugated E- or L-selectin was patterned on glass slides using the identical 
methodology as was used in the flow-based adhesion or rolling assays. Site densities of 
E- and L-selectin immobilized on glass surface were assessed by the DELFIA as 
previously described (51).  
 
3.2.11 Microfluidic flow based adhesion device fabrication 
The microfluidic device was fabricated using standard practices using a 
previously established methodology (51).  The dimensions of the device channel used in 
this experiment were 2 cm × 500 µm × 20 µm (length × width × height). 
   
3.2.12 Microfluidic flow-based adhesion and rolling assays 
The microfluidic device was cleaned in ethanol and dried with air before 
assembly on top of the patterned glass slide.  Via a syringe, 0.1% BSA in PBS was 
introduced into the channel and allowed to flow for 3 min until flow equilibrated.   The 
device was placed on a microscope stage and connected with a syringe pump to control 
flow.  The patches were identified via fluorescence visualization using a Nikon TE300 
(Tokyo, Japan).  50 μl of coated microspheres suspended in 0.1% BSA in PBS (2x106 
microspheres/ml) were added to the inlet channel.  The percent binding was determined 
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by dividing the number of interacting microspheres by the total number that passed over 
each patch.  A 20x field of view was used and each perfusion lasted 3 min.  For rolling 
experiments, the microchannel device was assembled to a non-patterned selectin coated 
glass slide, with all other conditions remaining the same.  Rolling velocities were 
determined by dividing the distance the microsphere center of mass traveled by the time 
taken to travel that distance for each condition tested (67, 138).  
 
3.2.13 Mathematical model of 2-D selectin-mediated cell adhesion on micropatches 
The model for selectin binding to 2-D micropatches utilized here was discussed in 
detail previously (51).  All calculations are similar with the exception of koff, which was 
calculated based on the one-pathway model for step-wise bond rupture (50).  The step-
wise model was chosen as binding was found to be mediated by a larger number bonds 
(>5) and simultaneous bond rupture was unlikely.  The kinetic constants used were 
determined via single molecule force spectroscopy. 
 
3.2.14 Statistical analysis  
Data are expressed as means ± S.E.M. or S.D. of at least 3 independent 
experiments.  Statistical significance of differences between means was determined by 
Student’s t test or one-way analysis of variance followed by the either the Tukey or Sidak 





3.3.1 Comparison of the kinetic and micromechanical properties of 
PODXL/MUC16- E-/L-selectin via single-molecule force spectroscopy  
Single-molecule force spectroscopy has been utilized to determine the kinetic 
properties of selectin-ligand bonds in both purified protein-protein and protein-cell 
systems (42, 45, 67).  Incorporation of the purified protein (e.g., MUC16 or PODXL) into 
a lipid bilayer allows for its physiologically relevant orientation and provides a consistent 
binding interface, while eliminating the potential contribution of other selectin ligands 
present on the tumor cell surface (42, 67, 139).  Here, we utilize single-molecule force 
spectroscopy to evaluate the binding strength of MUC16 and PODXL interactions with 
both E- and L-selectin.  In this assay, E- or L- selectin-coated cantilevers were brought in 
contact with immunopurified MUC16 or PODXL inserted in a lipid bilayer for a constant 
dwell time and retracted at designated retraction speeds.  The bond rupture force (tensile 
strength) and loading rates of single binding events were measured over a range of 
retraction velocities (Figure 3.1A) (42, 139).  Dilute E-/L-selectin and ligand 
concentrations on the cantilever tips and lipid bilayer, respectively, were selected to 
ensure single bond formation (42, 139).  To validate the measurements obtained using 
immunopurified MUC16 and PODXL (Figure 3.1B), we also tested E-/L-selectin binding 
to MUC16-expressing (PODXL-knockdown) and PODXL-expressing (MUC16-
knockdown) SW1990 pancreatic cancer cells (52, 53). 
For all interactions tested, the rupture force varied linearly with the natural log of 
the bond-loading rate for nearly the entire loading rate regime (Figure 3.2A, B).  The 
rupture force-loading plots were similar for both immunopurified ligand-selectin pairs 
 49 
(Figure 3.2A, B) and their respective knockdown cell-selectin counter parts.  Mean 
rupture force and rupture force distribution were similar for both protein-protein and cell-
protein systems (e.g., 71 pN for MUC16-E-selectin and 74 pN for MUC16-expressing 
(PODXL-knockdown) SW1990-E-selectin at 1000 pN/s).  Using the least-squares fit to 
the plot of mean rupture force versus the natural log of the loading rate the Bell models 
parameters, unstressed off-rate 𝑘𝑜𝑓𝑓°  (s
-1) and reactive compliance 𝑥𝛽  (nm) were 
determined for all E-/L-selectin interactions.  Both protein-protein and cell-protein 
systems displayed similar kinetic constants for each pair of interactions (Figure 3.3).  
Specifically, the 𝑘𝑜𝑓𝑓°  was nearly identical for all respective pairs, while 𝑥𝛽  was 
moderately lower for the cell-L-selectin system compared to the immunopurified 
MUC16/PODXL-L-selectin system (Figure 3.3), likely due to the minor differences in 
protein glycosylation (136, 137).  This is in line with prior observations showing that 
knockdown of a sialofucosylated protein (e.g., CD44v) increases the extent of 
glycosylation (HECA-452 reactivity) in other glycoproteins (e.g., PODXL) (136, 137).  
Overall, given the similarities in the mechanical properties of both systems, we conclude 
that immunopurified MUC16 and PODXL incorporated bilayers represent a reliable 
system for measuring the interactions between these ligands and E-/L-selectin on the 
single-molecule level. 
The binding frequency for immunopurified MUC16 with E-/L-selectin was 13.6% 
and 17.3%, respectively (Figure 3.2D,E).  While the binding frequency of PODXL-L-
selectin interaction was in the same range at 16.3%, it was notably higher at 23.3% for 
the PODXL-E-selectin pair (Figure 3.2D,E), suggesting a higher on-rate.  The addition of 
EDTA (10 mM) suppressed the binding of all interacting pairs down to basal level 
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(~5%), which is in accordance with the Ca2+ dependence of E- and L-selectin-dependent 
binding (138).  These findings, in conjunction with the minimal binding found with a 
selectin-blank bilayer interaction (data not shown), help verify the specificity of the 
selectin-ligand interactions studied here.   
The MUC16-E-selectin bond displayed a higher rupture force (tensile strength) at 
all loading rates when compared to the MUC16–L-selectin bond (71 pN to 56 pN, 
respectively, at a loading rate of 1000 pN/s) (Figure 3.2A).  The 𝑘𝑜𝑓𝑓°  was found to be 
markedly lower for the MUC16-E-selectin bond (0.26 s-1) than for the MUC16-L-selectin 
bond (0.82 s-1), whereas no significant differences were observed for 𝑥𝛽  (Table 3.1).  
Similarly, the PODXL-E-selectin bond displayed a higher rupture force at all loading 
rates than the PODXL-L-selectin bond (e.g., 69 pN to 62 pN, respectively, at a loading 
rate of 1000 pN/s) (Figure 3.2B).  The 𝑘𝑜𝑓𝑓°  was lower for the PODXL-E-selectin bond 
(0.33 s-1) when compared to the PODXL-L-selectin dissociation (0.49 s-1), while no 
significant difference was found for 𝑥𝛽.  Bell model parameters for all binding pairs were 
validated using Monte Carlo simulations (Figure 3.2C).  Taken together, both MUC16 
and PODXL-E-selectin bonds were determined to be mechanically stronger than the like 
ligand-L-selectin bonds, as evident by the higher tensile strength, lower bond off-rate and 
thus lower susceptibility to rupture.  Although MUC16- and PODXL- E-selectin bonds 
have similar kinetic properties and tensile strengths, the PODXL-L-selectin bond is 
mechanically stronger than the MUC16-L-selectin bond.  
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3.3.2 Single-molecule kinetic and micromechanical properties along with contact 
time and site density dictate MUC16 and PODXL binding to E-/L-selectins under 
flow 
To study the biophysics of MUC16/PODXL-selectin binding under flow, we 
quantified the extent of MUC16- and PODXL- coated microspheres binding to selectins 
as a function of contact time and selectin site density.  Receptor-ligand contact time is 
regulated by the shear stress and length of the selectin-coated surface in the direction of 
flow.  Using photolithography, E- and L-selectin- coated patches with lengths varying 
from 10-160 μm and a width of 10 μm were micropatterned onto a glass slide (51).  The 
patterns were spaced 100 μm apart in the direction of flow and selectin-free regions were 
coated with inert bovine serum albumin (BSA).  Over the course of the 3-min 
experiment, polystyrene microspheres (2x106/ml) coated with either MUC16 or PODXL 
at equivalent site densities (~20 sites/μm2, Figure 3.7) were perfused over the 
micropatches at prescribed wall shear stresses. Of note, this site density is in the same 
range of site densities reported in literature (141-143). The number of ligand-coated 
microspheres interacting on each patch for each experiment was recorded (Nb).  The 
fraction of microspheres binding to each patch (Nb/NT) was determined by dividing the 
interacting microspheres (Nb) by the total number of microspheres to flow over the patch 
(NT).   
Longer selectin patch lengths increased the fraction of interacting microspheres as 
ligand-selectin contact time increases with increasing patch lengths (Figure 3.4).  Along 
these lines, we also observed a consistent increase in the fraction of interacting 
microspheres with decreasing shear stresses and thus correspondingly increasing contact 
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times for all tested interactions (e.g., 4.6%, 6.6% and 12.1% capture efficiency for 
PODXL-E-selectin interaction using 160 μm long patches coated with E-selectin (3000 
sites/µm2) at 2, 1 and 0.5 dyn/cm2, respectively) (Figure 3.4H).  This monotonic 
relationship between capture efficiency and shear stress indicates that the shear threshold 
effect, which is observed in leukocyte tethering (144), does not occur for MUC16- or 
PODXL- selectin interactions in the shear stress regime studied here.   
To investigate the effect of selectin density on capture efficiency, the slides were 
incubated with three concentrations of E- or L-selectin. Using a modified europium assay 
(51), we determined the surface site densities of E- and L-selectin plated at 
concentrations of 5, 10 and 20 μg/ml to be approximately 1800, 3000, and 4800 
sites/μm2, respectively (Figure 3.8).  These site densities are in a range similar to those 
reported in literature (51, 145, 146). Decreasing selectin densities decrease binding for all 
selectin-ligand pairs (e.g., 7.9%, 6.5% and 5.5% for MUC16-E-selectin interaction at 1 
dyn/cm2 using 160 µm long patches) (Figure 3.4A-C).  Ligand-L-selectin binding 
followed a similar trend; however, the fraction of interacting microspheres was 
considerably lower than that for ligand-E-selectin interactions (e.g., 3.3%, 1.9% and 0.9% 
for MUC16-L-selectin interaction at 1 dyn/cm2 using 160 µm patches) (Figure 3.4D-F).  
Taken together, the higher tensile strength and lower 𝑘𝑜𝑓𝑓°  measured by single-molecule 
force spectroscopy predict the enhanced capacity of MUC16 and PODXL to bind to E-
selectin over L-selectin.  
The critical patch length (CPL), defined as the minimum patch length to achieve 
at least 2% binding, increases with increasing shear stress and decreases with increasing 
selectin density for both the MUC16 and PODXL-E-selectin interactions (Table 3.2).  In 
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line with the force spectroscopy data, the critical patch length was longer for ligand-L-
selectin interactions when compared to E-selectin interactions at all shear stresses and 
selectin site densities studied indicating that the weaker L-selectin-mediated binding 
requires lower shear stresses and higher selectin site densities to achieve similar binding.     
 
3.3.3 Multiple bonds are needed for tethering to selectins under flow 
As shear stress increases, multiple selectin-ligand bonds are often needed to 
mediate cell tethering to a surface (50, 51).  To determine the number of 
MUC16/PODXL-selectin bonds required to mediate microsphere tethering in shear flow, 
we fitted the experimental binding data with an analytical multiple bond model (51).  
This model estimates not only the minimum number of bonds needed for tethering but 
also the lumped binding affinity (AcMrMlKon) by simultaneously optimizing the two 
parameters (Figure 3.9).  The model successfully captured the binding profile for all 
selectin-ligand pairs examined (Figure 3.5).  For all cases, the bond number increased 
with increasing shear stress.  However, the minimum bond number varied for the each 
interaction based on their binding profiles.     
According to the model, the minimum bond number for MUC16-coated 
microspheres tethering to E-selectin ranges from 4 to 10 when the shear stress increases 
from 0.5 to 2 dyn/cm2 (Figure 3.5A).  In comparison, the PODXL-E-selectin interaction 
requires one less bond to mediate binding (3-9 bonds) in shear flow (0.5-2 dyn/cm2) 
(Figure 3.5B).  When fewer bonds are required for tethering, such receptor-ligand 
interactions can be initiated at lower contact times, and thus shorter patches, as is the case 
for PODXL-E-selectin relative to MUC16-E-selectin (Figure 3.5A,B).  For both 
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MUC16/PODXL-E-selectin interactions, bonds increase in a shear dependent manner 
(Figure 3.5A,B).  A similar shear-dependent trend was noted for the MUC16/PODXL-L-
selectin interaction (Figure 3.5C,D).  While both MUC16/PODXL-L-selectin interactions 
are mediated by 5 bonds at 0.5 dyn/cm2, fewer bonds are required for PODXL-L-selectin 
than MUC16-L-selectin binding at higher shear stresses (Figure 3.5C,D).  
The lumped affinity term AcMrMlKon considers the interacting contact area (Ac), 
the receptor site density (Mr), the ligand site density (Ml) and the binding affinity (Kon) 
calculated for each interaction.  Given the equivalent values of Mr and Ml for all samples, 
the lumped binding affinity is a direct measure of 2-D binding affinity (AcKon).  The 
model predicts that the PODXL tethering to E-selectin has a ~2 fold higher AcMrMlKon 
than MUC16-E-selectin at shear stresses ranging from 0.5-2 dyn/cm2 (Table 3.3).  This 
result is in line with the increased binding frequency measured for the PODXL-E-selectin 
pair by single-molecule force spectroscopy (Figure 3.2D).  In contrast, the lumped 
affinity is modestly higher for the MUC16-L-selectin than the PODXL-L-selectin pair 
(Table 3.3).  
 
3.3.4 Single-molecule kinetic and micromechanical properties along with bond 
number regulate MUC16 and PODXL-dependent rolling on selectins in shear flow 
Microspheres (2x106/ml) coated with MUC16 or PODXL at equivalent site 
densities (~20 sites/µm2) were perfused over glass slides coated with either E-selectin 
(700 and 1500 sites/µm2) or L-selectin (4800 sites/μm2).  These selectin site densities 
were chosen as the perfused microspheres displayed clear rolling behavior.  Slower 
rolling of ligand-coated microspheres was observed on E-selectin as compared to L-
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selectin substrates (Figure 3.6).  As expected, microspheres rolled more slowly on 
surfaces coated with higher E-selectin density (1500 versus 700 sites/μm2) (Figure 
3.6A,B), as this increases the number of receptors available for binding.  On E-selectin 
substrates, MUC16-coated microspheres rolled significantly slower than PODXL-coated 
microspheres at the higher E-selectin density and at all shear stress tested (Figure 3.6B) 
even though the single-molecule kinetic and micromechanical properties are similar for 
MUC16 and PODXL interactions with E-selectin.  This difference in rolling velocity is 
attributed to the higher number of MUC16 versus PODXL bonds with E-selectin needed 
to support tethering (Figure 3.5A,B).  As such, the same loading rate is distributed among 
more MUC16-E-selectin than PODXL-E-selectin bonds of similar tensile strength for 
individual bonds, thereby supporting slower MUC16-dependent rolling at each prescribed 
shear stress level (Figure 3.6B).  On L-selectin surfaces, both ligands displayed a rather 
transient rolling behavior, with PODXL-coated microspheres rolling significantly slower 
than MUC16-coated microspheres at lower (0.5 and 1 dyn/cm2) but not at the higher 
shear stress of 2 dyn/cm2 (Figure 3.6C).  In the low shear regime (0.5 dyn/cm2), both 
MUC16- and PODXL- coated microspheres tether to L-selectin with an identical bond 
number (Figure 3.5C, D).  Thus, the slower rolling velocity mediated by PODXL is 
attributed to lower 𝑘𝑜𝑓𝑓°  and higher tensile strength of PODXL-L-selectin interaction 
(Table 3.4).  At the higher shear stress level of 2 dyn/cm2, the difference in rolling 
velocity is no longer statistically significant because the differences in the kinetic and 
micromechanical properties of single bonds between PODXL versus MUC16 with E-
selectin are masked by the higher number of MUC16-L-selectin bonds  (Figure 3.5C,D) 




The adhesive interactions between selectins on host cells and their respective 
ligands expressed on tumor cells are known to facilitate tumor cell arrest in the 
microvasculature and promote cancer metastasis (31, 133).  While the biophysics of 
leukocyte binding to selectins has been well studied (43, 131, 147), little is known about 
the mechanics of selectin-mediated tumor cell adhesion.  As circulating tumor cells 
contact the blood vessel wall, selectin-mediated interactions support rolling and facilitate 
subsequent firm adhesion, making them a vital part of the metastatic cascade.  Cell 
adhesion relies on the balance between the adhesive forces of receptor-ligand pairs and 
disruptive hydrodynamic forces (148).  We herein employed force spectroscopy and a 
microfluidic assay in conjunction with a mathematical model to delineate the 
contributions of the single-molecule kinetic and micromechanical properties of selectin-
ligand bonds as well as the number of selectin-ligand bonds to pancreatic cancer cell 
tethering and rolling in shear flow.  A quantitative analysis of receptor-ligand binding 
kinetics of functional selectin ligands expressed by metastatic tumor cells, such as 
MUC16 and PODXL, in the presence of shear flow will further the understanding of the 
metastatic process. 
P-selectin glycoprotein-1 (PSGL-1) expressed by leukocytes is a known ligand of 
P-, E- and L-selectin.  PSGL-1-selectin interactions have been extensively studied using 
diverse biophysical assays (43, 45, 144, 147, 149-152).  Although the unstressed off-rate, 
𝑘𝑜𝑓𝑓° , is similar for PSGL-1, MUC16 and PODXL binding to E-selectin, the PSGL1-E-
selectin bond is markedly stronger than MUC16-, PODXL- E-selectin bonds, as 
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evidenced by its lower reactive compliance, 𝑥𝛽, and higher tensile strength (Table 3.4) 
(140).  Similarly, the PSGL-1-L-selectin bond displays a lower reactive compliance and 
higher rupture force than MUC16-, PODXL- L-selectin bonds (Table 3.4).  As expected, 
the single-molecule bond of E- or L-selectin with monovalent sLex is markedly weaker 
than all aforementioned respective ligand-selectin pairs (Table 3.4) (153).    
Cell binding to a substrate occurs when an individual bond or a cluster of bonds 
are formed under flow that are capable of withstanding the dispersive hydrodynamic 
forces, thereby tethering the cell to the surface.  Because the single bonds between 
MUC16 or PODXL with E-selectin are stronger than the respective ones with L-selectin 
(Table 3.1), fewer bonds are required to mediate microsphere tethering to E-selectin than 
L-selectin in shear flow.  As such, the binding frequency of MUC16- or PODXL- coated 
microspheres is higher for E-selectin than L-selectin at equivalent site densities and shear 
stresses.  Along these lines, the critical patch length is lower for E-selectin than L-
selectin.  It is noteworthy that while MUC16 and PODXL bonds with E-selectin have 
similar tensile strengths, a shorter critical patch length is required for the PODXL-E-
selectin interaction.  This is due to the lower number of bonds needed to tether PODXL- 
versus MUC16- coated microspheres to an E-selectin-coated surface (Figure 3.5A,B) 
coupled with its higher affinity (Table 3.3).  Also, the lower number of bonds required to 
mediate tethering of PSGL-1-expressing cells to L-selectin coupled with its higher tensile 
strength relative to MUC16- or PODXL-L-selectin bond can help explain the markedly 
higher binding frequency of PSGL-1-expressing cells to L-selectin micropatches (51).   
A plateau in the extent of PODXL- and MUC16- dependent tethering to E-
selectin is observed for patch lengths longer than 40 and 80 μm, respectively, where a 
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further increase in patch length no longer increases binding.  The plateau initiation point 
was found to directly relate to the critical patch length and the apparent multiple bond 
off-rate in the presence of force (koff,n), which considers the unstressed off-rate and 
reactive compliance of the single bond (𝑘𝑜𝑓𝑓°  and 𝑥𝛽) as well as the number of bonds 
formed (n), and the hydrodynamic force on the microsphere (f) (50).  As shown in Eqn. 1, 
we assumed that at the initiation of microsphere tethering, the hydrodynamic force is 
distributed evenly among every bond, and when n-bonds break serially they do so in a 
stepwise fashion such that the force is redistributed among the remaining bond(s).   
 















                     Equation 3.4.1 
  
               The microsphere is assumed to dissociate when all bonds have ruptured, and 
interaction time is calculated by summing the total time needed to dissociate all bonds.  
Here, higher values for the apparent koff,n can result from either decreased bond strength 
or the formation of fewer bonds.  In the case of E-selectin binding, single-bond tensile 
strength is similar for both PODXL and MUC16, and the faster plateauing of the 
PODXL-E-selectin interaction results from the lower bond number required for tethering.   
Several studies have reported slower rolling on E-selectin versus L-selectin due to 
the lower unstressed off-rate 𝑘𝑜𝑓𝑓°  associated with E-selectin binding (150, 154).  We also 
see this trend; however, it appears that the number of bonds needed for adhesion in shear 
flow also plays an important role in regulating the rolling velocities of MUC16- and 
PODXL- coated microspheres on E- and L-selectin.  Although the 𝑘𝑜𝑓𝑓°  of single bonds 
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between MUC16 and PODXL with E-selectin are similar, we observed significant 
differences in their respective rolling velocities.  As determined by fitting the multi-bond 
model to the experimental data, an additional bond is needed to initiate MUC16-E-
selectin compared to PODXL-E-selectin binding (Figure 3.5A, B).  As such, the apparent 
koff,n is lower for MUC16-E-selectin at all shear stress levels.  If we consider microsphere 
rolling to consist of two steps: (i) the microsphere moving either at the hydrodynamic 
velocity (V=Ud) or (ii) it is bound (with V=0), this result makes sense.  A larger number 
of bonds must be broken to release the microsphere from the surface; the presence of 
more bonds allows the microsphere to spend more time in the bound state, thereby 
slowing the rolling velocity provided that the on-rate is significantly fast.  This behavior 
is also noted for L-selectin binding where at 0.5 dyn/cm2 both MUC16- and PODXL- 
coated microspheres require 5 bonds for binding, and rolling is 𝑘𝑜𝑓𝑓°  dependent.  At the 
shear stress level of 2 dyn/cm2, the increased number of bonds needed for MUC16-L-
selectin tethering acts as a natural break, slowing its rolling to similar levels to those of 
PODXL-L-selectin indicating that bond clusters may play a critical role in cell rolling 
stability (155, 156).  Differences in rolling velocities between E- and L-selectin pairs 
likely also result from differences in bond tensile strength that has been reported to 
influence rolling (45, 140).  Therefore, the interplay of the tensile strength, 𝑘𝑜𝑓𝑓° , and 
bond number regulates the rolling velocities of MUC16- and PODXL- coated 
microspheres on E- and L-selectins. In addition to these parameters, cell deformation 
affects rolling in shear flow (157). 
MUC16 and PODXL have been identified as functional E- and L-selectins ligands 
that are overexpressed in metastatic pancreatic cancer cells (52, 53).  In this study, we 
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utilized the combination of single- molecule bond characterization and microfluidic 
assays coupled to mathematical model to characterize ligand-dependent tethering and 
rolling in physiologically relevant flow conditions.  We found that the single-molecule 
kinetic and micromechanical properties and the number of bonds needed for tethering 
predict the binding interactions and rolling of MUC16- and PODXL-coated microspheres 
on E-/L- selectin coated surfaces.  This integrated approach contributes to a better 
understanding of how MUC16 and PODXL bind to E-/L-selectins in the presence of 
hydrodynamic shear, which can lead to improved diagnostic assays and to the prevention 

















3.5 Tables and Figures 
 
Interaction 𝑘𝑜𝑓𝑓°  (𝑠−1) 𝑥𝛽 (nm) 
MUC16–E-selectin 0.26 ± 0.08 0.34 ± 0.02 
MUC16–L-selectin 0.82 ± 0.04 0.36 ± 0.01 
PODXL–E-selectin 0.33 ± 0.05 0.33 ± 0.01 
PODXL–L-selectin 0.49 ± 0.04 0.35 ± 0.02 
 
Table 3. 1 Bell model parameters for PODXL and MUC16–E/L-selectin 
interactions.  
 Bell model parameters were determined using a least-squares fit to the plot of linear region of 

















  MUC16-E-selectin and (L-selectin) PODXL-E-selectin and (L-selectin) 
 
   Selectin density (sites/μm2) 
Shear tress (dyn cm-2) 1800 3000 4800 1800 3000 4800 
2 120 (NB) 80 (NB) 80 (NB)   160 (NB) 40 (NB) 40 (NB) 
1 40 (NB) 40 (NB) 20 (80)   40 (NB)  20 (NB)  20 (80)  
0.5 40 (80)  20 (80)  10 (40)   10 (80)  10 (80)  10 (40)  
 
Table 3. 2 Critical patch length of PODXL and MUC16–E/L-selectin interactions. 
NB indicates no binding. The critical patch length of selectin is defined as the minimum 
patch length required for MUC16 or PODXL coated microshperes to initiate 2% binding 
at a given shear stress and selectin site density. The numbers inside the parentheses 












Binding pair             AcMrMlKon (s-1) 
 
       Shear stress (dyn/cm2) 
  0.5  1    2 
MUC16-E-selectin 10.1   42.6 151.7 
MUC16-L-selectin 16.1   47.1 124.8 
PODXL-E-selectin 26.3 105.1 300.2 
PODXL-L-selectin   8.6   38.1 115.7 
 
Table 3. 3 AcMrMlKon for MUC16- and PODXL- coated microspheres tethering on 
E-/L-selectin coated surface as predicted by the multi-bond model. 
The multi-bond model was fitted to the experimental data and optimized for both the 
number of bonds needed to achieve tethering and lumped affinity (AcMrMlKon) for 
MUC16- and PODXL-coated microspheres tethering to 3000 sites/μm2 E- or L-selectin 


















Binding pair 𝑘𝑜𝑓𝑓°  (𝑠−1) 𝑥𝛽 (nm)  
Rupture force @1000 pN/s 
(pN) 
MUC16–E-selectin  0.26 ± 0.08 0.34 ± 0.02   71 
PODXL–E-selectin  0.33 ± 0.05 0.33 ± 0.01   69 
PMN (PSGL-1)–E-selectin*  0.31 ± 0.06 0.12 ± 0.01 156 
sLeX–E-selectin§  0.30 0.5   48 
MUC16–L-selectin 0.82 ± 0.04 0.36 ± 0.01   56 
PODXL–L-selectin 0.49 ± 0.04 0.35 ± 0.02   62 
PMN (PSGL-1)–L-selectin* 0.85 ± 0.10 0.17 ± 0.01   93 
sLeX–L-selectin§ 6 0.45   29 
 
Table 3. 4 Comparison of the binding parameters for ligand - E/L-selectin pairs. 
*Data presented from Hanley et al. [42] with Bell model kinetic constants for linear 
region (100-10,000 pN/s) and rupture forces estimated from provided figures. §Data 
presented from Zhang et al. [43] with Bell model kinetic constants for linear region (100-
10,000 pN/s) and rupture forces estimated from provided figures. Where appropriate, data 














Figure 3. 1 Single molecule force spectroscopy Force Displacement traces and 
western blots image.    
(A) Typical force-displacement traces acquired from force spectroscopy experiments 
where an E/L-selectin fuctionalized cantilever was brought in contact hundreds of times 
with either immunopurified PODXL or MUC16 incorporated in a lipid vesicle deposited 
on a PEI-cushioned glass slide.  Red arrows indicate rupture events with the loading rate 
estimated based on the slope of the linear ramping in force immediately before bond 
rupture.  (B) MUC16 and PODXL were immunopurified from SW1990 cells and were 
subjected to SDS-PAGE under reducing conditions followed by immunoblotting with an 





Figure 3. 2 Micromechanical properties of immunopurified MUC16/PODXL 
binding to E/L-selectin using single molecule force spectroscopy.   
Rupture force as a function of loading rate for immunopurified (A) MUC16-E/L-selectin 
and (B) PODXL-E/L-selectin interaction.  Data represent the mean ± S.E.M. of 3-4 
experiments run for each binding pair.  Least-squares fitting of the Bell model were used 
to determine kinetic parameters.  (C) Rupture force distribution was obtained both 
experimentally (bars) and computationally through Monte-Carlo simulations (line) based 
on Bell model kinetic parameters for immunopurified PODXL-E-selectin binding.  (D-E) 
Frequency of binding between immunopurified MUC16 and PODXL with E-selectin and 
L-selectin in the absence and presence of the divalent cation chelator EDTA.  Tips coated 
with 10 μg/ml E-/L-selectin were brought in contact with either MUC16 or PODXL 
incorporated lipid bilayers.  The frequency of binding was measured in with and without 
the presence of 10 mM EDTA. Data represent the mean ± S.E.M. of 3-4 independent 
experiments. *P< 0.05.   
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Figure 3. 3 Bell Model kinetic properties of protein-protein and cell-protein 
interactions.   
(A, C) Unstressed off-rate (s-1) and (B, D) reactive compliance (nm) for MUC16 and 
PODXL interactions with E/L-selectin using a range of retraction velocities (5-25μm/s).  
Data represent mean ± S.D. of 3-5 independent experiments which each had at least 
1,250 approach/retract cycles.  Cantilever tips coated with E/L-selectin were brought in 
contact with immunopurified MUC16 or PODXL incorporated lipid bilayers or MUC16-
expressing (PODXL-KD) or PODXL-expressing (MUC16-KD) SW1990 cells.  *P< 0.05 
with respect to both MUC16-L-selectin and PODXL-KD SW1990-L-selectin in (A).  *P< 
0.05 with respect to both PODXL-L-selectin and MUC16-KD SW1990-L-selectin 
interactions in (C).  *P< 0.05 with respect to the indicated interactions (B, D).   
 68 
 
Figure 3. 4 Fraction of interacting microspheres with E/L-selectin coated patches at 
designated shear stresses.   
Microspheres (2x106/ml) coated with either MUC16 or PODXL at equivalent site 
densities flowed at prescribed shear stresses over glass surfaces containing patches coated 
with three site densities of either E- or L-selectin. The number of MUC16 (A-F) or 
PODXL (G-L) coated microspheres interacting with each patch was counted and 
normalized based on the microsphere flux over each patch.  Data represent the fraction of 







Figure 3. 5 Fitting of the multi-bond model to the experimental data.   
Immunopurified MUC16 (A, C) or PODXL (B, D) coated microspheres flowed over 
glass surfaces patterned with 3000 sites/μm2 E-selectin (A, B) or L-selectin (C, D) coated 
patches of varying lengths.  The multi-bond model was fitted to the experimental data 
(points) and optimized for both AcMrMlKon and n-bonds, with the solid lines representing 





Figure 3.6 Average rolling velocities of MUC16- and PODXL- coated microspheres 
on E/L-selectin.   
Average rolling velocities (μm/s) of microspheres (2x106/ml) coated with either MUC16 
or PODXL at equivalent site densities on immobilized E-selectin (A, B) or L-selectin 
(C).  Data were recorded at prescribed wall shear stresses and represent the mean ± 














Figure 3.7 The multi-bond model determines the number of bonds and lumped 
affinity (Acmrmlkon) needed to mediate PODXL-coated microsphere tethering on E-
selectin in shear flow.  
Fitting of the multi-bond model to experimental data for PODXL-coated microspheres 
interacting with 3000 sites/μm2 E-selectin at 0.5 dyn/cm2 (A) and at 1 dyn/cm2 (C). The 
sum of squares of residual (B) and (D) was calculated by fitting the model to the 
experimental data shown in (A) and (C), respectively. The lumped binding affinity 







Figure 3.8 PODXL and MUC16 site density on microspheres and SW1990 cells as 
determined by quantitative flow cytometry.  
Representative flow cytometric histograms of MUC16 and PODXL on (A) protein-coated 
microspheres and (B) SW1990 pancreatic cancer cells. Microspheres and SW1990 cells 
were stained by indirect single-color immunofluorescence using anti-PODXL or anti-
MUC16 mAbs or their respective isotype control antibodies (purple). Using the Quantum 
FITC-5 MESF Kit in conjunction with Simply Cellular anti-mouse IgG microspheres 
(Bangs Laboratories, Fisher, IN), the site density of MUC16 and PODXL on (C) protein-
coated microspheres and (D) SW1990 cells were calculated. Data represent the mean ± 






Figure 3.9 Determination of E- and L- selectin surface site density.  
(A) E-selectin or (B) L-selectin was conjugated with europium (Eu+3) using the DELFIA 
Eu-Labelling Kit and purified via gel filtration chromatography.  Elution fractions 
positive for both protein (absorbance at 562 nm following BCA assay) and Eu+3 content 
(high time-resolved fluorescence in RFU) were pooled and concentrated.  (C) The 
purified europium-conjugated E- or L-selectin was used to determine the surface site 















E-SELECTIN MEDIATED ROLLING 
INCREASES PANCREATIC TUMOR CELL 
ADHESION TO HYALURONIC ACID 
 
Tumor cell extravasation is a complex process, initiated when cells roll and arrest 
on the vessel wall through the formation of specific bonds. The strength, availability, and 
number of receptor-ligand bonds regulate the rate which tumor cells tether, roll and 
adhere to host cells.  While we have recently explored the mechanics of selectin-mediated 
rolling pertinent to cancer metastasis, little is known regarding how cell rolling on 
selectins affects adhesion to a second protein with differing kinetic properties.  In this 
regard we sought to evaluate the critical parameters of the pancreatic tumor adhesion to 
hyaluronic acid mediated by rolling on E-selectin in physiologically relevant flow. We 
utilized a microfluidic assay and multicomponent protein patterning to evaluate E-
selectin and HA binding as a function of fluid shear stress, contact time and protein 
distance.  We show that tumor cells rolling on E-selectin were ~40X more likely to bind 
to HA than non-rolling cells at both low and high shear stresses. Further, the ligand-E-
selectin interaction initiates adhesion to HA in a twofold manner, both physically slowing 
cells and allowing cells to orient close to the surface and increasing the on rate of 
adhesion. Understanding the critical parameters tumor cell adhesion in physiologically 
relevant shear stresses is vital for production of improved diagnostic assays and to better 




 Metastasis is a multistep process, in which cancer cells migrate from the primary 
tumor to the circulatory system where they extensively interact with the endothelial wall 
before extravasating and colonizing a distal organ. Tumor cell extravasation from the 
vasculature requires cells to first to roll and then arrest on the vessel wall through the 
formation of specific bonds. The probability of cell binding depends on the frequency of 
collision between membrane-bound receptors and endothelial ligands, the strength of 
these bonds and the length of time the cell interacts with the ligand presenting region (51, 
158). 
E-selectin and hyaluronic acid (HA) play a pivotal role in the cell-cell interactions 
that are pertinent to cancer cell rolling and arrest.  E-selectin is expressed on activated 
vascular endothelial cells and promotes the tethering and rolling of malignant cells (31, 
132, 133).  PODXL and MUC16 are the major functional ligands of E-selectin that are 
expressed on pancreatic tumor cells (52, 53) and both MUC16-, PODXL-E-selectin 
bonds have been demonstrated to facilitate rolling interactions with E-selectin at high 
shear stresses, and at low ligand and receptor site densities (158).  HA is a major 
component of the extracellular matrix in most tissue, and is upregulated on the surface of 
endothelial cells activated with an inflammatory stimuli (74, 75). CD44 is expressed on 
Pa03c pancreatic cancer cells (Figure 4.7), is the major cell ligand for hyaluronic acid 
(HA), (67-69) and has been implicated in pancreatic cancer metastasis (159).  HA 
binding to CD44 has been indicated to increase cancer metastasis and invasion (76, 77) 
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and the HA-CD44 bond has been found to enable slow cell rolling (under 5 μm/s) (67, 
78, 79) and in some instances firm adhesion at low shear stresses (78, 79). 
To explore how rolling on E-selectin facilitates pancreatic cell adhesion to HA we 
utilized multicomponent micropatterning, to deliver two proteins in geometrically defined 
patterns on a glass substrate. Multicomponent micropatterning has been utilized to 
measure cell adhesion (160), cell binding in shear flow (161, 162) and to separate 
circulating tumor cells from  leukocytes and other cells types (161, 162).  However 
limitations exist, typically only simple geometries can be patterned with a 
multicomponent system (161, 162), or they rely on chemistry to achieve the desired 
pattern (161). Our system uses a simple flow based coating method (163) to achieve 
geometrically complex patterns in close proximity to one another.  This allowed us to 
pattern both E-selectin and HA, 30 µm apart in complex geometric patterns and observe 
how rolling on E-selectin pancreatic tumor cell adhesion with HA. 
Here we show that rolling on E-selectin promotes pancreatic tumor cell adhesion 
to HA. Rolling cells were ~40X more likely to bind to HA than non-rolling cells and 
where more likely to adhere to HA at higher shear stresses that non-rolling cells.  Rolling 
on E-selectin facilitates binding with HA even at E-selectin patch lengths under 40 μm 
and on HA patches as low as 10 μm. Knockdown of the major E-selectin receptor 
PODXL attenuates rolling on E-selectin but does not decrease the rate of adhesion on HA 
once cells have rolled. This approach uncovers the physical interdependence of these 
bonds and indicates how selectin mediated tumor cell rolling can initiate adhesion with a 
secondary ligand, which can be utilized to improved diagnostic assays and better 
understand the metastatic spread of pancreatic tumor cells. 
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4.2. Materials and Methods 
 
4.2.1. Cell culture 
Human pancreatic adenocarcinoma Pa03c cells were obtained from the American 
Type Culture Collection (Manassas, VA).  Pa03c PODXL-KD cells were generated as 
previously described (52, 53).  All Pa03c cells were cultured in DMEM with 10% FBS 
with 700 µg/ml G418 and 0.5 µg/ml puromycin added to the PODXL-KD and control 
media, respectively (Life Technologies, Carlsbad, CA).  
 
4.2.2 Cell lysate and western blot analysis 
Whole cell lysate of Pa03c cells was generated as previously described (52, 53).  
Lysates were separated by a 3–8% Tris-acetate SDS-PAGE gel. Proteins were then 
transferred to an Immuno-blot PVDF membrane and blocked for 30 min in blocking 
buffer.  Membranes were stained with anti-CD44 mAb (2C5) and rinsed with TBS/0.1% 
Tween 20, before incubation with horseradish peroxidase-conjugated secondary antibody. 
SuperSignal West Pico chemiluminescent substrate was then used to develop the 
immunoblot. 
 
4.2.3 Pattern device fabrication 
The microfluidic device used for patterning glass slides with E-selectin and HA 
was fabricated using standard practices and our previously established methodology (51). 
The PDMS pattern features channels with height 10 μm that open to the triangular 
(bottom) or rectangular (top) regions used to pattern E-selectin and HA respectively 
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(Figure 4.1A).  The triangular (E-selectin) regions have a 200 μm base and 160 μm width 
while the four rectangular regions (HA) have a 10, 40, 80 and 160 μm width and 200 μm 
base.  The triangular and rectangular regions align such that a cell passing over one 
region will pass over the second region in succession. 3mm diameter inlet and outlet 
holes were punched in both the top and bottom channels.  The gap between the two 
regions was set to 30, 60 and 120 μm.      
 
4.2.4 E-selectin and HA patterning  
A pre-cleaned glass slide and the PDMS pattern device were plasma treated for 2 
minutes. Following cleaning the two were adhered together. HA at 50 μg/ml was added 
to the inlet of the top channel and PBS was added to the inlet of the bottom channel.  The 
devices were incubated overnight at 4°C. Next, the HA was removed and replaced with 
PBS.  Concurrently the PBS in the bottom channel was removed and FITC-conjugated 
goat anti-human IgG Fc fragment specific antibody (Sigma, St. Louis, MO) was added to 
the inlet of the bottom channel.  The antibody was removed and washed with PBS before 
adding recombinant E-selectin Fc chimera at a concentration of 10 μg/ml. Following E-
selectin incubation, the PDMS device was then removed, the slide was washed and 
blocked in 1% BSA in D-PBS for at least 1 hour prior to the running of experiments 
 
4.2.5 Microfluidic flow based adhesion device fabrication 
The microfluidic device was fabricated using standard practices using a 
previously established methodology (51).  The dimensions of the device channel used in 
this experiment were 2 cm × 1000 µm × 22.5 µm (length × width × height).   
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4.2.6 Microfluidic flow-based adhesion and rolling assays 
The microfluidic flowchamber was cleaned in ethanol and dried with air before 
assembly on top of the patterned glass slide.  Via a pipette, 0.1% BSA in PBS was 
introduced into the channel and allowed to flow to equilibrate the device.   The device 
was placed on a microscope stage and 100 μl of Pa03c-SC or PODXL-KD cells 
suspended in 0.1% BSA in PBS (1x106 cells/ml) were added to the inlet channel and 
allowed to flow via gravity.  A 10x field of view was used and each perfusion lasted at 
least 3 min.  
 
4.2.7 Data analysis 
To track the cells over the course of the 3 minute video, we utilized the existing 
code package produced by Eric M. Furst from the University of Delaware for cell 
tracking.  We set the maximum cell radii to a value of 21 µm, and the size of a pixel in 
the x and y dimensions to 1.32 and 1.51 µm/pixel, respectively. The output is a matrix of 
cell position and time data which was further processed. We then excluded incomplete 
tracks, which were not bright enough to pass entirely through the frame and clumped 
cells, which enter the frame within 2 radii of one another.  By hand we excluded regions 
of the video which incoming cells contact previously bound cells on the device. 
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4.2.8 Data processing  
Using Matlab we then analyzed the fluorescent images of the patterned surface to 
identify the boundaries of both the E-selectin and HA regions.  The E-selectin region was 
then separated into ten sections of increasing patch length ranging from 10-160 μm.  The 
program then analyzes each cell track with respect to these regions and indicates: the 
binned position of the cell, if the cell binds in either region (rolling or firm adhesion), the 
overall velocity of the cell, and the cell velocity in each region and the hydrodynamic 
velocity of all non-interacting cells.  Interacting cells are identified if they are in a 
binding region (E-selectin or HA) and have an instantaneous velocity less than 50% of 
the bulk cell instantaneous hydrodynamic velocity for at least five frames (.17 seconds).  
Cells adhering to HA were also confirmed via a manual inspection. As a result of this 
process, data can be compiled easily for a large number of cells and different 
combinations of rolling and firm adhesion parameters can be easily analyzed.  
 
4.2.9 Data acquisition validation 
To validate the automated results, all the cells in three selected videos were both 
manually and automatically tracked.  Both of the data sets were run through data 
processing and the results were compared.  Matched cell tracks were then compared 
using the Bland Altman test to compare the two measurement methods.  
 
4.2.10 Mathematical model of 2-D selectin-mediated cell adhesion on micropatches 
The model for selectin binding to 2-D micropatches utilized here was discussed in 
detail previously (51, 158).  The calculations consider all bonds to break simultaneously 
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(50).  The 𝑓 𝜏⁄  was determined to be 689 pN/dyn-cm2 assuming the cell is more like a 
neutrophil than a bead and considering the cell radius of 10um (131).  The kinetic 
constants for the CD44v-HA bond used were 𝑘𝑜𝑓𝑓       °  = .005 s
-1 and 𝑥𝛽  = .59 nm, 
determined via single molecule force spectroscopy in a previous work (67).   
 
 
4.2.11 Statistical analysis  
Data are expressed as means ± S.E.M. or 95% confidence intervals of at least 3 
independent experiments.  Statistical significance of differences between means was 
determined by one-way analysis of variance followed by the either the Tukey or Sidak 





4.3.1 Microfluidic device design and cell tracking 
Experiments were performed with Pa03c pancreatic cancer cells, tracking their 
binding as they encountered patches of E-selectin (rolling) and HA (slow rolling and firm 
adhesion).  In brief using standard microfabrication principles (163-165) we patterned a 
glass slide with E-selectin patches of length 10-160 μm and hyaluronic acid (HA) patches 
with lengths of 10, 40, 80 and 160 μm in geometrically defined regions with a gap 
distance between the two regions of 30, 60 and 120 μm (Figure 4.1 A-C). Using a 
microfluidic chamber, MUC16/PODXL and CD44v expressing metastatic pancreatic 
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cancer cells (Pa03c) were then perfused over the two regions and all cells were tracked 
using a modified code package produced by Eric M. Furst (University of Delaware).  
Using a custom Matlab program, we identified cells as they flowed over the E-selectin, 
gap, and HA regions.  As cells enter the E-selectin region they are separated into ten bins 
corresponding to the average length of E-selectin patch the cells encounter (10-160 μm).  
Next, the gap distance and HA patch length that the cell encounters is also recorded.  For 
example, a cell can pass over the 160 μm E-selectin region, the 30 μm gap and the 40 μm 
HA region.  Each cell track is then analyzed with respect to these regions and the cell 
position, velocity, and binding in either the E-selectin and/or HA regions were identified.  
To confirm the validity of this method used to track cells, our automated tracking 
system was compared against manually tracking cells and no differences cell position or 
cell speed was found for either the E-selectin, or HA regions (Figure 4.8A, C and E). 
Minor differences were found using the Bland-Altman analysis to compare the two 
analysis methodologies (Figure 4.8B, D and F).  Overall given the minor differences of 
these measurements, the similarities of the bulk populations and the similar percent of 
rolling cells determined by both methodologies (Figure 4.8G) we have confidence that 
using the automated tracking is a reliable methodology to track cells in this system.  
   
4.3.2 Cell rolling on E-selectin mediates adhesion to HA 
Pa03c cells were tracked as they passed over the E-selectin region, the gap region 
and HA region respectively. Cells either interacted with E-selectin/HA or passed over 
these regions without binding. Four outcomes were possible, a cell could bind only to 
either the E-selectin or HA regions, to both the E-selectin and HA regions, or to neither 
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of the regions.  Non-binding cells passed over the patches at the hydrodynamic cell 
velocity.  Cells interacting with E-selectin displayed a clear rolling behavior (Figure 
4.1D). The fraction of interacting cells decreased with shear stress and increased with 
longer E-selectin patch lengths due to increased ligand-selectin contact times (Figure 
4.2A). These trends are similar to that of MUC16 of PODXL coated microspheres 
interacting with E-selectin (10 μg/ml) as described in a recent study (158). Cells 
interacting with E-selectin increase their average speed once they entered the gap region 
and the HA region as they began to accelerate to the hydrodynamic velocity (Figure 4.9) 
(166).  
After passing over the E-selectin region and the gap, cells encountered hyaluronic 
acid (HA) patches with lengths of 10, 40 and 160 μm. Binding to HA was prolonged and 
cells did not transiently roll but rather adhered for times ranging from a half a second to 
several minutes. In this region, non-rolling cells bind infrequently with hyaluronic acid 
although binding frequency increases with increasing HA patch lengths (Figure 4.2B).  
Moreover, HA binding frequency increases significantly when cells first roll on E-
selectin (Figure 4.2B). Cells rolling first on E-selectin were ~40x times more likely to 
bind to HA (HA patch length 40 μm, for both the 30 and 60 μm gaps) and the increased 
binding was consistent over all HA patch lengths (Figure 4.2B).  The 120 μm gap was 
large enough to disrupt binding of rolling cells as minimal binding to HA was observed.  
4.3.3 Cell rolling and cell velocity influences Pa03c cell adhesion to HA  
Given the number of cells measured, we were able to assess the binding and 
speeds of pancreatic tumor cells as they passed over and interacted with the E-selectin 
and HA regions. Clear trends are formed for the different binding categories when 
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plotting the gap velocity vs. the hydrodynamic velocity for every cell (Figure 4.3 A and 
B). Non-interacting cells have a gap velocity equal to the hydrodynamic velocity, 
indicating these cells do not slow down in either pattered region as expected (Figure 
4.3B). Non-E-selectin binding yet HA binding cells bind at lower hydrodynamic 
velocities and have a depressed gap velocity when compared to non-interacting cells 
(Figure 4.3B). E-selectin binding and non-HA binding cells were observed at lower 
hydrodynamic velocities and feature a decreased gap velocity compared to non-
interacting cells (Figure 4.3B).  Both E-selectin and HA binding cells have a gap 
velocity/hydrodynamic velocity that is significantly decreased when compared to all 
other binding categories, indicating that these cells slow considerably due to rolling 
before passing over the HA patches.    
We next sought to explore the reasons for increased HA binding of rolling cells.  
For cells that first rolled on E-selectin, the percentage of HA binding increases with 
decreasing patch lengths (Figure 4.4A).  This counterintuitive result makes sense when 
examining the gap velocity of rolling cells per E-selectin patch length.  As the patch 
length increases the cell velocity in the gap region increases (Figure 4.4B) because rolling 
on smaller E-selectin patches must occur immediately before the gap while cells rolling 
on larger patches can break their rolling interaction before the gap and allow the cell to 
increase speed.  Taken together cells which roll on shorter patch lengths of E-selectin 
(>40 μm) can facilitate adhesion to HA and cell speed is a critical determinant of cell 
binding to HA.   
When binning all rolling and non-rolling cells by shear stress and plotting these 
values against the HA binding frequency, it is clear that rolling allows cells to bind to HA 
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more frequently and at higher shear stresses when compared to non-rolling cells (Figure 
4.4C). This is consistent even at higher shear stresses where the HA binding of non-
rolling cells is minimal. Interestingly when plotting HA binding frequency vs. gap 
velocity, rolling cells are still more likely to bind to HA than non-rolling cells (Figure 
4.4D).  This indicates that that act of rolling increases the likelihood of firm adhesion 
compared to non-rolling cell regardless of cell speed in the gap before the HA region.  
Further both non-rolling and rolling cells bind more frequently to HA at lower gap 
velocities again indicating the importance of cell speed in HA binding.   
 
4.3.4 PODXL-KD attenuates rolling on E-selectin but does not affect binding with 
HA once cells have rolled  
We then looked to observe the effect of knocking down the major E-selectin cell 
receptor PODXL on cell rolling on E-selectin and adhesion to HA.  In this regard we 
knocked down PODXL from the surface of Pa03c cells and perfused these cells over the 
E-selectin and HA patches. We found that PODXL-KD Pa03c cells interacting with E-
selectin showed a clear rolling behavior, and that decreased shear stress and longer E-
selectin patch lengths increased the fraction of interacting cells. However, PODXL-KD 
cells interact with E-selectin patches at a lower frequency than control cells at a shear 
stress of .5 dyn/cm2 and E-selectin patch lengths longer than 40 μm (Figure 4.5A). 
Interestingly PODXL-KD cells that first roll on E-selectin, bind to HA at a similar 
frequency as control cells (Fig. B and C).  This is consistent for both the 30 and 60 μm 
gap lengths and indicates that the depletion of PODXL in Pa03c cells primarily impacts 





Determining the biophysics of pancreatic cancer cell membrane receptors and 
their ligands relevant to metastasis is critical as it not only improves the understanding of 
the cell adhesion process but also uncovers critical parameters needed for diagnostic tools 
and devices (167).  In this regard we developed a platform to observe and measure the 
critical parameters in E-selectin mediated cell adhesion to HA in physiologically relevant 
flow conditions.  Our work utilizes multicomponent protein patterning in geometrically 
defined patterns with microfluidic channels to profuse cells over ligand-coated patches 
and measure cell tracks using a custom made cell analysis program.  This allows us to 
measure how cell-ligand interactions with E-selectin influence cell-ligand binding with 
HA using shear stress, ligand patch length and gap distance as input parameters.  The 
analysis reveals that pancreatic tumor cell rolling on E-selectin increases the frequency of 
binding to HA ~40X when compared to non-rolling cells. Further, rolling Pa03c cells can 
facilitate binding to HA at higher shear stresses than non-rolling cells.  Rolling on E-
selectin facilitates binding with HA even at E-selectin patch lengths under 40 μm and 
once rolling occurs, cells bind to HA patches as low as 10 μm.  The knockdown of the 
major E-selectin receptor PODXL attenuates rolling on E-selectin but does not decrease 
the rate of adhesion with HA once cells have rolled.  Overall rolling on E-selectin 
increases cell adhesion with HA and is likely vital to cell-ligand binding observed in the 
metastatic process. 
 87 
As we observed in this study and have seen in others, Pa03c cells facilitate rolling 
on E-selectin and the depletion of PODXL in these cells was found to decrease their 
binding frequency to E-selectin (52).  The PODXL-E-selectin bond facilitates rolling as 
the bond is sufficiently strong while minimal bonds are required for rolling at low shear 
stresses (158).  The unstressed dissociation constant (𝑘𝑜𝑓𝑓       ° ) of .33 s
-1 and reactive 
compliance (𝑥𝛽) of .33 nm places this interaction in the rolling regime (158).  In contrast 
the CD44v-HA bond is mechanically stronger with a 𝑘𝑜𝑓𝑓       ° of .005 s
-1 however this bond 
is more susceptible to rupture in the presence of force as the 𝑥𝛽 is .59 nm (67).  The lower 
𝑘𝑜𝑓𝑓       ° value likely contributes to the stable slow rolling and firm adhesion observed for 
CD44 expressing cells binding to HA when compared to ligand-selectin interactions (49, 
67, 78, 79, 158).  We chose HA as a secondary binding protein because of the faster 
binding kinetics compared to the PODXL-E-selectin bond.  Because of the high bond 
lifetime of the CD44v-HA bond we would expect Pa03c cells to be capable of firm 
adhesion if a sufficient number of bonds can form during the interaction time.  Likewise, 
we observed that rolling on E-selectin increases the rate CD44-HA binding at higher 
shear stresses and that the binding interactions are more stable and long lasting (Figure 
4.4C and Figure 4.6A and B). Applying the multi-bond model to the experimental data 
which solves simultaneously for both lumped binding affinity (AcMrMlKon) and the 
number of bonds to facilitate binding (n-bonds) for the CD44v-HA interaction reveals 
that both rolling and non-rolling cells bind to HA with 5 bonds, (Figure 4.6C) however 
cells which roll first on E-selectin have a higher (AcMrMlKon) (Figure 4.6D).  Given that 
the receptor and ligand densities (MrMl) are the same for both populations this indicates 
that the 2D binding affinity (AcKon) is increased for rolling cells and this increase in 
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affinity likely contributes to the increased frequency of binding and more stable adhesion 
observed by these cells on HA (Figure 4.6A and B). 
    Cells adhering to HA, which do not first roll on E-selectin, make up a specific 
subset of the total cell population where adhesion occurs primarily at low shear stresses 
(Figure 4.3).  In fact ~80% of these events occur under .5dyn/cm2 and it is likely that 
lower hydrodynamic shear is necessary to facilitate adhesion to HA (78).   However, even 
at lower shear stress the percentage of HA binding cells is low compared to cells which 
first roll on E-selectin (Figure 4.4C).  Cells which roll on E-selectin do so in a shear 
dependent manner, where increased binding is observed at lower shear stresses and 
binding decreases with increasing shear stress (Figure 4.10).  Of the rolling population, 
cells bind to HA more frequently at lower shear stresses (4% and 3.8% at .15 and .36 
dyn/cm2 respectively) but also have increased binding at higher shear regimes (3.5% at 
.71 dyn/cm2) (Figure 4.4C). This increase in cell adhesion at higher shear stresses, likely 
results in part, because of the slower speed of the cells immediately before reaching the 
HA region.  We observe that slower cell speeds increase the adhesion frequency with HA 
of rolling cells (Figure 4.4A and B).  However, the cell speed in the gap region is not the 
only determinant of cell adhesion with HA as the HA binding frequency for cells with 
similar gap velocities is increased for rolling cells compared to non-rolling cells.   
Interestingly because both PODXL-KD and PODXL expressing Pa03c cells which first 
roll on E-selectin bind to HA with similar frequencies we do not believe that this increase 
in binding is related to a selection of highly expressing PODXL and CD44v cells.   
Likely the increase in HA binding of rolling cells is related to hydrodynamic 
forces that disrupt adhesive forces before the necessary bonds form to initiate firm 
 89 
adhesion.  Non-rolling cells can orient anywhere in the 25 μm channel and can have a 
lower contact area (Ac) with HA as they pass over the ligand coated patches. As a result 
they bind infrequently to HA and have a lower 2D binding affinity (AcKon).  Rolling cells 
orient at the ligand interface and therefore can more easily form the CD44v-HA bonds 
necessary for adhesion (higher AcKon) (Figure 4.6D).  However, when cells pass from the 
E-selectin region not only does the cell speed increase but hydrodynamic forces can 
disrupt the cell from the binding interface.  This likely results in the lower binding 
frequency observed with 120 μm gap. Cell rolling on E-selectin likely works to initiate 
adhesion to HA in a twofold manner, both physically slowing cells and allowing them to 
orient close to the surface to facilitate stronger adhesion with HA.  This allows cells to 
bind to HA more frequently at higher shear stresses and form more stable interactions 
with HA, slowing the cell rolling velocity and initiating longer cell-ligand interactions 
with HA (Figure 4.6A and B).  
Here we uncover the physical interdependence of MUC16/PODXL-E-selectin and 
CD44v-HA bonds and the critical parameters that lead to pancreatic tumor cell adhesion 
in physiologically relevant shear flow.  This approach allows us to determine how tumor 
cell rolling on E-selectin can initiate adhesion with a secondary ligand, which can be 
utilized to improved diagnostic assays and better understand the metastatic spread of 







Figure 4. 1 Flowchamber device schematic with the two binding regions highlighted.  
 (A) Device schematic of the multi-protein patterned device.  (B) E-selectin region 
highlighted in yellow, this region is separated into ten sections for analysis.  (C) HA 
region with the 10 μm, 40 μm, 160 μm and 80 μm regions highlighted in yellow.  Both 
regions were imaged after following flowing either Alexa-488 or Alexa-568 to pattern the 
glass slide. (D) Pa03c cell (green) rolling on E-selectin region (red). Interacting cell is 





Figure 4. 2 E-selectin facilitates Pa03c cell rolling and rolling increases frequency of 
binding to HA.  
(A) The fraction of interacting cells with E-selectin increases with increasing patch 
length. (B) Frequency of binding to HA for cells that roll (red and blue) or that do not roll 
on E-selectin (black) before binding to HA for the 30 μm, 60 μm and 120 μm gaps (shear 
stress of .5 dyn/cm2).  Data represents mean ± 95% confidence intervals, p** < .01 for 













Figure 4. 3 Hydrodynamic cell velocity versus gap velocity for all cells.   
(A) Cells binding to E-selectin and/or HA show a decreased gap velocity.  Black line 
indicates slope of 1.  (B) Normalized gap velocity (gap velocity/ hydrodynamic cell 
velocity) shows that cells, which bind to both E-selectin and HA show a depressed 
normalized gap velocity when compared to only E-selectin or HA binding cells and non-




Figure 4. 4 Factors that influence Pa03c cell binding to HA.   
(A) Percent of cells binding to HA which first roll on E-selectin binned by E-selectin 
patch length. Data represents mean ± 95% confidence intervals. (B) Normalized gap 
velocity (gap velocity/hydrodynamic velocity) of cells which roll on E-selectin binned by 
E-selectin patch length. Data represents mean ± S.E.M.  (C) Percent of cells binding to 
HA for rolling and non-rolling cells with increasing shear stress (D) Percent of cells 





Figure 4. 5 PODXL-KD decreases cell rolling on E-selectin but has a minimal affect 
on cell binding to HA.   
(A) The fraction of interacting cells on the E-selectin region with increasing patch lengths 
for control and PODXL-KD Pa03c cell at .5 dyn/cm2. Frequency of binding to HA for 
cells that first roll on E-selectin for control and PODXL-KD Pa03c cells for the (B) 30 
μm and (C) 60 μm gap distances (shear stress of .5 dyn/cm2).  Data represents mean ± 










Figure 4. 6 Pa03c cells which adhere to HA and roll first on E-selectin bind longer 
and roll slower.   
All cells interacting with HA were hand tracked once they initiated binding. (A) The 
percentage of cells that bind to HA for longer than 2 seconds. Data represents mean ± 
95% confidence intervals. (B) The rolling velocities of all cells that interact with HA.  
Data represents mean ± S.E.M.  (C) The multi-bond model was fitted to the experimental 
data (points) and optimized for both AcMrMlKon and n-bonds, with the solid lines 
representing the model prediction for Pa03c cell binding to HA.  Data represents mean ± 
95% confidence intervals. (D) The AcMrMlKon (lumped binding affinity) determined 
based on the experimental data. 
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Figure 4. 7 Western blots image of Pa03c cells immune-blotted for CD44.  
Pa03c cells and were subjected to SDS-PAGE under reducing conditions.  This was 
followed by western blotting using an anti-CD44 mab.  Pa03c cells express CD44v but 









Figure 4. 8 Comparison between manually and automatically tracked cells.  
Cells were tracked manually (by hand) and using the Matlab tracking program. Identical 
cells were identified and are compared. (A and B) Average X position of cells and the 
respective Bland-Altman analysis. (C and D) Cell velocity in the E-selectin region the 
respective Bland-Altman analysis.  (E and F) Cell velocity in the HA region the 
respective Bland-Altman analysis. (G) Percentage of interacting cells in the E-selectin 
region for the period of time measured.  For A, C, E data represents mean ± S.E.M and 






              
 
Figure 4. 9 Cell velocities of rolling cells as they pass through the different regions of 
the device.   
Once cells leave the E-selectin region they increase their speed as they begin to reach the 
hydrodynamic velocity.  Data represents mean ± S.E.M., p**** < .0001 with respect to 











                         
Figure 4. 10 Percent of interacting cells with E-selectin as a function of shear stress.   
Cells were binned by increasing shear stress at a set E-selectin patch length (70 μm).  












LOSS OF OBSCURIN IN HUMAN 
PANCREATIC DUCTAL EPITHELIAL 
CELLS INCREASES CELL MOTILITY AND 
DYNAMICS 
 
Obscurins are giant cytoskeletal proteins with structural and regulatory roles that 
are encoded by the OBSCN gene.  Mutations to the OBSCN gene have been associated 
with pancreatic ductal carcinoma (PDAC) and the loss of giant obscurin from other 
cancers has lead to increased tumorigenicity and cell migration.  Here we establish that 
obscurin expression is depleted in PDAC tissue and metastatic cell lines, but remains 
unaltered in normal pancreatic tissue and non-tumorigenic human pancreatic ductal 
epithelial cells (HPDE). Stable clones of HPDE cells lacking giant obscurins result in the 
modification of two major pathways, RhoA and PI3K/AKT which in turn leads to major 
cytoskeletal alterations including faster actin dynamics at cell-cell junctions, increased 
microtubule dynamics and decreased focal adhesion density.  Further, the loss of obscurin 
in HPDE cells leads to increased cell migration speeds through trifurcating channels and 
increased cellular dynamics. Treating these cells with a PI3K inhibitor decreases 
migration speeds in both confined and unconfined microchannels. Identifying biomarkers 
such as giant obscurins that increase cell migration and cytoskeletal dynamics is critically 
important to the prevention and treatment of pancreatic cancer metastasis. 
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5.1 Introduction  
 
Obscurins are giant cytoskeletal proteins with structural and regulatory roles that 
are encoded by the gene OBSCN that spans 150 kb on chromosome 1q42 in humans (84, 
85).  The gene undergoes alternate splicing which results in at least 4 isoforms (84, 85).  
Obscurin A is ~720 kDa and contains various signaling and adhesion domains, including 
repetitive immunoglobulin (Ig) and fibronectin-III (Fn-III) domains on the amino-
terminus and IQ motif, src-homology 3 and Rho-guanine nucleotide exchange factor 
(Rho-GEF) and pleckstrin homology (PH) motif interspersed by nonmodular sequences 
on the carboxyl-terminus (86, 87).  Obscurin B, with a mass of ~870 kDa contains two 
serine/threonine kinase domains in place of the nonmodular sequences (84, 85) (Figure 
5.1A). Smaller obscurin isoforms contain the serine/threonine kinase domains may also 
be expressed independently (~55 kDa) or in tandem (~145 kDa) (88). 
Analysis of 13,023 genes in colorectal and breast cancer found 189 highly 
mutated genes and only TP53 and OBSCN were commonly mutated genes in both tumor 
types (80). In normal breast epithelial cells, obscurins were highly expressed and present 
at cell-cell junctions (89), however obscurin expression is markedly decreased in breast 
cancer cells as well as late stage breast cancer biopsies (89, 91).  The depletion of giant 
obscurins from breast epithelial cells has been correlated with increased apoptotic 
resistance (89), the disruption of adherence junctions leading to epithelial-to-
mesenchymal transition (EMT), as well as increased tumorigenicity, microtentacle 
formation and metastasis (91, 92).   However, to this day the role of giant obscurins in 
pancreatic cancer has gone unexplored. 
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Recently, mutations in the OBSCN gene have been associated with pancreatic 
ductal adenocarcinoma (81, 82). Given that obscurin has numerous binding domains, the 
effect of obscurin depletion in other cancers and its implications in pancreatic cancer, we 
looked to comprehensively evaluate how loss of obscurin in pancreatic epithelial cells 
affects cell biophysics, migration and tumor formation.  Our studies indicate that when 
giant obscurins depleted from pancreatic cancer tissue biopsies but present in normal 
pancreatic tissue. Further, the loss of obscurin from normal pancreatic cells induces a 
migratory phenotype with alterations to cytoskeletal dynamics through decreases in 
RhoA and increases PI3K/AKT activity. Thus, leading to increased tumor formation and 
metastasis in vivo. 
 
5.2 Materials and Methods 
 
5.2.1 Reagents and monoclonal antibodies 
The antibodies used were as follows; rabbit polyclonal: phospho-PI3K p85 
(Tyr458)/p55 (Tyr199) (4228, Cell Signaling Technology Inc), PI3K total (C33D4, Cell 
Signaling Technology Inc), rabbit monoclonal Phospho-Akt (Ser473) (D9E) XP  (4060, 
Cell Signaling Technology Inc), AKT (pan) (4691, Cell Signaling Technology Inc), 
mouse monoclonal RhoA (ARH04, Cytoskeleton), rabbit monoclonal Actin(AB-5 BD) 
rabbit Hsp 90 (C45G5, Cell Signaling Technology Inc), Obscurin-COOH terminal 
antibody, Obscurin Ig 58/59 antibody and NH2-terminal obscurin [11]. 
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5.2.2 Cell culture 
SW1990 and CFPAC-1 were obtained from the American Type Culture 
Collection (Manassas, VA). The human pancreatic ductal epithelial (HPDE) as well as 
the Pa03C and Pa07C cells have been previously described (168). HPDE cells were 
cultured in keratinocyte SFM supplemented with 30 g/ml bovine pituitary extract and 0.1 
ng/ml epidermal growth factor (Invitrogen, Carlsbad, CA). CFPAC-1, SW1990, Pa03C, 
and Pa07C cells were cultured in DMEM supplemented with 10% FBS and 50 mg/ml 
gentamicin.  Panc5.04 were provided by Denis Wirtz and were cultured in DMEM 
supplemented with 10% FBS (99). 
 
5.2.3 Generation of stable cell lines 
A set of 2 short hairpin RNA (shRNA) which target human gene OBSCN and one 
control (scrambled) shRNA were obtained (Origene).  Transfections of the HPDE cell 
line were performed using Lipofectamine 3000 (Invitrogen).  500ug/ml puromycin 
(HPDE) was added to the media three days after transfection to select for stably 
transfected cells.   Stable clones expressing obsc shRNA-1, shRNA-2 or shRNA-ctrl were 
prorogated in the same resistance media. For the transduction of Panc5.04 cells, obsc 
shRNA-1, shRNA-2 or shRNA-ctrl was incorporated in a viral vector, which contained a 
GFP domain for sorting, grown in 293T cells.  The virus was harvested and purified.  
Panc5.04 cells were transduced at a 1:10 virus to media ratio.  Cells expressing GFP were 
sorted and the stable clones were propagated. Experiments were performed with pooled 
clones of each stable line.  
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5.2.4 Immunofluorescence and confocal microscopy  
Cells were fixed with 3.7% paraformaldehyde and permeabilized with .25% 
Triton X-100 in PBS.  Cells were then blocked in 10% normal goat serum (NGS) in PBS 
containing 1% bovine serum albumin (BSA) and then were incubated overnight with the 
primary antibodies specified in text.  Before being stained for secondary Alexa-fluor-488 
or 568 (LifeTechnologies) at a 1:200 dilution unless specified otherwise. Slides were 
mounted with prolong gold antifade reagent and imaged using either a LSM510 or 
LSM700 confocal microscope under either 40x or 63x magnification. 
 
5.2.5 Immunohistochemistry 
Human pancreatic cancer tumor array slides containing pancreatic ductal 
carcinoma and matched normal adjacent tissue were examined (US Biomax Inc, 
Rockville MD, USA).  We analyzed 3 biopsies of IDC grade-1, 2 biopsies of IDC grade 
1/2, 51 biopsies of IDC grade 2, 12 biopsies of IDC grade 2/3, and 7 biopsies of IDC 
grade 3 tumors. The tissue microarray was deparaffinized in xylene and rehydrated using 
ethanol washes.  The samples were then subject to antigen revival using 10mM sodium 
citrate buffer at 90C and washing with cold water. Tissue sections were then washed with 
TBS (Tris buffered saline) with .025% Triton X-100 (TBST).  Slides were blocked with 
10% NGS in TBS with 1% BSA for at least 4 h prior to incubation with rabbit polyclonal 
Ig58/59 antibody in TBS with 1% BSA overnight at 4C.  Slides were washed with TBST 
and incubated with Alexaflour-488 secondary.  Following 5 washes with TBST the 
samples were mounted with prolong gold antifade reagent and imaged using a LSM700 
confocal microscope under 40x magnification. 
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5.2.6 Western blot analysis 
Cell lysates were prepared using radio immunoprecipitation assay (RIPA) buffer 
with protease inhibitor (Roache, Mannheim, Germany).  Protein lysates were were 
separated using a 3-8% Tris-acetate SDS-PAGE gel or a 4-12% Bis-Tris gel (Bio-Rad, 
Hercules, CA) and transferred to an nitrocellulose membrane.  For obscruin western blots 
the membrane was blocked for 8 h in 10% milk in PTA (PBS, tween-20, sodium azide) 
buffer before staining with primary antibody.  Alkaline phosphatase-conjugated 
antimouse IgG (1:3000, Jackson ImmunoResearch, West Grove PA, USA) was used and 
the membrane was developed. For RhoA, PI3K and AKT westerns membrane was 
blocked for 1 h in 1% BSA in TBST (Tris buffered saline, tween-20) buffer before 
staining with primary antibody.  The gels were washed before being incubated with the 
appropriate horseradish peroxidase (HRP)-conjugated secondary antibody and the 
membrane was developed. 
 
5.2.7 Microchannel device fabrication 
The microchannel device was fabricated using standard lithography, as previously 
described. (99, 165, 169).  In brief, SU-8 photoresist was spin coated onto a silicon wafer 
to a thickness of 10 μm and exposed to ultraviolet light through a photomask to cross-link 
the pattern. The photomask contained the variable “cross” shaped patterns or straight 
microchannels. The “cross” design features a base channel (10µm) trifurcating to three-
branch channels with varying widths of 3, 6 and 10µm.  The straight channels design 
features channels with varying widths (3, 6, 10, 20, 50µm) and a length of 200 µm. The 
wafer was then treated as previously describe to complete the design (99, 165, 169).  In 
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brief the PDMS device was prepared by mixing 10:1 PDMS with curing agent and 
pouring the PDMS over the silicon wafer.  After degassing the PDMS was baked, pealed 
off the master and the appropriate inlet and out ports were punched into the device.  The 
device and glass cover slips were cleaned and plasma treated before being irreversibly 
sealed together forming the microchannels.  The device surface was functionalized using 
type-1 collagen (20 μg/ml in PBS) which was added to the inlet ports and incubated for 1 
h at 37 °C (99, 165, 169). 
 
5.2.8 Microchannel seeding and cell migration 
Microchannels were seeded and data was analyzed according to standard practices 
as previously described (99, 165, 169) with images taken every 20 mins.  For cells treated 
with LY294002 or BKM120, the inhibitor was dissolved in DMSO and the inhibitor or 
equivalent volume of DMSO was added to culture media prior to the start of the 
migration experiment. 
 
5.2.9 Fluorescence recovery after photobleaching (FRAP) 
Cells were transfected with LifeAct-RFP using Lipofectamine 3000 (Invitrogen) 
using conventional methods.  48 h later after transfection, they were re-plated on a glass 
slide coated in collagen in PDMS wells and allowed to adhere for 24 h and allowed to 
form a confluent monolayer.  Samples were imaged with Zeiss LSM 700 laser scanning 
confocal microscope (Carl Zeiss).  Circular regions with a 4 um diameters were selected 
at the cell-cells borders and were photobleached with 555-nm laser at 100% power.  
Images were captured every 1.04 seconds before and after photobleacing using x63X/1.4 
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N.A. oil immersion objective and the LSM software. Analysis of the images was 
previously described (91) At least 20 images of the cell-cell borders were analyzed per 
cell set. 
 
5.2.10 EB1 assay for measuring microtubule dynamics 
Cells were transfected with EB1-GFP or EB1-RFP using Lipofectamine 3000 
(Invitrogen) using conventional methods.  48 h later after transfection, they were re-
plated on a glass slide coated in collagen in PDMS wells and allowed to adhere for 24 h 
at ~50% confluencey.  Samples were imaged with Zeiss LSM 700 laser scanning 
confocal microscope.  Cells were imaged a 3.08 second intervals for 6.16 minutes.  Life 
history plots and kymographs of microtubules in each cell were generated.  MT growth 
rates were then determined from the kymographs. Approximately 20 MT in each cell 
were analyzed and at least 11 cells per condition were imaged. 
 
5.2.11 Total internal reflectance fluorescence (TIRF) microscopy 
Cells (50,000 per slide) were seeded on a collagen coated glass cover slip or glass 
bottom dish and allowed to adhere for 24 hr.  Cells were fixed and stained as described 
previously (99, 170) using anti phospho-paxillin primary (1:50) and Invitrogen Alexa 568 
secondary antibody (1:2000). Stained cells were imaged by total internal reflection 
fluorescence (TIRF) microscopy using a 3i Mariana inverted microscope (Intelligent 
Imaging Innovation, Inc) using a 100x/1.45 N.A. oil immersion objective and Slidebook 
8.0 software (Intelligent Imaging Innovation, Inc).  Images were processed and quantified 
as previously described (99, 170) After normalizing for background staining, images 
 109 
were made binary, and the particle analyzer tool was used in ImageJ to measure pY-
paxillin– positive punctate areas >0.1 µm2.  The total focal adhesion area, number of 
focal adhesions per area and the area of focal adhesions were then determined. TIRF 
experiments were repeated three times, for a total of at least 40 cells per condition. 
 
5.2.12 RhoGTPase Pulldown 
Cells with either OBSCN or ctrl-shRNA were grown and harvested for Rho 
GTPase pulldowns as per the manufacturer’s protocols (Cytoskeleton, Inc). The pulldown 
assay was performed as per the manufacturer’s protocols (Cytoskeleton, Inc). 
Densitometry was performed using ImageJ software. 
 
5.2.13 Statistical analysis 
Statistical analysis was performed using the students T-test or two proportion Z 
test unless otherwise noted.  
 
5.3 Results  
 
5.3.1 Obscurin is highly expressed in human pancreatic epithelial cells and down 
regulated in PANC tissue 
Obscurin was indicated as a frequently mutated gene in PDAC and therefore we 
investigated the expression of giant obscurin in several pancreatic cell lines (81, 82).  A 
panel of pancreatic cancer and normal cell lines were evaluated for giant obscurin A and 
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B through immunoblotting using an antibody against the COOH terminus of giant 
obscurin proteins. We tested one human epithelial pancreatic cell line, HPDE (human 
pancreatic ductal epithelial) and four metastatic cell lines including CFPAC-1 and Pa03c 
(isolated from liver metastases of pancreatic tumors), Pa07c (a peritoneal pancreatic 
metastasis), and SW1990 (isolated from the splenic metastasis of a pancreatic tumor). 
HPDE cells express the highest levels of giant obscurin A and B while SW1990 express 
intermediate levels of obscurin and CFPAC-1 and Pa03c cells express low levels of giant 
obscurin (Figure 5.1B).  This is consistent with a serial analysis of gene expression which 
indicate the same trends in mRNA levels for the all cells lines tested (HPDE, Pa03c and 
Pa07c) (168).   Interestingly giant obscurin was present in normal HPDE, while it was 
expressed in lower levels in the tumor forming SW1990 cells but was virtually absent 
from other cancer cell lines tested. We believe this correlates with the epithelial nature of 
HPDE and SW1990 (52) and the slower migration velocity of SW1990 cells in 
confinement (65).  
The staining of obscurin using antibodies targeting COOH terminus of the 
obscrurin (89) confirmed the expression of obscurin in HPDE (Figure 5.1C).  Here 
obscurin is localized at the cell interior, in the nucleus and at the perinuclear/cytoplasmic 
puncta. It is notably absence of obscurin from cell-cell junctions.  When HPDE cells are 
treated with 10% FBS for 24 hrs obscurins are localized at the cell membrane and the 
localization profile resembles that of SW1990 cells (Figure 5.7A and B and 5.10).  
Nuclear and cell-cell junction localization of obscurin is consistent with observations of 
obscurin localization in breast epithelial cells (89).    
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To explore if obscurin expression correlates with pancreatic tumor progression, 
we investigated the expression profile of obscurins in human biopsies of pancreatic tissue 
using fluorescent immunohistochemistry.  Biopsies of 75 PDAC or adenosquamous 
carcinoma biopsies and matched normal adjacent tissue stained using an antibody 
specific to Ig58/59 of giant obscurin A and B (Figure 5.1A) and imaged using confocal 
microscopy.  Obscurin is highly expressed in acinar cells and the ductal and lobular 
epithelium of normal pancreatic tissue (Figure 5.2A). It was found to be localized both 
membraneously (ductal) and in the cell interior, especially in acinar cells, and at times in 
the nucleus. However, obscurins are markedly reduced in the highly differentiated PDAC 
tissue (Figure 5.2A and B).  Normal pancreatic tissue expressed high levels of obscurin in 
~70% of patients while matched tumor samples highly express obscurin in under 20% of 
patient samples (Figure 5.2C) and obscurin expression was found to decrease with 
increasing tumor grade (Figure 5.2D). In tumor tissue samples, obscurin was localized 
primarily to the membranes of ductal cells and to puncta throughout the tumor. 
 
5.3.2 The downregulation of giant obscurins increases cell dynamics and migration 
through trifurcating microchannels 
Considering the decreased levels of giant obscurins A and B in metastatic 
pancreatic cancer lines and in high-grade pancreatic tumor tissue we examined the role of 
obscurin in cell migration.  In this regard we generated stable HPDE cell lines expressing 
shRNA plasmids targeting obscurin A and B (shRNA-1 targeting Ig9 and shRNA-2 
targeting Ig45), which reduced obscurin expression and a control shRNA (shRNA-ctrl) 
(Fig 1C).  
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To examine the impact of the obscurin downregulation on HPDE cell migration in 
trifurcating microchannels, we developed “cross”-shaped PDMS microchannels with a 
base channel (10µm) trifurcating to three-branch channels with varying widths of 3, 6 
and 10µm (Fig 3). This device looks to mimic complex and asymmetrical physical 
microenironments which cells encounter as they migrate from a primary tumor (171, 
172). Cells were imaged as the migrated up the base to the trifurcation (intersection) 
region and eventually to one of the three channel branches (Figure 5.3A).  Obscurin-KD 
HPDE cells spent less time in the intersection regardless of the branch dimensions (3-10-
6, 10-10-10, and 3-10-10 µm, channel width in microns for left, center, and right 
branches respectively)(Figure 5.3E-F).  This result was consistent for both the presence 
and absence of 10% FBS in the media (Figure 5.11).   
In symmetrical “cross”-shaped (10-10-10 µm) microchannels (Figure 5.3G-I), cell 
speeds and shape factors were analyzed in the three regions.  Obscurin-KD HPDE cells 
migrated with a faster velocity in the trifurcation region, thus confirming the lower time 
observed for KD cells in the intersection.   In the trifurcation region, obscurin-KD HPDE 
cells were also more protrusive (lower solidity) and less circular than control cells 
indicating these cells were more dynamic.   
 
5.3.3 Cellular dynamics and the role of RhoA 
Rho GTPase proteins, including RhoA, are largely involved in regulating the cell 
cytoskeleton (173). Decreases in RhoA activity have been indicated to decrease FA size 
and stress fiber formation, increase MT dynamics (94-96) and drive tumor cell migration 
and invasion (97).  Given that the RhoGEF motif of giant obscurin A and B specifically 
 113 
binds and activates RhoA (92), RhoGTPase pull-down was performed to assess RhoA 
activity in obscurin-KD HPDE cells.  We determined that the obscurin-KD decreased 
levels of active RhoA in HPDE cells (Figure 5.4C).  To further explore the effects of 
obscurin mediated RhoA depletion we assessed effects of obscurin-KD in HPDE cells on 
microtubule dynamics and focal adhesion expression.  
 
Since RhoA has been indicated to stabilize microtubules (174) and the loss of RhoA has 
been associated with increased MT dynamics (94) we quantified MT growth using EB1-
GFP which binds to the plus end (+TIP) of growing microtubules (175) and imaged cells 
using live-cell confocal microscopy. Control or obscurin-KD HPDE cells containing the 
EB1-GFP plasmid were imaged over 6 min, and growing microtubules comets were 
tracked (Figure 5.4A).  The growth rate of microtubules in obscurin-KD HPDE cells 
significantly was faster when compared to control HPDE cells indicating more dynamic 
MT assembly (Figure 5.4B and 5.9B).  
Because myosin II is a downstream effector of RhoA/ROCK pathway and 
increased myosin II activity promotes tyrosine-phosphorylation of paxillin (98, 99) we 
utilized TIRF microscopy to explore pY-paxillin expression in the focal adhesion of 
obscurin-KD and control HPDE cells (Figure 5.4D).  We found the loss of obscurin 
decreased both focal adhesion density and average focal adhesion size in HPDE cells 
(Figure 5.4E) indicating a decrease in myosin II activity.  This taken together with the 
MT data indicates that the loss of obscurin and consequential decrease in RhoA activity is 




5.3.4 Cellular dynamics and obscurin localization 
Given the increase cell dynamics and faster migration through a trifurcating 
microchannels as well as the decrease in active RhoA we assessed whether the obscurin-
KD affected actin dynamics. We quantified actin dynamics as cell-cell junctions using 
fluorescence recovery after photobleaching (FRAP).  LifeAct-RFP was expressed by both 
control and obscurin-KD HPDE and these cells were grown to a confluent monolayer.  
Cells with intense fluorescence at cell-cell junctions were selected, and bleached in a 
4µm diameter circular region. After ~60 seconds the fluorescence recovers at the cell-cell 
junction, although not to the extent of the prebleach levels (Figure 5.7C and D).  When 
HPDE cells (both control and obscn-KD) were grown in normal growth media no 
difference was found in either the mobile fraction or the half-life of actin recovery 
(Figure 5.7C).  However, when cells were grown in media with 10% FBS 24 h prior to 
imaging, obscn-KD HPDE cells displayed a higher mobile fraction when compared to 
control HPDE cells, while no significant difference was observed for half-life (Figure 
5.7D).    Therefore changes in actin dynamics correlate with obscurin localization (Figure 
5.7A and B).  Only in the presence of FBS, when obscurin is localized to the cell-cell 
junctions does the loss of giant obscurins increase actin dynamics (Figure 5.7). 
 
5.3.5 Migration of obscurin depleted HPDE cells are decreased after treatment with 
PI3K inhibitors. 
Recently we determined that the PH domain of obscurin binds to the p85 
regulatory subunit of phophsoinositide-3 kinase (PI3K) in breast epithelial cells (93).  
 115 
Given that upregulation of the PI3K pathway has found in 50% of human cancers, 
including pancreatic cancer and generally correlates increased proliferation and migration 
in a chemotactic gradient we investigated if the depletion of obscurin affects the PI3K 
pathway and modulates cell migration (176-179). We sought to examine if the enhanced 
motility and cell dynamics of obscurin downregulated HPDE cells are due in part to the 
activation of the PI3K/AKT pathway.  In this regard we evaluated protein levels of 
pPI3K/p85 and pAKT via immunoblotting.  We determined that levels of pPI3K/p85 
(Tyr458) regulatory subunit and pAKT (Ser473) were upregulated in obscurin depleted 
HPDE cells while levels of PI3K and AKT remain constant (Figure 5.5A).  
We next evaluated the ability of single HPDE cells treated with the PI3K 
inhibitors LY294002 or BKM120 to migrate through collagen type I-coated 
microchannels with varying widths (6, 10, 20 and 50 µm) and a constant height of 10 µm 
imaged with live-cell phase-contrast microscopy. These channels were selected because 
treated cells could migrate into them more easily than the “cross” design discussed 
earlier.  We found that obsc-shRNA HPDE cells migrated significantly slower when 
treated with both 25µM LY294002 and 2µM BKM120 compared to cells treated with 
DMSO (Figure 5.5 C and E).  These differences were consistent for both unconfined (50 
and 20µm) and confined (10 and 6µm) channel migration.  In contrast ctrl-shRNA HPDE 
cells treated with either LY294002 or BKM120 migrated through both unconfined and 
confined microchannels at the same speed when compared to DMSO treated cells (Figure 
5.5 B and D). Taken together, these data indicate that activation of the PI3K/AKT 
pathway in obscrurin depleted HPDE cells increases cell migration and that the inhibition 
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of the PI3K/AKT pathway impairs single cell migration of obscurin depleted HPDE cells 
resulting in decreased cell migration speed. 
 
3.5.6 Downregulation of obscurin Panc5.04 cells shows faster migration and cell 
dynamics 
Too confirm the previous migration and cytoskeletal dynamics results we 
performed these experiments with obscurin expressing Panc5.04 cells, which are derived 
from a stage IIB pancreatic tumor.  These cells express giant obscurins A and B and 
therefore we depleted the giant obscurin isoforms using shRNA targeting Ig45 of 
obscurin (Figure 5.6B).  Consistent with HPDE cells, obscurin-KD Panc5.04 cells 
express increased levels pPI3K/p85 regulatory subunit and downstream effectors pAKT 
as well as well as decreased levels of active RhoA (Figure 5.6E and I). Furthermore, 
Panc5.04 OBSCN-KD cells migrate faster through symmetrical and asymmetrical 
trifurcating microchannels (Figure 5.6C and D), display faster actin dynamics at cell-cell 
junctions as well as increased microtubule dynamics and decreased focal adhesion area 
(Figure 5.6F-H, J-M).  Given the mechanobiological similarities with HPDE cells, we 




In cancer, cells develop genetic alterations, which result in uncontrolled 
proliferation and the activation of complex signaling pathways that encourage cell 
survival, migration and invasion.  While studies have shown that obscurin depletion from 
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breast epithelial cells increase resistance to apoptosis, EMT protein expression, cell 
migration and tumorigenicity (89, 91), little is known about how giant obscurins affect 
normal pancreatic tissue and cells.  In this regard, we comprehensively evaluated how 
loss of obscurin in pancreatic cells affect cell biophysics, migration and tumor formation.  
Consistent with the observation for breast tumor tissue, pancreatic tumor biopsies 
grade >1 showed significantly decreased levels of obscurin (Figure 5.2A).  This supports 
the observation that mutations in the OBSCN gene have been associated with pancreatic 
ductal adenocarcinoma and adjacent pancreatic intraepithelial neoplasia, which are 
precursors invasive ductal adenocarcinoma (81, 82). In tumor tissue biopsies, obscurins 
were absent from invasive adenocarcinoma cells that invaded into the pancreatic 
parenchyma (Figure 5.2A) indicating obscurin depleted cells are more invasive.   This is 
supported by the increased in cell migration speed and cytoskeletal cell dynamics 
observed for obscurin depleted epithelial cells (Figure 5.3D-I, 5.4B, E and 5.6).  
Interesting obscurin localization in the pancreatic ductal epithelium and acinar resembles 
that of the HPDE cells where obscurin is localized at the cell-cell junctions and cell 
interior in the presence of FBS (Figure 5.7).   
The loss of obscurin from HPDE and Panc5.04 results in increased RhoA activity 
and the activation of the PI3K/AKT pathway.  Rho family GTPases and their downstream 
effectors are critical to cell migration and motility (179, 180). RhoA inhibition can lead to 
either decreased levels of migration through inhibition of cell contractility or increased 
migration through decreasing cellular adhesion in a cell dependent manner (181). The 
depletion of RhoA in breast and prostate tumor cells is associated with cell elongation, 
the formation of actin rich protrusions and increased cancer cell invasion (97). The 
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expression the obscurin RhoGEF domain in kidney cells resulted in increased levels of 
active RhoA while the depletion of obscurin in breast epithelial cells resulted in 
decreased levels of RhoA (92, 182). Our results show decreased activity of RhoA in 
obscurin depleted pancreatic epithelial cells.  Increased actin dynamics and decreased FA 
density can result from decreased RhoA activity, which effects contractility and is 
associated with cell adhesion (96).  Further, RhoA depletion is associated with increase 
MT dynamics and rear retraction in cell migration (94, 179).   Therefore, the altered actin 
and MT dynamics, and FA expression in obscurin-KD pancreatic epithelial cells likely 
results from decreases in RhoA activity and is at least partially responsible for the faster 
cell migration decision making in trifurcating microchannels.   
We have also show that the activation of PI3K/AKT pathway in obscurin depleted 
pancreatic epithelial cells.  Obscurin is thought to bind and inactivate the PI3k/p85 
regulatory subunit making it unable to modulate the PI3K/p110 catalytic subunit, thus 
leading to aberrant activation of the pathway (93).   Increased activation of the 
PI3K/AKT pathway affects many cellular processes including cell survival, apoptosis, 
stemness, motility and invasion, factors which ultimately result in increased 
tumorigenicity and metastasis (183, 184).  The activation of this pathway in obscurin 
depleted HPDE and Panc5.04 cells likely in part leads to the increased in vitro cell 
migration.      
Panc5.04 cells were selected as an alternative to HPDE because they are 
tumorigenic cells with a similar heteroginity profile to HPDE cells (185-187).  A study 
which differentiated pancreatic tumor and metastatic pancreatic cells into subgroups 
based on several factors including nuclear size distribution and entropy cells size 
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distribution indicates that Panc5.04 are more like HPDE cells than metastatic pancreatic 
tumor cell lines (187).  Therefore they are an excellent alternative for HPDE for future in 
vivo experiments. 
Here we observed the depletion of giant obscurins from PDAC tissue and 
metastatic cell lines, but it is abundant in normal pancreatic tissue and human pancreatic 
ductal epithelial cells. We find that the loss of obscurin from HPDE cells results in the 
modification of two major pathways, RhoA and PI3K/AKT which results in major 
cytoskeletal alterations including faster actin dynamics at cell-cell junctions, increased 
microtubule dynamics and decreased FA density.  This leads to increased migration 
speeds and decision making in trifurcating channels.  Identifying markers which promote 















 Figure 5. 1 Obscurin expression in pancreatic cell lines and the localization of 
obscurin in HPDE cells. 
  (A) Schematic of giant obscurins A and B with the binding domains illustrated. (B) 
Immunoblots showing the expression giant obscurin isoforms for one normal pancreatic 
cell lines (HPDE) and several cancer cell lines (CFPAC-1, SW1990, Pa03C, and Pa07C). 
(C) Immunostaining used to determine the expression of obscurin in HPDE cells. 
Obscurin (green) is localized in the cell interior, at perinuclear/cytoplasmic puncta and in 








Figure 5. 2 Pancreatic tissue microarray staining for obscurin shows loss of obscurin 
in pancreatic ductal adenocarcinoma (PDAC) tissue when compared to normal 
tissue.  
(A) Representative images of pancreatic tissue biopsies of grade 1-3 pancreatic 
adenocarcinoma and matched normal tissue. Hematoxylin and eosin (H&E) stained 
images display a boxed region (left), which was imaged using confocal (right) after 
staining with the obscurin Ig 58/59 antibody (green) and dapi (blue). (B) Obscurin 
expression normalized to the levels of obscurin in the normal tissue for the entirety of 
each matched tissue sample. Data represents mean ± S.E.M, p** < .0001 (C) Obscurin 
levels were graded for tissue sample on a 0-3 scale based on obscurin intensity. Tissue 
samples were evaluated for elevated levels (grade 2 or greater) of obscurin expression in 
PDAC and normal tissue. Data represents mean ± 95% confidence intervals, p** < .0001  
(D) Tissue samples were evaluated for obscurin intensity PDAC and normal tissue and 
plotted as a function the tumor grade. Data represents mean ± S.E.M, p* < .01, p** < 










Figure 5. 3 Obscurin-KD HPDE cells spend less time in symmetrical and 
asymmetrical trifurcations and are more dynamic.  
(A) Schematic of the symmetrical “cross” shaped device.  Cells migrate into the channel 
base, and through the trifurcation region to the branch region. Both the base and each 
branch channel have a width of 10µm. (B) Time-lapse images of control and obscurin 
shRNA-1 HPDE cells migrating through symmetrical “cross” shaped microchannels.  
Arrowheads point to individual cells as they migrate through the device. (C) Giant 
obscurins A and B are downregulated in HPDE following the stable transduction with 
obscurin shRNA-1 or -2 compared to control cells. (D-F) Time that migrating HPDE 
cells spent in the intersection of the “cross” shaped devices that trifucate into branches 
with widths from left to right of either (D) of 3, 10 and 6µm, (E) of 3, 10 and 10µm, or 
(F) or 10, 10 and 10µm. (G) The average speed (H) Circularity and (I) solidity of HPDE 















Figure 5. 4 Obscurin-KD HPDE cells display faster microtubule dynamics and 
decreased FA density and size.  
(A) Time lapse images showing the EB1-GFP comets of HPDE ctrl and obscurin-shRNA cells. 
White dots indicate growing microtubules. (B) Microtubule growth rate of HPDE cells. (C) 
Active RhoA is decreased in HPDE cells expressing obscurin shRNA-1. Actin and total RhoA act 
as loading controls. (D) Representative TIRF microscopy images of HPDE cells (ctrl and obsc 
shRNA-1) stained with pY-paxillin to visualize focal adhesions (FAs). The cell boundary is 
traced in yellow. (E) Average focal adhesion size per cell, the average focal adhesion density per 
cell and the average focal adhesion area per cell area. Data represents mean ± S.E.M, p* < .05, 








Figure 5. 5 Downregulation of obscurin in HPDE cells increases PI3K activity and 
treatment with a PI3K inhibitor decreases migration speeds in these cells.  
(A) Levels of pPI3K (Tyr458) and the downstream effector pAKT (Ser473) were 
increased in obscurin knockdown HPDE cells.  HPDE control cells when treated with the 
PI3K inhibitor (B) ly294002 or (D) BKM120 showed no difference in cell migration 
speeds through straight microchannels with widths varying from 6 to 50µm. HPDE 
obscurin shRNA-1 cells when treated with the PI3K inhibitor (C) ly294002 or (E) 
BKM120 displayed a decrease in cell migration speeds through straight microchannels 
with widths varying from 6 to 50µm.  Data represents mean ± S.E.M, p* < .05, p*** < 




Figure 5. 6 Downregulation of obscurin in Panc5.04 cells display the same 
mechanobiogical phenotype as HPDE obscurin depleted cells. 
(A) Immunostaining shows the expression of obscurin in Panc5.04 cells. Obscurin 
(green) is localized in the cell interior, in the nucleus, and at cell-cell junctions. White 
arrows heads indicate obscurin localization of obscurin at cell-cell contacts and at the cell 
leading edge. (B) Giant obscurins A and B are downregulated in Panc5.04 cells following 
the stable transduction with obscurin shRNA compared to control cells. (C) Obscurin 
shRNA Panc5.04 cells migrate through the intersection of the symmetrical “cross” 
microchannel device with a faster speed and in less time than control Panc5.04 cells. (E) 
Active RhoA is decreased in Panc5.04 cells expressing obscurin shRNA. (F) Lifeact-RFP 
expressing Panc5.04 cells were bleached at a circular region of 4 μm in diameter at the 
cell-cell junction and imaged as actin recovered.  FRAP curve shows the faction of actin 
recovery versus time. (G) The mobile fraction of actin and the (H) half-life of actin 
recovery are shown. (I) Levels of pPI3K (Tyr458) and the downstream effector pAKT 
(Ser473) were increased in obscurin knockdown Panc5.04 cells.  (J) Microtubule growth 
rate of Panc5.04 cells. (K-M) Average focal adhesion size per cell, the average focal 
adhesion density per cell and the average focal adhesion area per cell area for Panc5.04 












Figure 5. 7 HPDE cells with decreased levels of obscurin show faster actin dynamics 
only in the presence of FBS, when obscurins localize at cell-cell contacts.  
 Immunostaining used to determine the expression of obscurin in HPDE cells in the (A) 
absence and (B) presence of FBS.  Arrowheads indicate obscurin the localization of 
obscurin at cell-cell contacts in the presence of 10% FBS.  (C and D) FRAP was 
performed on life-act expressing HPDE in the (C) absence and (D) presence of FBS. 
FRAP curve shows the faction of actin recovery versus time.  The mobile fraction of 
actin and the half-life of actin recovery are shown.  Actin recovers faster for HPDE obsc 






Figure 5. 8 Obscurin-KD HPDE cells spend less time in a symmetrical or 
asymmetrical trifurcation and are more dynamic, with shRNA-2.  
(A-C) Time that migrating shRNA-2 and crtl shRNA HPDE cells spent in the 
intersection of the “cross” shaped devices that trifucate into branches with widths from 
left to right of either (A) of 3, 10 and 6µm, (B) of 3, 10 and 10µm, or (C) or 10, 10 and 
10µm. (D) The average speed (H) circularity and (I) solidity of HPDE cells in the 
trifurcation region. Data represents mean ± S.E.M, p* < .05, p** < .01.   
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Figure 5. 9 Obscurin-KD HPDE cells display faster microtubule dynamics and 
decreased FA density and size, with shRNA-2.  
(A) Active RhoA is decreased in HPDE cells expressing obscurin shRNA-1 and shRNA-
2. Actin and total RhoA act as loading controls.  (B) Microtubule growth rate of obscurin 
shRNA-2 and crtl-shRNA HPDE cells. (C-E) Average focal adhesion size per cell, the 
average focal adhesion density per cell and the average focal adhesion area per cell area. 
Data represents mean ± S.E.M, p* < .05, p** < .01, p*** < .001.   
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Figure 5. 10 Obscurin staining of SW1990 cells.  
Immunostaining used to determine the expression of obscurin in SW1990 cells.  
Arrowheads indicate the localization of obscurin at cell-cell contacts.  Obscurin 
localization in SW1990 cells are similar to that of HPDE cells treated with 10% FBS, 










Figure 5. 11 Obscurin-KD HPDE cells spend less time in a symmetrical or 
asymmetrical trifurcation in the presence of 10% FBS. 
(A-C) Time that migrating shRNA and crtl shRNA HPDE cells spent in the intersection 
of the “cross” shaped devices that trifucate into branches with widths from left to right of 
either (A) of 3, 10 and 6µm, (B) of 3, 10 and 10µm, or (C) or 10, 10 and 10µm.  Cells 
were treated with FBS for 24 h prior to the start of the experiment. Data represents mean 













CHARACTERIZATION OF MONOBODY 
SCAFFOLD INTERACTIONS WITH LIGAND 
VIA FORCE SPECTROSCOPY AND 
STREERED MOLECULAR DYNAMICS 
 
Monobodies are antibody alternatives derived from fibronectin that are 
thermodynamically stable, small in size, and can be produced in bacterial systems. 
Monobodies have been engineered to bind a wide variety of target proteins with high 
affinity and specificity. Using alanine-scanning mutagenesis simulations, we identified 
two scaffold residues that are critical to the binding interaction between the monobody 
YS1 and its ligand, maltose-binding protein (MBP). Steered molecular dynamics (SMD) 
simulations predicted that the E47A and R33A mutations in the YS1 scaffold 
substantially destabilize the YS1-MBP interface by reducing the bond rupture force and 
the lifetime of single hydrogen bonds. SMD simulations further indicated that the R33A 
mutation weakens the hydrogen binding between all scaffold residues and MBP and not 
just between R33 and MBP. We validated the simulation data and characterized the 
effects of mutations on YS1-MBP binding by using single-molecule force spectroscopy 
and surface plasmon resonance. We propose that interfacial stability resulting from R33 
of YS1 stacking with R344 of MBP synergistically stabilizes both its own bond and the 
interacting scaffold residues of YS1. Our integrated approach improves our 
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understanding of the monobody scaffold interactions with a target, thus providing 




High affinity proteins are utilized in a wide spectrum of applications ranging from 
chemical and biological threat detection (188) to protein-based therapeutics (189). 
Although monoclonal antibodies have traditionally been favored as therapeutic 
biomolecules, they are large in size, require eukaryotic expression for production (108), 
and generally offer poor thermal stability (109). As a result, synthetic antibody mimetic 
proteins based on molecular scaffolds have gained popularity. Utilizing a conserved 
protein scaffold as a platform and combinatorial engineering techniques, selections for 
high affinity binding or conformational stability can be performed (110, 111). Synthetic 
domains have also been engineered to produce biosensors (190, 191) and achieve binding 
to a wide array of molecules (116, 192). Engineered protein scaffolds have been explored 
for use as both therapeutics (112) and diagnostics (113). An increased understanding of 
how scaffold structure affects interactions with ligands will facilitate the engineering of 
improved scaffold proteins. 
The protein of interest in this study is derived from the tenth fibronectin III 
domain (FNfn10) scaffold (114, 115). Similar to the immunoglobulin (Ig) 
complementarity determining region, the ~94 amino acid peptide contains a β-sheet 
backbone and three relevant loop domains (BC, DE, and FG) (114, 115). The three loops 
have been diversified using phage or yeast display combinatorial libraries to produce 
proteins known as monobodies, with low nanomolar (116, 117) to picomolar Kd values 
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(118) and the capability to bind to targets such as small ubiquitin-related modifiers 
(SUMO) (119), maltose-binding protein (MBP) (116, 117), lysozyme (118), and fyn 
kinase (120). Comparable binding affinity to antibodies coupled with the absence of 
disulfide bonds, ease of production in bacterial systems (114, 121), and high thermal 
stability (122) are reasons why monobodies have become attractive alternatives to 
antibodies as therapeutic biomolecules. 
A better understanding of monobody interactions with their ligands 
(paratope/epitope binding) will allow for improved monobody design. Here, we have 
studied the interaction of monobody YS1 with its ligand, maltose-binding protein (MBP), 
with a focus on scaffold interactions. YS1 was developed by Koide et al. (116) utilizing a 
Y/S binary combinatorial library platform to diversify amino acids on the BC, DE, and 
FG loops of the FNfn10 scaffold. The monobody was originally named MBP-74 but was 
subsequently renamed YS1 (117). The X-ray crystal structure of YS1 bound to MBP 
shows the convex paratope of YS1 binding to the sugar binding pocket of MBP (116, 
117). Based on the crystal structure, the interacting paratope of YS1 includes both loop 
and scaffold proteins. Alanine-scanning mutagenesis indicates that the BC loop of the 
monobody does not significantly contribute to binding, but that alanine mutations at 
seven of the nine residues of the FG loop result in greater than 10-fold decrease in 
affinity (117). Although it has been speculated that the contacts with the scaffold residues 
are a crystallization artifact (116), the effect of mutations on these scaffolds has not been 
reported. Previous studies on monobodies have mainly focused on altering the BC, DE, 
and FG loops to achieve high binding affinities and increased protein stability (116, 117, 
193). While scaffold modifications have been considered in modifying monobody 
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structural stability (194, 195) and in combination with loop modifications (119), little 
work has focused solely on how interacting scaffold residues affect binding kinetics. 
Utilizing computational modeling and biophysical analyses we have explored how 
scaffold modifications affect YS1-MBP binding kinetics. 
Structure-based design of therapeutic molecules is becoming increasingly 
important with the growth of structural databases and increased computing speeds (125, 
126). Whereas the x-ray crystal structure reveals interactions in the context of a static 
crystal, molecular dynamics simulations can show instantaneous molecular movement 
and are useful for determining the preferred motion of proteins (196). Through steered 
molecular dynamics (SMD) an external force is applied to a binding pair and the 
dissociation interactions are measured with respect to time (197). As a result, the 
structural mechanics of the unbinding process can be explored. Single molecule force 
spectroscopy is a biophysical method to experimentally examine such processes, and has 
been utilized to measure binding kinetics of cell-to-cell interactions protein-protein 
interactions between single molecules (41-43, 47, 67, 139, 140).  
Typically only a small fraction of buried residues contributes to the majority of 
the binding affinity in binding interactions. These residues are referred to as hot spots 
(198, 199). Hot spots have been studied in a wide a range of human antibodies and other 
natural proteins, and modification of these residues has a substantial destabilizing effect 
on the protein interface (198, 199). We sought to identify the hot spots of the YS1-MBP 
interface on the previously unstudied scaffold interactions using computational alanine-
scanning mutagenesis. By coupling molecular simulations and biophysical tools we have 
characterized the critical interacting β-sheet residues of YS1 and assessed their influence 
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on binding kinetics. With the increasing interest in the development of scaffold based 
mimetic proteins, an understanding of scaffold hot spots will lead to the creation of 
better-targeted therapeutics. 
 
6.2 Materials and methods 
 
6.2.1 Construction, expression, and purification of TMD-MBP 
The plasmid encoding the CD44 trans-membrane domain (TMD) fused to MBP 
utilizes the isopropyl b-D-1-thiogalactopyranoside (IPTG)-inducible T7 promoter to 
allow for the cytoplasmic expression of TMD-MBP (139). TMD-MBP was expressed and 
purified using an amylose affinity chromatography column as described except that 
BL21(DE3) cells were used (139). 
 
6.2.2 Construction, expression, and purification of wild-type and mutated 
Monobody YS1 
The pHFT2 plasmid encoding the YS1 gene with a (His10) tag at the N-terminus 
(116) was a gift from Shohei Koide (University of Chicago). The R33A and E47A 
mutations were made by site directed mutagenesis in this plasmid and verified by DNA 
sequencing. The monobodies were expressed and purified from BL21(DE3) cells. Cells 
were grown in M9 media with 10 g/L tryptone, with expression induced with IPTG. 
Expressed monobodies were immobilized and purified using a GE HisTrap HP column 
via their N-terminal His10 tag. The purified monobodies were dialyzed at 4°C against 300 
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volumes of phosphate-buffered saline (PBS, pH 7.4). Monobody concentrations were 
determined using their extinction coefficients. 
 
6.2.3 Molecular dynamics simulations 
The starting coordinates for the molecular dynamics (MD) simulations were 
obtained from the crystal structure of YS1 in complex with MBP (Protein Data Bank ID: 
2OBG) (116). The R33A and E47A in silico mutations were generated by replacing 
either R33 or E47 with alanine. Both wild-type and mutated YS1 were fully solvated in a 
rectangular water box of 80×87×80 Å3 by using the Visual Molecular Dynamics program 
(200). Sodium and chloride ions were added to neutralize the system, which yielded 
51,635 atoms in total. The MD simulations were performed by following a protocol 
similar to our previous study (139). In brief, the NAMD software was used to perform 
MD simulation by using a CHARMM22 force field and the TIP3P water model (201-
203). Periodic boundary conditions were applied to avoid finite size effects, and 
electrostatic interactions were simulated using the particle-mesh Ewald sum method 
(204). A 12 Å cutoff distance was applied for calculating van der Waals interactions. The 
system has gone through energy minimization by a 20,000-steps-of-conjugate gradient 
with heavy atoms fixed followed by another 20,000 steps with all atoms free. After 
gradually heating from 0 to 300 K in 60 ps, the system is equilibrated for at least 2.5 ns 
with temperature at 300 K and pressure at 1 atm by using the Langevin dynamics method 
(205, 206). The profile of RMSD plots for the backbone atoms of monobody-MBP 
complex reached a plateau value, which indicated that the systems had reached an 
equilibrium state. 
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The steered molecular dynamics (SMD) simulations were performed using six 
pairs of monobody-MBP complexes randomly selected from the equilibrated systems. A 
constant pulling speed of 10 Å/ns was applied through a spring with a stiffness of 70 
pN/Å on the residue Val72, which is near the center of mass of the monobody. The 
pulling direction was designed to pull the monobody away from the center of mass of 
MBP. The Cα atoms of the 322, 325 and 326 residues of the MBP were constrained to 
their equilibrated positions. These residues were chosen because they are located on the 
opposite side of the binding pocket of MBP. The generalized born implicit solvent 
(GBIS) model implemented in the NAMD was used to manipulate the water molecules in 
SMD simulations. Periodic boundary conditions were considered in all SMD studies. 
However, Particle mesh Ewald method is not supported in the GBIS. The solvent 
molecular electrostatics were calculated by the Poisson-Boltzmann equation which 
models water as a dielectric continuum in NAMD (207). Production runs were performed 
by using a computer equipped with eight CPUs and 12 GB RAM. Each simulation 
contains 4 ns data and took approximately five days to finish. Snapshots were saved in 
every 0.5 ps to analyze the dissociation trajectory. Simulations of mutated monobodies 
followed the same protocol as mentioned above. 
Hydrogen bonds were calculated using the VMD software utilizing the hbonds 
plugin v1.2, which measures the hydrogen bonds of each interacting YS1 residue 
throughout the trajectory.  Hydrogen bonds were considered to be formed between the 
hydrogen donor (D) and another atom (the acceptor, A) given that the distance D-A is 
less than the cut-off distance at 3.5Å and the angle D-H-A is within the cut-off angle at 
180±60 degrees (208). Only polar atoms were considered in the calculation.  
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6.2.4 Alanine-scanning mutagenesis 
Following the annealing and equilibrium achieved using MD simulation, the 6-8 
randomly selected monobody-MBP complexes were entered into to the computational 
alanine-scanning program on the Robetta server (209) (http://robetta.bakerlab.org/) and 
the DrugScorePPI webserver (210) (http://cpclab.uni-duesseldorf.de/dsppi/main.php).  
Here, all amino acids at the YS1-MBP interface were identified and individually mutated 
to alanine. The change in binding free energy (∆∆Gbind) or the change in the mutated 
complex partner protein stability in isolation (∆Gpartner) was measured.  Additionally the 
degree of buriedness was identified for interfacial residues. The binding free energy 
function utilized here accounts for solvation interactions, shape complementarity of 
interacting atoms, and the polar interactions of both ion pairs and hydrogen bonds 
(Robetta) (209) or was based on adapted knowledge-based distance-dependent pair 
potentials (DrugscorePPI) (210). The degree of buriedness analysis indicates the number 
of atoms within a radius of 4Å of an interfacial residue with a higher score indicating a 
more buried residue.   
 
6.2.5 Lipid bilayer preparation 
Lipid solution was prepared by first dissolving 8 mg of DMPC (1,2-dimyristoyl-
sn-glycero-3-phosphocholine) into 8 mL of lipid buffer B (20 mM Tris-HCl, 50 mM 
NaCl, 1 mM CaCl2, 0.1% (w/v) Triton X-100)(42, 43, 139). A total of 130 uL of TMD-
MBP (80 µg/mL) was added to 380 µL of lipid solution and incubated for 2 h at 37ºC. 
The resulting solution was transferred to a 10 kDa MWCO dialysis cassette and dialyzed 
three times for 12 h each against 1 L of lipid buffer A (20 mM Tris-HCl, 50 mM NaCl, 1 
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mM CaCl2) (42, 139). Lipid-protein solutions were then stored at 4ºC in a translucent 
glass vial under nitrogen for up to one month. The TMD-MBP bilayer was prepared by 
first plasma cleaning a glass slide for 5 min and immediately submerging it in a solution 
of 100 ppm polyethyleneimine (PEI) in 0.5 mM KNO3 for 20 min before rinsing with DI 
water and drying with nitrogen (42, 139). Slides were further dried in a vacuum 
desiccator prior to use. Under a slightly dampened towel to prevent complete dehydration 
the PEI-coated glass slide was incubated with a 4 mL droplet of the lipid-protein solution 
for 2h. Slides were then rinsed three times in Hank’s balanced salt solution (HBSS) 
before being immersed HBSS prior to force spectroscopy experiments. A PEI-coated 
glass slide was incubated with only the lipid solution (without the TMD-MBP protein) 
and used as a negative control to determine the binding specificity as before (139). 
 
6.2.6 Cantilever functionalization 
To provide a suitable surface for coating with soluble proteins, molecular force 
probe cantilevers (Veeco, Plainview, NY) were silanized with 2% (v/v) 3-
aminopropyltriethoxysilane in acetone (42, 140). The cantilevers were first incubated in a 
30 µg/ml solution of anti-histidine antibody for 30 min before being incubated for 1 h in 
a 3 mg/mL solution of wild-type or mutated monobody YS1 protein in Dulbecco’s PBS 
containing 50-fold molar excess of the crosslinker bis(sulfosuccinimidyl) suberate (BS3; 
Pierce, Rockford, IL). The reaction was quenched with Tris buffer. To block nonspecific 
interactions, cantilevers were incubated in 1% bovine-serum albumin in Dulbecco’s PBS. 
Protein solution concentrations were optimized to result in a low proportion of binding 
events during force-spectroscopy experiments (~20 binding events per 100 contacts). 
 145 
 
6.2.7 Single-molecule force spectroscopy 
Force spectroscopy experiments were conducted using a Molecular Force Probe 
(MFP-1D; Asylum Research, Santa Barbara, CA). Using thermal oscillation method, a 
triangular cantilever (nominal spring constants of 10 pN/nm) was calibrated, with its 
deflection measured by laser reflection onto a split photodetector (45, 211). The petri dish 
containing the MBP-incorporated or blank lipid bilayer slides and Hanks’ balanced salt 
solution buffer was placed on the stage and positioned to be directly below the cantilever. 
The cantilever height was adjusted such that each approach cycle generated a slight force 
(~1–2 nN) onto the lipid bilayer before reproach. For each run, reproach velocity was 
varied from 5 to 25 mm/s, and the dwell time was set to 20 ms (45, 211). Rupture forces 
and loading rates were calculated from force-versus-distance traces using IgorPro 4.09 
software (WaveMetrics, Lake Oswego, OR). The Bell model parameters (𝑘 𝑜𝑓𝑓𝑜  and 𝑥𝛽) 
were tabulated using a least-squares fit to the rupture force against the logarithm of 
loading rate (42, 45, 140). At least four individual experiments and >1000 successful 
events were run for MBP binding to the wild-type YS1 and the R33A and E47A samples 
with the exception of the control samples, which were tested by three individual 
experiments. A new cantilever was freshly prepared, calibrated, and tested for each 
individual experiment. 
 
6.2.8 Surface plasmon resonance 
The binding kinetics between wild-type or mutated monobody YS1 and their 
target protein MBP were measured using a BIAcore 3000. The running buffer used was 
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HBS-P at pH 7.4 with 10 mM HEPES, 150 mM NaCl, and 0.005% (v/v) Tween 20 
(BIAcore, Piscataway, NJ). A low density of ~200 RU of biotinylated MBP (Avidity, 
Aurora, CO) was immobilized onto a streptavidin SA chip (BIAcore) to avoid mass-
transport limited effect. For binding assays, either wild-type or mutated monobody YS1 
protein (0-137 nM) was injected for 100 s at a flow rate of 60 mL/min and followed by 
washing with buffer for 10 min. Reference curves generated from an uncoated flow cell 
and multiple injections of running buffer provided a double-reference. The binding 
sensorgrams were analyzed by the global fitting of 1:1 bimolecular interaction model, 
and the dissociation equilibrium constant (Kd) was calculated by the dividing kon by koff 
(212). BIAevaluation 3.0 software (BIAcore) was utilized for data analysis and self-
consistency examination was performed as described (213). 
6.3 Results 
 
6.3.1 Computational simulations predict R33 and E47 as critical scaffold framework 
residues 
To identify the critical YS1 residues involved in YS1-MBP binding, we first 
executed a computational alanine-scanning mutagenesis analysis utilizing molecular 
dynamics and Robetta and DrugScorePPI simulations to analyze the binding interface. 
Specifically, each of the YS1 interacting residues was individually mutated to alanine.  
The change in binding free energy (∆∆Gbind) and the protein stability of the mutated 
complex partner in isolation (∆Gpartner) were calculated (210, 214).  ∆Gpartner represents 
the predicted stabilizing or destabilizing effect of the alanine mutation on free YS1 and is 
a component of ∆∆Gbind with large values signifying decreased YS1 stability and the 
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potential of decreased binding.  Additionally, the degree of buriedness was calculated for 
interfacial residues (210) as a high degree of residue burial is necessary albeit not 
sufficient for hot spot identification (199). The three calculations were taken together to 
identify pivotal binding residues. 
Simulations predict that YS1-MBP binding hot spots are localized to the FG-loop 
and the scaffold (Figure 6.1). Amino acids mutations in both the BC-loop and DE-loop 
were predicted to have an insignificant effect on protein complex stability as alanine 
mutations in both loops caused minimal negative perturbations of ∆∆Gbind (less than 
about 0.25 kcal/mol) and ∆Gpartner (< 0 kcal/mol). Six amino acids in the FG-loop (Y75, 
Y77, Y78 Y79, Y80 and Y81) and two in the scaffold framework (R33 and E47) were 
predicted to be important binding residues.  The FG-loop amino acids were identified 
based on their high ∆∆Gbind (> 1.5 kcal/mol) or their high ∆Gpartner value (> 1 kcal/mol).  
In a previous experimental alanine-scanning mutagenesis study of the FG loop, the 
Y75A, Y77, Y78, Y79A, Y80A, Y81A and Y82A mutations caused the largest reduction 
in affinity (≥ 1.5 kcal/mol) (117). The two scaffold residues were identified based on 
their high ∆Gpartner value (> 1 kcal/mol), their high degree of buriedness (greater than 5.5) 
and because they had the highest ∆∆Gbind of any non-FG- loop residues (Figure 6.1). As 
common in interfacial hot spots, the residues are grouped in close proximity to one 
another and make contact with the target protein MBP (Figure 6.2A, B) (198, 199).  
Since monobodies feature a structure similar to the antibody variable domain, 
most YS1 studies focus on the modification of three exposed loops corresponding to the 
three complementarity determining regions in antibodies (116, 117). Here, we explored 
the impact of modifications to the R33 and E47 residues, which reside in the C and D β-
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sheets of the scaffold, respectively. Based on the large value of ∆Gpartner (3.04 kcal/mol) 
and a larger ∆∆Gbind, we anticipated that R33A mutation would have a greater 
destabilizing effect on the YS1-MBP interaction than E47A mutations (∆Gpartner 1.04 
kcal/mol). We analyzed the effect of these mutations using SMD simulation as well as 
two biophysical tools: surface plasmon resonance (SPR) and single molecule force 
spectroscopy.  
 
6.3.2 Use of Steered Molecular Dynamics predicts a crucial role of R33 in scaffold 
stabilization 
SMD simulations were performed using six randomly selected pairs of 
monobody-MBP complexes at equilibrium. Pulling was performed at a constant speed of 
10 Å/ns with a spring stiffness of 70 pN/Å on residue V72 of the monobody and was 
designed to pull the monobody away from the center of mass of MBP. Water molecules 
were simulated by the generalized born implicit solvent (GBIS) model implemented in 
NAMD. Each simulation lasted 4 ns with data points saved every 0.5 ps for analysis. 
SMD enabled the quantification of the contribution of each residue to the YS1-MBP 
binding interaction (197). 
In order to reduce computational time we utilized the generalized born implicit 
solvent in NAMD for water modeling.  The GBIS electrostatics calculation first 
determines and then utilizes the Born radius of each atom to quantify the atom’s exposure 
to solvent and its dielectric screening from other atoms. GBIS simulations of the 
repulsive and the attractive components of the nonpolar solvation free energy of small 
molecules are in agreement with explicit models (215).  NAMD’s GBIS capability has 
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been utilized for simulating several large protein structures (216, 217) and validated for 
the simulation of a ribosome undergoing two major conformational changes (207). In this 
instance, GBIS and TIP3P explicit solvent structures closely agree, with a root-mean-
square deviation between models of 1.5 Å (207).  
The mechanics of bond rupture can be separated into three distinct regions (Figure 
6.3B). First, as the pulling force increases linearly, the number of hydrogen bonds 
remains relatively constant. As the applied force reaches the rupture force the hydrogen 
bonds begin to break one by one. When all bonds have broken and YS1 and MBP are 
completely dissociated, the force reaches background levels. The lifetimes of hydrogen 
bonds involving specific residues of the YS1 scaffold are comparable to those of the FG 
loop (Figure 6.3D). Thus, predictions from SMD simulations indicating the importance of 
scaffold residues in the YS1-MBP interaction are in line with the findings from 
computational alanine-scanning mutagenesis. 
Destabilizing mutations, which decrease bond duration time between the 
interacting residues in the presence of force, reduce the overall interaction time between 
YS1 and its ligand, thereby indicating weaker binding. Based on the SMD simulation, the 
E47A mutation reduces the interaction lifetime between the YS1 and MBP by 30% and 
causes the hydrogen bonds to break earlier and at a faster rate (Figure 6.4A, B). Coupled 
with the moderate decrease in binding force, this result suggests that the E47A mutation 
decreases the overall strength of the interaction. The R33A mutation has a more profound 
effect than E47A, reducing the overall bond lifetime by 50% and the binding force by 
~30% (Figure 6.4D, E). Both E47A and R33A mutations have little effect on the duration 
of hydrogen bonds involving residues of the monobody loops. Instead, they affect the 
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duration of hydrogen bonds between the monobody scaffold residues and MBP (Fig 4.c, 
f). The E47A mutation decreases hydrogen bond duration in the E47 residue alone, and 
has little effect on the other scaffold residues, likely resulting in the modest decrease in 
the overall YS1-MBP bond duration observed with the E47A mutation. In contrast, the 
R33A mutation not only reduces the duration of the hydrogen bond at R33 but also at the 
other interacting residues of the scaffold (Figure 6.4F). Consequently, this mutation 
substantially destabilizes the bond and results in a more significant loss of intermolecular 
recognition. This destabilization and subsequent synergistic bond weakening likely 
contributes to the larger ∆∆Gbind and ∆Gpartner predicted in the computational alanine-
scanning mutagenesis analysis and further supports a major role for R33 in the YS1-MBP 
interaction. 
 
6.3.3 Single-molecule force spectroscopy supports the role of E47 and R33 in YS1-
MBP interaction 
Single-molecule force spectroscopy was utilized to characterize the binding 
kinetics of the R33A and E47A mutant variants of YS1 with MBP. MBP was properly 
oriented in a lipid bilayer via an attached transmembrane domain from the human CD44 
transmembrane protein as in our previous study of the interaction of MBP with a DARPin 
(139). YS1, YS1(E47A), and YS1(R33A) coated cantilevers were brought in contact with 
MBP for a constant dwell time and retracted at a predetermined retraction speed. The 
tensile strength of the bond (bond rupture force) and loading rates of single binding 
events were recorded over a range of retraction velocities (42, 139). The concentrations 
of YS1 on the cantilever and MBP in the lipid bilayer were selected to yield a binding 
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event percentage of ~20% (Figure 6.5A) as this frequency will ensure that the majority of 
binding events (>89%) are caused from the breakage of single bonds (based on the 
Poisson distribution) (42, 140).  
The tensile strength measured for YS1 binding to MBP was in the range of 35-80 
pN over a wide range of loading rates (Figure 6.5B). The E47A mutation reduces the 
rupture force by approximately 10-15 pN over a similar range of loading rates, indicating 
that the E47 residue plays an auxiliary role in this interaction. Using the Bell model 
(127), the values for the unstressed off-rate 𝑘 𝑜𝑓𝑓𝑜  (second
-1) and reactive compliance 𝑥𝛽 
(nm) for YS1(E47A) were determined by plotting mean rupture force against the 
logarithm of the loading rate and fitting the data with a least-squares regression line 
(Figure 6.5B). The E47A mutant increased 𝑘 𝑜𝑓𝑓𝑜  of the binding interaction 3-fold 
compared to the YS1 (Table 6.1). Larger values of 𝑘 𝑜𝑓𝑓𝑜  are indicative of shorter 
unstressed bond lifetime and weaker binding. Interestingly the reactive compliance, 
which reflects the susceptibility of the bond to rupture under stress, was similar for both 
the wild-type and mutant monobodies.  In accordance with the Bell Model (127), an 
applied force (f) will alter the bond off rate (𝑘𝑜𝑓𝑓) by the following equation: 𝑘𝑜𝑓𝑓/𝑘 𝑜𝑓𝑓𝑜  
= exp(f𝑥𝛽/𝑘𝐵T).  Therefore, the similar 𝑥𝛽 values observed here and in other studies (139) 
indicate a similar sensitivity to rupture in the presence of force. Collectively, the E47A 
mutation decreases the strength of the YS1-MBP bond as indicated by its lower tensile 
stress and shorter unstressed bond lifetime. 
In concert with both scanning alanine mutagenesis and SMD simulations, force-
spectroscopy also revealed that the R33A mutation had a pronounced destabilizing effect 
on the monobody-MBP interaction, as evidenced by the dramatic decrease in binding 
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frequency down to basal levels (Figure 6.5A). Of note, the auxiliary role of the E47A 
mutation is further substantiated by our findings showing that this mutation did not 
significantly affect binding frequency of monobody-MBP interaction (Figure 6.5A).  
 
6.3.4 Surface Plasmon Resonance confirms that the pivotal role of the scaffold 
residue R33 in YS1-MBP interaction 
SPR experiments were performed to determine the binding kinetic constants (Kd, 
kon, koff). YS1, YS1(R33A), and YS1(E47A) were flowed over a chip sensor coated with 
biotinylated MBP (Figure 6.6). In accordance with the single molecule force 
spectroscopy results, the R33A mutation reduced the binding signal to non-significant 
levels, further demonstrating the critical role of R33 in the YS1-MBP interaction. 
Binding of MBP to both YS1 and YS1(E47A) fit a 1:1 binding model and had equivalent 
Kd values of about 100 nM (Table 6.1). The E47A mutation resulted in no significant 
change in koff or kon. The similar kinetic constants found here are consistent with the 
similar binding frequency detected between MBP and YS1 or YS1(E47A) using single-
molecule force spectroscopy. The discrepancy in the dissociation rate constants obtained 
by SPR versus force spectroscopy between YS1-MBP and YS1(E47A)-MBP binding is 
likely due to differences in binding geometries (3D vs. 2D) (139). Overall, SPR data 
correlate well with both SMD simulations and single-molecule force spectroscopy data 
and indicate the R33A mutation substantially destabilizes YS1-MBP binding while the 
E47A mutation plays a less important role. 
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 6.4 Discussion 
 
A better understanding of how monobodies associate with their ligands will 
facilitate the development of robust binding pockets for higher affinity recognition and 
allow for the generation of improved monobodies. We used computational alanine-
scanning mutagenesis, SMD, single-molecule force spectroscopy and SPR to identify and 
characterize the effect of monobody scaffold residues on the binding interaction between 
monobody YS1 and MBP. Molecular simulations identified E47 and R33 as scaffold 
residues that contribute to monobody-MBP recognition. Mutation at E47 resulted in a 
weaker bond and reduced interaction duration, thereby suggesting an auxiliary role for 
E47 in monobody-MBP recognition. On the other hand, the R33 residue plays a key role 
in this interaction as R33A mutation abrogated binding in both experimental assays, an 
effect likely caused by the synergistic destabilization of the interacting scaffold residues 
(Figure 6.4F). 
Our Kd value for YS1-MBP binding obtained by SPR falls between the reported 
values of 73 nM and 135 nM of prior work, which also used SPR (116, 117). Those 
studies and ours indicate 1:1 binding kinetics. Previous mutagenesis work combined 
shotgun scanning mutagenesis with alanine-scanning mutagenesis for an analysis of YS1-
MBP binding, but focused only on the BC and FG loops (117). That study concluded that 
the BC loop of YS1 is robust to mutation whereas the FG is sensitive (117). A similar 
trend was also observed in our in situ scanning alanine analysis (Figure 6.1), where 
DrugScorePPI predicts the interfacial FG loop residues that were most important for the 
interaction (116).  
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Although previous studies have primarily focused on varying loop residues to 
achieve higher binding affinities, recent work has demonstrated the importance of 
monobody scaffold residues in binding (119, 218). Interactions between monobodies and 
small ubiquitin-related modifier (SUMO) proteins were found to rely heavily on both FG 
loop and scaffold binding, and scaffold modifications were required to generate the 
desired isoform specificity of the monobody (119). A focus on scaffold residue diversity 
has generated monobodies capable of binding to the Abl SH2 domain with low 
nanomolar affinities due primarily to scaffold binding (218). Koide et al. noted that the 
scaffold interactions found in the YS1-MBP crystal structure were possibly due to the 
lattice packing because the contacts were polar and charged and the region showed little 
to no chemical shift perturbation in an NMR study (117). However, R33 has been a point 
of interest in several monobody studies. R33 was found at multiple binding interfaces, 
and its mutation has led to either increased or deceased binding strength when coupled 
with additional scaffold and loop amino acid modifications (119, 218). In our study, 
molecular dynamics simulations, single-molecule force spectroscopy and SPR studies 
indicate that R33 is critical for the YS1-MBP interaction.  
Hot spots in natural proteins tend to have nonrandom compositions with the 
second most abundant amino acid being arginine (199, 219). Its presence at hot spots is 
thought to occur due to its ability to form several favorable interactions including 
electron delocalization through the guanidinium motif and the ability to form up to five 
hydrogen bonds (199). As predicted by DrugscorePPI scanning alanine mutagenesis and 
exemplified in both SPR and force spectroscopy experiments, the R33A mutation was 
shown to destabilize YS1-MBP binding. Robetta predictions indicated the R33A 
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mutation decreases YS1 stability, a result that likely contributes to the loss of 
intermolecular recognition in the biophysical assays. R33 is at the center of the scaffold 
interface (Figure 6.7C, D). The equilibrated molecular representation of the binding 
interface (Figure 6.7E, F) shows R33 of YS1 stacking with R344 of MBP effectively 
burying both arginines. Arg-Arg stacking has been observed in numerous protein-protein 
interfaces although the reason for its occurrence is not yet fully understood (220, 221). 
Arginine stacking is thought to drive the formation of protein interfaces, primarily 
through polarization effects resulting in the seclusion of solvent however, both 
hydrophobic and electrostatic-solvation effects can play secondary roles (220). Arg-Arg 
stacking has been observed in MD simulations using both explicit and implicit water 
models and alternate force fields (222, 223). In YS1-MBP binding the two positively 
charged guanidinium groups stack parallel to one another in a form between the 
staggered and eclipsed conformations. This interaction appears to be vital for high MBP 
affinity.  
SMD simulations (Figure 6.4F) reveal the R33A mutation reduces the hydrogen 
bond duration of surrounding interacting residues of the scaffold. Hydrogen bonding 
between R33 and E47 allows E47 to hydrogen bond effectively with the R344 residue of 
MBP (Figure 6.7E, F). The stability of this interaction contributes to the lengthy bond 
duration of E47 and MBP (Figure 6.3D). A similar effect can be found in ySMB-1 
binding to ySUMO where polar interactions between arginine and asparagine appear to 
stabilize glutamic acid to construct a robust scaffold interaction (119). Although 
additional interacting scaffold residues form hydrogen bonds with durations comparable 
to R33, alanine mutations here were not predicted to critically destabilize the binding 
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interface.   These residues are less buried than either R33 or E47 (Figure 6.1C) and 
further away from the R33 residue such that alanine mutations here are not likely to 
critically destabilize the interface.  In fact, although the E47A mutation alters the binding 
interface modestly, the mutation was not predicted to disrupt the stacking effect (Figure 
6.8). In our work, the R33 residue exhibits two critical characteristics: it anchors the 
scaffold to MBP via arginine stacking and establishes hydrogen bonding between the 
YS1 scaffold and MBP. Without the stabilization of the arginine stacking, the R33A 
mutation has a noticeable and unfavorable conformational change in both YS1 and MBP 
upon binding (Figure 6.7B).  
In summary, we have elucidated the importance of the scaffold interaction in 
YS1-MBP binding through a systematic approach involving molecular modeling and 
biophysical analyses. Our results further illustrate the importance of the R33 scaffold 
residue in monobody-target binding, thus providing vital knowledge for the improved 











6.5 Tables and Figures 
 
Table 6. 1 Comparison of experimentally determined kinetic constants for 
mutations at critical scaffold residues as determined by scanning alanine 
mutagenesis simulations.  
N.B. represents no binding. This No binding is defined as having a binding frequency 
under 5% for single molecule force spectroscopy or displaying an <5 RU response 

















Figure 6. 1 Computational simulations predict the critical residues of YS1 at the 
YS1-MBP binding interface.   
(a) DrugscorePPI webserver prediction of changes in binding free energy (∆∆Gbind) upon 
alanine mutation. (b) Robetta prediction of the effect of alanine mutation on mutated 
protein complex partner in isolation (∆Gpartner). Residues V29, Y31, V45, T49 and K54 
were omitted as Robetta predictions failed to identify them as being present in 50% of the 
predicted binding complexes. (c) DrugscorePPI webserver prediction of the degree of 
buriedness of the interfacial residues at the YS1-MBP interface. Results are the mean ± 










Figure 6. 2 Two perpendicular views of the crystal structure of monobody YS1 
(cyan).  
DrugscorePPI simulation predicted that binding energy between YS1 and its target 
MBP is provided by two groups of interfacial residues: Tyr75, Tyr77, Try78, Try79, 
Tyr80 and Y81 (orange) which are located in the FG-loop; and Arg33 and Glu47 
(red) which belong to the framework of the scaffold. The PDB ID is 2OBG. The figure 









Figure 6. 3 Steered molecular dynamics (SMD) simulates the unbinding of 
monobody YS1 from its target MBP.  
(a) A schematic illustration showing the monobody YS1 (cyan) being pulled away 
from MBP (grey) under a constant pulling velocity on Val72, which is indicated in 
red. The retracting direction was selected to pull the center of mass of the 
monobody away from that of MBP as indicated by the red arrow. (b) Force-time 
course of SMD simulated unbinding of monobody YS1 from its target MBP. (c) The 
time evolution of the average number of hydrogen bonds and (d) hydrogen bond 
duration measured for each interacting residue between monobody YS1 and MBP 








Figure 6. 4 Steered molecular dynamics simulations of unbinding of (a-c) E47A 
and (d-f) R33A mutants from the target MBP.  
Equilibrated mutant YS1-MBP pairs were pulled apart at a constant speed and 
spring stiffness. During the dissociation event, (a and d) pulling force, (b and e) the 
number of hydrogen bonds between interacting residues, and (c and f) the duration 
of hydrogen bonds for each interacting residue were determined for both mutants. 







Figure 6. 5 Characterization of the kinetic and micromechanical properties of 
monobody YS1 binding to MBP using single-molecule force spectroscopy.  
(a) Frequency of binding events between MBP and YS1, YS1(E47A) or YS1(E33A). 
The last column (blank) represents a control experiment using a blank bilayer. Data 
represent the mean ± s.e.m. of at least three independent experiments. (b) Rupture 
force as a function of loading rate for the binding of YS1 (black circles) and 
YS1(E47A) (red triangles) to MBP. The lines are a nonlinear least-squares fitting of 
the Bell dissociation model for determining the unstressed off-rate (k0off) and 










Figure 6. 6 Binding interactions of monobodies and MBP analyzed using SPR.  
Representative sensograms were generated by perfusing (a) wild-type YS1 or (b) 
YS1(E47A) over biotinylated MBP immobilized SA chip at concentrations ranging 
from 0-137 nM for 100 seconds, followed by washing with buffer for 10 minutes. To 
generate the kon, koff and Kd a 1:1 Langmuir binding model was fit for YS1- and 
YS1(E47A) -MBP interaction. χ2 vales were 0.88 and 1.92 for YS1 and YS1(E47A), 
respectively. Data were analyzed using BIAevaluation 3.0 (BIAcore). 
 164 
Figure 6. 7 YS1 scaffold residues at the MBP interface.  
The interacting scaffold residues of (a) YS1 and (b) YS1(R33A) (both shown in 
yellow). The BC, DE and FG loops are represented orange, green, and red, 
respectively (c) Schematic illustration of the YS1-MBP interaction and (d) YS1 in 
which R33, E47, Y75, Y77, Y78 Y79, Y80 and Y81 are shown in red and the other 
interfacial residues of YS1 are shown in yellow. The side view (e) of the YS1 (yellow) 
and MBP (cyan) interface shows R33 of YS1 stacking with R344 of MBP to establish 
the hydrogen bond network between R33, E47, and R344. The top view (f) displays 
the arginines stacking. Schematic illustration of YS1-MBP interfacial interaction 
made using the equilibrated molecular representation based on the crystal structure 












                             
Figure 6. 8 Two perpendicular views of the YS1(E47A)-MBP interface showing Arg-
Arg stacking.  
The side view (a) of the YS1 (yellow) and MBP (cyan) interface shows R33 of YS1 
stacking with R344 of MBP in the presence of the E47A mutation. The top view (a) 
displays the arginines stacking. Schematic illustration of YS1(E47A)-MBP interfacial 
interaction made using the equilibrated molecular representation based on the crystal 




CONCLUSIONS AND FUTURE DIRECTIONS 
 
7.1 Distinct kinetic and mechanical properties govern mucin 16- and podocalyxin-
mediated tumor cell adhesion to E- and L-selectin in shear flow 
 
In Chapter 3 we utilized both single-molecule bond characterization and 
microfluidic assays along with a mathematical model (discussed in detail in Chapter 2) to 
characterize ligand-dependent tethering and rolling in physiologically relevant flow 
conditions.  We found that a series of factors including the single-molecule kinetic and 
micromechanical properties and the number of bonds needed for tethering can predict the 
binding and rolling interactions of MUC16- and PODXL-coated microspheres on E-/L- 
selectin coated surfaces.  This integrated approach can lead to a better understanding of 
how MUC16 and PODXL bind to E-/L-selectins in physiologically relevant 
hydrodynamic shear.  This can lead to the production of improved diagnostic assays and 
to the prevention of pancreatic metastasis. 
However, one must note that these results were obtained through ligand-coated 
microspheres interacting with selectin coated surfaces, which are not as physiologically 
relevant as cell-ligand or cell-cell interaction. In this study ligand-receptor interactions 
were studied because it is easier to obtain kinetic and micromechanical properties without 
the confounding affects associated with cell-cell or cell-receptor interactions.   In these 
interactions, cell deformability, ligand density and orientation can affect cell binding 
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(27).   For this study we wanted to eliminate these confounding affects, and hence used 
the present system.  However, in our second study we expand upon this work and used 
PODXL and MUC16 expressing Pa03c cells, assessing cell binding to receptor coated 
glass surfaces.   
 
7.2 E-selectin mediated rolling increases pancreatic tumor cell adhesion to 
hyaluronic acid 
 
 In Chapter 4 we demonstrate that pancreatic tumor cell rolling on E-selectin 
promotes adhesion to HA. Cells rolling on E-selectin were approximately 40X more 
likely to bind to HA than non-rolling cells at both low and high shear stresses. The 
knockdown of PODXL attenuates rolling on E-selectin but does not decrease the rate of 
adhesion on HA once cells have rolled. This approach uncovers the physical 
interdependence of the MUC16/PODXL-E-selectin and CD44v-HA bonds and uncovers 
the critical parameters involved in cell-receptor binding.  This knowledge can be utilized 
to improved diagnostic assays and better understand the metastatic spread of pancreatic 
tumor cells. 
This study explores how pancreatic tumor cells that express PODXL, MUC16 and 
CD44v bind to E-selectin and subsequently to HA in shear flow.  In the future we would 
like to take this project in several different directions, with one direction being to 
decouple the binding interactions further.  By using cell lines that have been knocked 
down for MUC16 or CD44 in addition to PODXL, we could further assess how these 
binding interaction influence cell rolling and firm adhesion.  In Chapter 3 we observed 
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differences between PODXL and MUC16 rolling and tethering to E- and L-selectin.  It 
would be prudent to see if these differences persist in a cell-receptor system.  A second 
direction would be to couple the interactions further and observed how pancreatic cancer 
cells roll and adhere to both E-selectin and HA where the two proteins are patterned 
together, rather than in distinct regions. E-selectin has been patterned with an anti-
EpCAM antibody to capture CTCs while excluding the leukocytes (161).  This technique 
could be modified to pattern multiple proteins on a surface in order to capture pancreatic 
tumor cells in geometrically defined regions.  In this setup we wouldn’t be observing how 
rolling on E-selectin affects binding to HA alone but rather observe binding in a more 
representative and physiological relevant ECM.  This work would translate nicely into 
studying cell-cell interactions where pancreatic tumor cells can be flowed over activated 
endothelial cells expressing relevant cell-surface proteins.  One proposed method to do 
this is discussed in the next section. 
Next we would like to investigate how PODXL and MUC16 affect metastasis in 
vivo.  While we have yet to extensively explore MUC16 as a metastasis driver in 
pancreatic cancer there are early indications that the loss of PODXL decreases cell 
migration in vitro and tumor formation in vivo in a subcutaneous model (Figure 7.1).  
However, while the subcutaneous tumor model is straightforward and easy to use, it is 
unable to recapitulate the tumor microenvironment and as a result tumors are unable to 
progress and metastasize in a manner similar to human cancers (224). Therefore, we have 
also begun experiments looking at the metastasis of PODXL expressing and PODXL-KD 
pancreatic cancer cell lines.   
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These experiments include the orthotopic implantation and hemispleen models.  
For the orthotopic model, PODXL expressing and PODXL-KD Pa03c and SW1990 cells, 
which are prepared either in matrigel or as 1mm3 sections of a subQ tumors are implanted 
into the pancreas of NOD/SCID mice.  The mice are then monitored and their survival 
can be measured (224).  At a set end date the remaining mice can be sacrificed and cell 
metastasis to the liver and other organs can be measured via H&E staining of organ cross 
sections or through hline-1 analysis of human DNA in these organs.  Further, the growth 
of the tumor in the pancreas can also be measured.   
We have also begun to study metastasis through a preclinical, murine pancreatic 
tumor model of hepatic metastases, which takes advantage of a tumor cell injection into 
the hemispleen.  In this model the spleen of the NOD/SCID mouse is divided and Pa03c 
or SW1990 tumor cells are injected slowly and washed with PBS (225).  This allows cells 
to pass through the circulatory system directly to the liver, mimicking the path that 
metastatic pancreatic tumor cells would travel in the vasculature.  The hemispleen model 
results in liver metastasis 100% of the time (225).  However, while the orthotopic 
implantation can model the entire metastatic cascade the hemispleen model captures just 
the final steps of the metastatic process, including cell rolling and adhesion, 
extravasation, and colonization.  However, this model remains more accurate than the tail 
vein injection for pancreatic cells because in the tail vein model, cells metastasize 
primarily to the lungs rather than the liver.  
We would expect that PODXL expressing SW1990 and Pa03c cells metastasize 
more easily in the orthotopic and hemispleen models, and mice treated with these cells 
would develop increased liver metastasis compared to PODXL-KD cells.  Because 
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control SW1990 and Pa03c have an increased ability to bind to E-selectin and firmly 
adhere to HA coupled with an increased ability to migrate in vitro and initiate tumors in 
vivo, they should display increased metastasis in these two models.     
 
7.3 Binding and migration of glial-restricted progenitor (GRP) cells in vitro, 
validated through in vivo models 
 
The loss of oligodendrocytes after stroke is one of the main causes of secondary 
neuron injury. GRPs have local re-myelinating potential after transplantation into the 
brain however, they express low levels of VLA-4 and therefore flow quickly through the 
brain vasculature and are cleared from the body when implanted through intraarterial 
methods.  Therefore we overexpressed VLA-4 in GRP cells to see if we could improve 
endothelial binding and migration in vitro and cerebral homing in the middle cerebral 
artery occlusion (MCAO) stroke model.  
 In this regard we designed a flowchamber that could either be coated with 
purified VCAM-1 or brain endothelial cells (Figure 7.2A).  We observed that GRPs 
expressing VLA-4 bound to both a VCAM-1 coated glass and activated brain 
endothelium with a significantly higher frequency than control GRP cells (Figure 7.2B).  
GRPs expressing VLA-4 cells also rolled with slower velocities on both surfaces.  
Further in vitro microchannel migration assays showed that GRPs expressing VLA-4 
migrate faster and further through both confined and unconfined channels (Figure 7.2C 
and D).  Taken together GRPs expressing VLA-4 should initiate binding and homing to 
brain endothelium in vivo. 
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 Using the middle cerebral artery occlusion (MCAO) stroke model and intraarterial 
infusion imaged with two-photon microscopy we observed that GRPs with VLA-4 
adhered to blood vessel walls in three-fold greater numbers than control GRPs. 
Furthermore migration through the vessel walls was observed for GRPs with VLA4, but 
not control GRPs (Figure 7.2F and G).  Taken together this data demonstrates (1) that in 
vitro binding assays such as the flowchamber developed for this study can replicate in 
vivo observations.  Here were observed a trend in rolling speed and binding frequency, 
which was preserved from the cell-receptor to the cell-cell level in vitro and eventually to 
the cell-cell level in vivo. (2) That observations in cell migration using in vitro 
microchannels directly translate to an in vivo setting.  This further validates these 
techniques as they translate well to clinically and physiologically relevant applications.  
 
7.4 Loss of obscurin from human pancreatic ductal epithelial cells increases cell 
migration and dynamics 
 
In Chapter 5 we observed that giant obscurins are depleted from PDAC tissue and 
metastatic cell lines, but they are abundant in normal pancreatic tissue and non-
tumorigenic human pancreatic ductal epithelial (HPDE) cells. Further, the loss of 
obscurin from HPDE cells results in the modification of two major pathways, RhoA and 
PI3K/AKT which in turn leads to major alterations of the cytoskeleton including faster 
actin dynamics at cell-cell junctions, increased microtubule dynamics and decreased focal 
adhesion density.  This in part leads to increased cell migration speeds through 
trifurcating channels.  This is critically important because identifying markers that 
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encourage tumor growth and metastasis is vital to the prevention and treatment of 
pancreatic cancer. 
 Similar to our approach with the PODXL expressing cells we plan to see how the 
losses of giant obscurins affect tumor formation and metastasis in vivo.  Because the loss 
of obscurins in Panc5.04 is correlated with increased PI3K activity as well as increased 
cell motility and cytoskeletal cell dynamics in vitro, we plan to examine the effects of 
obscurin depletion on tumorigenicity in vivo, considering upregulated PI3K activity can 
result in increased pancreatic tumor cell survival and growth in vivo (177).  The Panc5.04 
cell line was chosen for this work because the HPDE are nontumorigenic in vivo (226).  
In this regard plan to observed the formation of tumors for Panc5.04 ctrl-shRNA and 
obscn-shRNA in a subcutaneous model.   We expect, that similar to obscurin depleted 
breast epithelial cells, (91) obscurin-KD pancreatic cells will grow faster and form larger 
tumors than control cells.  If these results match our hypothesis, we will move forward 
with PI3K inhibitor in vivo studies, where we will observe the effects of treating obscurin 
depleted pancreatic tumors with the PI3K inhibitor BKM120 in a subQ mouse model. 
   Furthermore because we observe increased cell migration and dynamics for both 
HPDE and Panc5.04 depleted for giant obscurins we would like to study if these 
alterations affect metastasis in vivo.  Again we would utilize the orthotopic implantation 
and hemispleen models to assess cell metastasis.  In both instances increases in metastasis 
would tie more directly to increases in cell migration (intravasation and extravasation), 
survival and growth rather than cell binding in flow (although the loss of obscurin can 
increase microtentacle formation (ref 86).    
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7.5 Characterization of Monobody Scaffold Interactions with Ligand via Force 
Spectroscopy and Steered Molecular Dynamics 
 
In Chapter 6 we identified two scaffold residues (E47 and R33) that are critical to 
the binding interaction between the monobody YS1 and its ligand, maltose-binding 
protein using alanine-scanning mutagenesis. Through steered molecular dynamics 
simulations we predicted that alanine mutations to these residues in the YS1 scaffold 
would destabilize the YS1-MBP interface by reducing the bond rupture force and the 
lifetime of hydrogen bonds. Simulating the unbinding event indicated that the R33A 
mutation weakens binding between all scaffold residues and MBP and not just between 
R33 and MBP. We validated these simulations using single-molecule force spectroscopy 
and surface plasmon resonance. We propose that interfacial stability resulting from 
arginine-arginine stacking, which synergistically stabilizes both the arginine-arginine 
bonds and entire interacting scaffold residues of YS1. Our integrated approach improves 
the understanding of the monobody scaffold interactions with a target, thus providing 
guidance for the improved engineering of monobodies. 
With increased knowledge about the binding interface of conserved scaffold 
residues of monobodies, it is not unreasonable to believe that this can contribute to their 
improved design.  Interestingly while Arg-Arg stacking has been observed in multiple 
protein-protein interfaces although it is not yet fully understood (220, 221). What is 
known is that this interaction appears to be vital for high MBP affinity and may be 
critical for other monobody binding interfaces. In fact the R33 was found at multiple 
monobody interfaces for different binding interactions, and mutations here have led to 
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either increased or decreased binding strength when coinciding with additional scaffold 
and loop modifications (119, 218).  
Moving forward it would be interesting to use phage or yeast display 
combinatorial libraries to develop monobodies that could bind with high specificity and 
affinity to pancreatic cancer surface proteins like MUC16 and PODXL.  Recently, 
monobodies have been engineered to fight cancer.  Monobody NS1 was designed to bind 
to H- and K-RAS proteins and inactivate the RAF dimer leading to changes in cell cycle 
progression (123).  Additionally monobodies have been designed to bind to the Src 
homology 2 domain at the phosphotyosine-binding site effectively inhibiting Bcr-Abl 
kinase activity resulting in the cell death of chronic myelogenous leukemia cell lines in 
vitro (219).  Therefore it is clearly possible to design monobodies to bind to and inhibit 
the functionality PODXL or MUC16, or bind to obscurin at the Rho-GEF or PH domains 
to inhibit the activation of the RhoA or PI3K/AKT pathway.  Because minor 
improvements in treating cancer metastasis can have major benefits, targeting these 













Figure 7. 1 Migration and tumorigenicity is reduced in PODXL-KD SW1990 cells. 
(A) SW1990 cells with either scramble control or PODXL-KD shRNA were allowed to 
migrated through straight microchannels with widths varying from 6 to 50µm, under a 
gradient of 10% FBS. Scramble control cells migrated with faster velocity through both 
confined and unconfined microchannels when compared to PODXL-KD SW1990 cells. 
(B) 1x106 SW1990 cell with either control or PODXL shRNA were subcutaneously 
injected into the flank of NOD/SCID mice.  Tumors were measured every 3-4 days and 
the volume was estimated using the ellipsoid model. Data represents mean ± S.E.M, p* < 








Figure 7. 2 VLA-4 enhances GRP binding and migration both in vitro and in vivo 
Expression of VCAM-1 on HBEC cells that were non-activated (A) and activated with 
TNFα (B). Cell rolling velocity (C) and number of interacting cells per 3 minute 
experiment (D) of GRP cells in the flowchamber devices coated with activated HBEC 
(shear stress of 1dyn/cm2). (E) Average migration speed of naïve GRPs and VLA-
4+GRPs in straight microchannels with widths varying from 6 to 50µm. Intravital multi-
photon imaging of labeled (green) VLA-4+GRPs (F) and naïve GRPs (G) after 
intraarterial delivery, 24h after 60min MCAO, show that VLA-4 GRPs bind more 
frequency and migrate into to brain endothelium in vivo. Data represents mean ± S.E.M, 
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